TY - THES A1 - Karus, Christine T1 - Untersuchung der Architektur von Proteinstrukturen des Ranvier-Schnürrings mittels der super-hochauflösenden Mikroskopiemethode dSTORM T1 - Investigation of the architecture of protein structures of the Node of Ranvier using the super-high resolution microscopy method dSTORM N2 - Ranvier-Schnürringe spielen eine entscheidende Rolle bei der schnellen Weiterleitung von elektrischen Impulsen in Nervenzellen. Bei bestimmten neurologischen Erkrankungen, den Neuropathien, kann es zu Störungen in der ultrastrukturellen Organisation verschiedener Schnürring-Proteine kommen (Doppler et al., 2018, Doppler et al., 2016). Eine detailliertere Kenntnis der genauen Anordnung dieser Schnürring-Proteine und eventueller Abweichungen von dieser Anordnung im Krankheitsfall, könnte der Schlüssel zu einer vereinfachten Diagnostik von bestimmten Neuropathie- Formen sein. Ziel meiner Arbeit war es daher, die Untersuchung der ultrastrukturellen Architektur der (para-)nodalen Adhäsionsproteine Neurofascin-155 und Caspr1 unter Verwendung der super-hochauflösenden Mikroskopiemethode dSTORM (direct Stochastic Optical Reconstruction Microscopy) an murinen Zupfnervenpräparaten zu etablieren. Nach erster Optimierung der Probenpräparation für die 2-Farben-dSTORM sowie der korrelationsbasierten Bildanalyse, konnte ich mittels modellbasierter Simulation die zugrundeliegende Molekülorganisation identifizieren und mit Hilfe der Ergebnisse aus früheren Untersuchungen validieren. In einem translationalen Ansatz habe ich anschließend humane Zupfnervenpräparate von 14 Probanden mit unterschiedlichen Formen einer Neuropathie mikroskopiert und ausgewertet, um die Anwendbarkeit dieses Ansatzes in der Diagnostik zu testen. Obgleich keine signifikanten Unterschiede zwischen physiologischem und pathologischem neurologischem Gewebe hinsichtlich Neurofascin-155 und Caspr1 festgestellt werden konnten, scheint der Ansatz grundsätzlich dennoch vielversprechend zu sein, bedarf jedoch noch weiteren Anstrengungen hinsichtlich Probenpräparation, Auswertungs- und Versuchsprotokollen und einer größeren Anzahl an humanen Biopsien mit homogenerem Krankheitsbild. N2 - Nodes of Ranvier play a critical role in the rapid transmission of electrical impulses in neurons. In certain neurological diseases, the neuropathies, there may be disturbances in the ultrastructural organization of various nodal and paranodal proteins (Doppler et al., 2018, Doppler et al., 2016). A more detailed knowledge of the exact arrangement of these nodal and paranodal proteins and possible deviations from this arrangement in disease, could be the key to a simplified diagnosis of certain neuropathy forms. Therefore, the aim of my work was to establish the investigation of the ultrastructural architecture of the (para-)nodal adhesion proteins Neurofascin-155 and Caspr1 using the super-high resolution microscopy method dSTORM (direct Stochastic Optical Reconstruction Microscopy) on murine teased fibers. After initial optimization of sample preparation for 2-color dSTORM as well as correlation-based image analysis, I was able to identify the underlying molecular organization using model-based simulation and validate it using results from previous studies. In a translational approach, I then microscoped and evaluated human teased fibers from 14 subjects with different forms of neuropathy to test the applicability of this approach in diagnostics. Although no significant differences were found between physiological and pathological neurological tissue with respect to Neurofascin-155 and Caspr1, the approach still seems promising in principle, but requires further efforts with respect to sample preparation, evaluation and experimental protocols, and a larger number of human biopsies with more homogeneous disease patterns. KW - dSTORM KW - Ranvier-Schnürring Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-274568 N1 - die Dissertation ist ein Kooperationsprojekt dieser beiden Fakultäten ER - TY - THES A1 - Stallforth, Sabine T1 - Unterschiedliche Wirkungen der TNF-alpha-Rezeptoren auf De- und Regeneration peripherer NervenEine Studie an TNF-alpha-Rezeptor-Knockoutmäusen in zwei verschiedenen Tiermodellen für Nervenläsionen T1 - Different effects of TNF-alpha-receptors on de- and regeneration of the peripheral nerveA study in TNF-alpha-receptor-knockout-mice in two different models of nerve injury N2 - Noch immer ist die Behandlung von Neuropathien mit den gängigen therapeutischen Mitteln für viele Patienten sehr unbefriedigend. Als erfolgsversprechender therapeutischer Ansatz werden zur Zeit Wege erforscht, welche direkt in die molekularen Entstehungsmechanismen pathologischer Veränderungen und regenerationsfördernder Mechanismen eingreifen, um dadurch eine Heilung von Nervenschäden zu ermöglichen. Bisher sind die Erkenntnisse über diese Mechanismen nicht vollständig genug, um daraus eine sichere Behandlungsmöglichkeit abzuleiten. Wegweisende Erkenntnisse deuten sich allerdings durch Studien von unterschiedlichen Vertretern des Zytokinnetzwerkes an - darunter auch TNF-alpha - welche als molekulare Ursache neuropathischer Veränderungen diskutiert werden. In dieser Studie wurde an Knockoutmäusen der Einfluss des jeweiligen TNF-alpha-Rezeptors auf morphologische Veränderungen nach CCI (Chronic constriction injury) und Crush-Verletzung des N. ischiadicus untersucht. Nach 3,7,15 und 36 Tagen (CCI) bzw. 3,7 und 28 Tagen (Crush) wurden in Methylenblau gefärbten Semidünnschnitten intakte und degenerierte Nervenfasern, Makrophagen, Angioproliferation, Ödembildung udn Veränderung des Anteils nicht neuronaler Zellen lichtmikroskopisch beurteilt. Zusätzlich wurden Mac-1+ Makrophagen immunzytochemisch erfasst. Die Ergebnisse zeigten in beiden Modellen und bei beiden Knockouttypen eine starke axonale Schädigung, die von einer großen endoneuroalen Makrophagenansammlung begleitet war. Bei TNF-R1-/- Mäusen war eine stärkere und verlängerte Degeneration mit entsprechend höheren Makrophagenzahlen sichtbar. In den Immunzytochemischen Färbungen wiesen die TNF-R1-/- Mäuse hingegen den geringsten Makropahgenanteil auf.Trotz der starken Schädigung war die anschließende Regeneration im Gegensatz zu WT und TNF-R2-/- Mäusen besser. Die Ödembildung war bei den TNF-R2-/- nach CCI besonders stark ausgeprägt und von einer schlechten Regeneration gefolgt. Während die gefundenen Daten auf eine Beteiligung beider Rezeptoren während degenerativer Prozesse hindeuten, scheint insbesondere TNF-R2 regenerationsfördernde Effekte zu vermitteln. N2 - Current Treatment of neuropathic disorders is still dissatisfactory for many patients. A promising approach is the investigation of agents that directly interfere with molecular development of pathologic changes and regeneration. Up to now, consolidated findings of the underlying mechanisms are not yet sufficent to allow therapeutic intervention. Pathbreaking findings come from studies investigating different agents of the cytokine network - as e.g. TNF-alpha - that are discussed as molecular cause of neuropathic changes. This study investigated the influence of both TNF-alpha-receptors on morphologic changes after CCI (chronic constriction injury) and crush-injury of the sciatic nerve of TNF-R-knockoutmice. After 3,7,15 and 36 days (CCI), and 3,7 and 28 respectively (Crush),intact and degenerating nerve fibers, macrophages, angioproliferation, development of edema and changes in the amount of non-neuronal cells were acquired by light microscopy of toluidin-stained semithin sections. Additionally Mac-1+ macrophages were acquired via immuncytochemically stained sections. The results showed strong axonal damage in both knockout-types accompanied by large amounts of endoneurial macrophages. TNF-R1-/-mice showed a longer degeneration phase including respectively higher amounts of macrophages. In contrast the TNF-R1-/-mice revealed the fewest amount of macrophages in immunocytochemical sections. Despite the strong damage better nerve regeneration was observed compared to WT and TNF-R2-/-mice. Formation of edema was pronounced in TNF-R2-/- after CCI and followed by poorly regeneration. Whereas these findings point to a participation of both receptors in degeneration, TNF-R2 seems to support regeneration. KW - peripheral nerve KW - TNF KW - TNF-R1 KW - TNF-R2 KW - TNF-receptors KW - knockout KW - Crush KW - CCI KW - sciatic nerve injury KW - Cytokines KW - regeneration KW - degeneration KW - Degeneration KW - Regeneration KW - TNF-Rezeptor-1 KW - TNF-Rezeptor-2 KW - degeneration KW - regeneration KW - TNF-receptor-1 KW - TNF-receptor-2 Y1 - 2007 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-24808 ER - TY - JOUR A1 - Contarino, Maria Fiorella A1 - Smit, Marenka A1 - van den Dool, Joost A1 - Volkmann, Jens A1 - Tijssen, Marina A. J. T1 - Unmet Needs in the Management of Cervical Dystonia JF - Frontiers in Neurology N2 - Cervical dystonia (CD) is a movement disorder which affects daily living of many patients. In clinical practice, several unmet treatment needs remain open. This article focuses on the four main aspects of treatment. We describe existing and emerging treatment approaches for CD, including botulinum toxin injections, surgical therapy, management of non-motor symptoms, and rehabilitation strategies. The unsolved issues regarding each of these treatments are identified and discussed, and possible future approaches and research lines are proposed. KW - cervical dystonia KW - botulinum toxin KW - deep brain stimulation KW - physical therapy modalities KW - non-motor features Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-165225 VL - 7 IS - 165 ER - TY - JOUR A1 - Gabriel, Katharina M. A. A1 - Jírů-Hillmann, Steffi A1 - Kraft, Peter A1 - Selig, Udo A1 - Rücker, Victoria A1 - Mühler, Johannes A1 - Dötter, Klaus A1 - Keidel, Matthias A1 - Soda, Hassan A1 - Rascher, Alexandra A1 - Schneider, Rolf A1 - Pfau, Mathias A1 - Hoffmann, Roy A1 - Stenzel, Joachim A1 - Benghebrid, Mohamed A1 - Goebel, Tobias A1 - Doerck, Sebastian A1 - Kramer, Daniela A1 - Haeusler, Karl Georg A1 - Volkmann, Jens A1 - Heuschmann, Peter U. A1 - Fluri, Felix T1 - Two years' experience of implementing a comprehensive telemedical stroke network comprising in mainly rural region: the Transregional Network for Stroke Intervention with Telemedicine (TRANSIT-Stroke) JF - BMC Neurology N2 - Background Telemedicine improves the quality of acute stroke care in rural regions with limited access to specialized stroke care. We report the first 2 years' experience of implementing a comprehensive telemedical stroke network comprising all levels of stroke care in a defined region. Methods The TRANSIT-Stroke network covers a mainly rural region in north-western Bavaria (Germany). All hospitals providing acute stroke care in this region participate in TRANSIT-Stroke, including four hospitals with a supra-regional certified stroke unit (SU) care (level III), three of those providing teleconsultation to two hospitals with a regional certified SU (level II) and five hospitals without specialized SU care (level I). For a two-year-period (01/2015 to 12/2016), data of eight of these hospitals were available; 13 evidence-based quality indicators (QIs) related to processes during hospitalisation were evaluated quarterly and compared according to predefined target values between level-I- and level-II/III-hospitals. Results Overall, 7881 patients were included (mean age 74.6 years +/- 12.8; 48.4% female). In level-II/III-hospitals adherence of all QIs to predefined targets was high ab initio. In level-I-hospitals, three patterns of QI-development were observed: a) high adherence ab initio (31%), mainly in secondary stroke prevention; b) improvement over time (44%), predominantly related to stroke specific diagnosis and in-hospital organization; c) no clear time trends (25%). Overall, 10 out of 13 QIs reached predefined target values of quality of care at the end of the observation period. Conclusion The implementation of the comprehensive TRANSIT-Stroke network resulted in an improvement of quality of care in level-I-hospitals. KW - pilot project KW - care tempis KW - ischemic stroke KW - thrombolysis KW - areas KW - time KW - hospitals KW - mortality KW - outcomes KW - quality Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-229214 VL - 20 ER - TY - JOUR A1 - Ehling, P. A1 - Bittner, S. A1 - Bobak, N. A1 - Schwarz, T. A1 - Wiendl, H. A1 - Budde, T. A1 - Kleinschnitz, Christoph A1 - Meuth, S. G. T1 - Two pore domain potassium channels in cerebral ischemia: a focus on K2p9.1 (TASK3, KCNK9) N2 - BACKGROUND: Recently, members of the two-pore domain potassium channel family (K2P channels) could be shown to be involved in mechanisms contributing to neuronal damage after cerebral ischemia. K2P3.1-/- animals showed larger infarct volumes and a worse functional outcome following experimentally induced ischemic stroke. Here, we question the role of the closely related K2P channel K2P9.1. METHODS: We combine electrophysiological recordings in brain-slice preparations of wildtype and K2P9.1-/- mice with an in vivo model of cerebral ischemia (transient middle cerebral artery occlusion (tMCAO)) to depict a functional impact of K2P9.1 in stroke formation. RESULTS: Patch-clamp recordings reveal that currents mediated through K2P9.1 can be obtained in slice preparations of the dorsal lateral geniculate nucleus (dLGN) as a model of central nervous relay neurons. Current characteristics are indicative of K2P9.1 as they display an increase upon removal of extracellular divalent cations, an outward rectification and a reversal potential close to the potassium equilibrium potential. Lowering extracellular pH values from 7.35 to 6.0 showed comparable current reductions in neurons from wildtype and K2P9.1-/- mice (68.31 +/- 9.80% and 69.92 +/- 11.65%, respectively). These results could be translated in an in vivo model of cerebral ischemia where infarct volumes and functional outcomes showed a none significant tendency towards smaller infarct volumes in K2P9.1-/- animals compared to wildtype mice 24 hours after 60 min of tMCAO induction (60.50 +/- 17.31 mm3 and 47.10 +/- 19.26 mm3, respectively). CONCLUSIONS: Together with findings from earlier studies on K2P2.1-/- and K2P3.1-/- mice, the results of the present study on K2P9.1-/- mice indicate a differential contribution of K2P channel subtypes to the diverse and complex in vivo effects in rodent models of cerebral ischemia. KW - Kaliumkanal KW - Ischemia Y1 - 2010 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-68129 ER - TY - JOUR A1 - Üçeyler, Nurcan A1 - Urlaub, Daniela A1 - Mayer, Christine A1 - Uehlein, Sabrina A1 - Held, Melissa A1 - Sommer, Claudia T1 - Tumor necrosis factor-α links heat and inflammation with Fabry pain JF - Molecular Genetics and Metabolism N2 - Fabry disease (FD) is an X-linked lysosomal storage disorder associated with pain triggered by heat or febrile infections. We modelled this condition by measuring the cytokine expression of peripheral blood mononuclear cells (PBMC) from FD patients in vitro upon stimulation with heat and lipopolysaccharide (LPS). We enrolled 67 FD patients and 37 healthy controls. We isolated PBMC, assessed their gene expression of selected pro- and anti-inflammatory cytokines, incubated them with heat, LPS, globotriaosylceramide (Gb3), and tumor necrosis factor-α (TNF), and measured TNF secretion in the supernatant and intracellular Gb3 accumulation, respectively. We found increased TNF, interleukin (IL-)1β, and toll-like receptor 4 (TLR4) gene expression in FD men (p < .05 to p < .01). TNF and IL-10 were higher, and IL-4 was lower in the subgroup of FD men with pain compared to controls (p < .05 to p < .01). Hereby, TNF was only increased in FD men with pain and classical mutations (p < .05) compared to those without pain. PBMC from FD patients secreted more TNF upon stimulation with LPS (p < .01) than control PBMC. Incubation with Gb3 and an additional α-galactosidase A inhibitor did not further increase TNF secretion, but incubation with TNF greatly increased the Gb3 load in FD PBMC compared to controls (p < .01). Also, LPS incubation and heat challenge (40 °C) increased Gb3 accumulation in PBMC of patients compared to baseline (p < .05 each), while no alterations were observed in control PBMC. Our data show that TNF holds a crucial role in the pathophysiology of FD associated pain, which may open a novel perspective for analgesic treatment in FD pain. KW - Fabry disease KW - Fabry pain KW - tumor necrosis factor-α KW - peripheral blood mononuclear cells Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-229190 VL - 127 ER - TY - THES A1 - Leffler, Andreas T1 - TRPV1 ist ein polymodaler Rezeptor von nozizeptiven Spinalganglienzellen T1 - TRPV1 is a polympdal receptor in nociceptive spinal sensory neurons N2 - In der vorliegenden Arbeit wurde mittels der Whole-Cell Patch-Clamp Methode sensible Neurone von transgenen Mäusen untersucht, bei denen das Gen für TRPV1 (transient receptor potential V1) deletiert wurde. Das Ergebniss wurde mit den Daten von Wildtyp Mäusen verglichen. TRPV1 (früher VR1; vanilloid receptor 1) wird nahezu selektiv in sensiblen Neuronen exprimiert und wird im heterologen Expressionssystem durch Vanilloide, Hitze (> 43°C) und Protonen aktiviert. Durch diese Eigenschaften scheint TRPV1 für die rezeptiven Eigenschaften polymodaler Nozizeptoren von großer Bedeutung zu sein. Als ein Model des peripheren afferenten Neurons wurde die Aktivierbarkeit kultivierter Spinalganglienzellen durch Vanilloide, Protonen und Hitze elektrophysiologisch untersucht. Während etwa 35% der Wildtyp-Zellen Vanilloid-sensibel waren, fehlte in Zellen der TRPV1-knockout Maus jegliche Vanilloid-Sensibilität. Auch bei der Protonen-Sensibilität wurde eine signifikante Reduktion in TRPV1-knockout Zellen beobachtet. In Wildtyp-Zellen wurde eine hohe Protonen-Sensibilität fast ausschliesslich in Vanilloid-sensiblen Zellen beobachtet. Hitze-induzierte Einwärtsströme mit einer Aktivierungsschwelle bei 43°C wurden ausschliesslich in Vanilloid-sensiblen Zellen der Wildtyp-Maus beobachtet. Dagegen wurden Hitze-induzierte Einwärtsströme mit einer Aktivierungsschwelle über 53°C in sowohl Wildtyp- als auch in TRPV1-knockout Zellen beobachtet. Im Bezug auf die Bedetung von TRPV1, wurde die Funktionalität zwei distinkter Populationen von Spinalganglienzellen, NGF- bzw. GDNF-abhängigen Neuronen, durch eine Lebendfärbung mit IB4-FITC untersucht. Hinsichtlich Vanilloid-, Protonen-, Hitze-Sensibilitöt wurden jedoch keine Unterschiede zwischen IB4-negative und IB4-positive Neuronen beobachtet. Die vorliegende Studie zeigt damit, dass TRPV1 für Vanilliod-Sensibilität sensibler Neurone essentiell ist. Weiterhin konnte gezeigt werden, dass TRPV1 ein wichtiges Transduktionselement für sowohl die Protonen-Sensibilität als auch für die Hitze-Sensibilität in Spinalganglienzellen darstellt. Die Daten dieser zellulären Untersuchungen konnten in weiteren in vitro und in vivo Untersuchungen bestätigt werden (Caterina et al., 2000). N2 - In the present study, the whole-cell patch-clamp technique was applied to investigate sensory neurons from wildtype-mice and from mice lacking TRPV1 (transient receptor potential V1). TRPV1 (previously VR1; vanilloid receptor 1) is specifically expressed in sensory neurons and when heterologously expressed, TRPV1 is activated by vanilloids, heat (> 43°C) and protons. Thus these properties strongly suggest that TRPV1 is significantly contributing to the receptive properties of polymodal nociceptors. As model for the peripheral afferent neuron, the sensitivity of cultured dorsal root ganglia (DRG) neurons to vanilloids, protons and heat was investigated. Whereas 35% of the wildtype-cells were sensitive to vanilloids, none of the TRPV1-knockout cells generated vanilloid-evoked inward-currents. Furthermore, the proton-sensitivity of TRPV1-knockout neurons was significantly reduced. In wildtype-cells, large proton-evoked inward-currents were restricted to vanilloid-sensitive cells. Heat-evoked inward-currents with a threshold for activation around 43°C were only observed in vanilloid-sensitive neurons from wildtype mice. In contrast, heat-induced currents with a threshold for activation > 53°C were observed in both wildtype- and knockout neurons. In respect to the role of TRPV1 sensory neurons, functional properties of two distinct populations of DRG neurons were investigated. NGF- respectively GDNF-dependent neurons were separately investigated after staining of vital neurons with IB4-FITC. In the present study, the vanilloid-, proton- and heat-sensitivity of IB4-negative and IB4-positive neurons were not significantly different. The present study clearly demonstrates that TRPV1 is the only vanilliod-sensitive receptor in sensory neurons. Furthermore, TRPV1 is an important detector for both protons and heat in nociceptive sensory neurons. The data from this cellular essay were in good agreement with other in vitro and in vivo essays (Caterina et al., 2000). KW - Schmerz KW - Nozizeptor KW - Spinalganglion KW - TRP KW - VR1 KW - Pain KW - Nociceptor KW - Dorsal Root Ganglion KW - TRP KW - VR1 Y1 - 2003 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-10748 ER - TY - JOUR A1 - Pozzi, Nicoló G. A1 - Palmisano, Chiara A1 - Reich, Martin M. A1 - Capetian, Philip A1 - Pacchetti, Claudio A1 - Volkmann, Jens A1 - Isaias, Ioannis U. T1 - Troubleshooting gait disturbances in Parkinson’s disease with deep brain stimulation JF - Frontiers in Human Neuroscience N2 - Deep brain stimulation (DBS) of the subthalamic nucleus or the globus pallidus is an established treatment for Parkinson’s disease (PD) that yields a marked and lasting improvement of motor symptoms. Yet, DBS benefit on gait disturbances in PD is still debated and can be a source of dissatisfaction and poor quality of life. Gait disturbances in PD encompass a variety of clinical manifestations and rely on different pathophysiological bases. While gait disturbances arising years after DBS surgery can be related to disease progression, early impairment of gait may be secondary to treatable causes and benefits from DBS reprogramming. In this review, we tackle the issue of gait disturbances in PD patients with DBS by discussing their neurophysiological basis, providing a detailed clinical characterization, and proposing a pragmatic programming approach to support their management. KW - Parkinson’s disease KW - freezing of gait (FOG) KW - deep brain stimulation (DBS) KW - subthalamic nucleus (STN) KW - globus pallidus pars interna (GPi) KW - pedunculopontine nucleus (PPN) Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-274007 SN - 1662-5161 VL - 16 ER - TY - JOUR A1 - Cruccu, Giorgio A1 - Pennisi, Elena M. A1 - Antonini, Giovanni A1 - Biasiotta, Antonella A1 - Di Stefano, Giulia A1 - La Cesa, Silvia A1 - Leone, Caterina A1 - Raffa, Salvatore A1 - Sommer, Claudia A1 - Truini, Andrea T1 - Trigeminal isolated sensory neuropathy (TISN) and FOSMN syndrome: despite a dissimilar disease course do they share common pathophysiological mechanisms? JF - BMC Neurology N2 - Background: Patients presenting with bilateral trigeminal hypoesthesia may go on to have trigeminal isolated sensory neuropathy, a benign, purely trigeminal neuropathy, or facial-onset sensory motor neuronopathy (FOSMN), a malignant life-threatening condition. No diagnostic criteria can yet differentiate the two conditions at their onset. Nor is it clear whether the two diseases are distinct entities or share common pathophysiological mechanisms. Methods: Seeking pathophysiological and diagnostic information to distinguish these two conditions at their onset, in this neurophysiological and morphometric study we neurophysiologically assessed function in myelinated and unmyelinated fibres and histologically examined supraorbital nerve biopsy specimens with optic and electron microscopy in 13 consecutive patients with recent onset trigeminal hypoesthesia and pain. Results: The disease course distinctly differed in the 13 patients. During a mean 10 year follow-up whereas in eight patients the disease remained relatively stable, in the other five it progressed to possibly life-threatening motor disturbances and extra-trigeminal spread. From two to six years elapsed between the first sensory symptoms and the onset of motor disorders. In patients with trigeminal isolated sensory neuropathy (TISN) and in those with FOSMN neurophysiological and histological examination documented a neuronopathy manifesting with trigeminal nerve damage selectively affecting myelinated fibres, but sparing the Ia-fibre-mediated proprioceptive reflex. Conclusions: Although no clinical diagnostic criteria can distinguish the two conditions at onset, neurophysiological and nerve-biopsy findings specify that in both disorders trigeminal nerve damage manifests as a dissociated neuronopathy affecting myelinated and sparing unmyelinated fibres, thus suggesting similar pathophysiological mechanisms. KW - amyotrophic-lateral-sclerosis KW - atrophy Kennedys-disease KW - trigeminal nerve KW - neuronopathy KW - trigeminal neuropathy KW - FOSMN KW - facial pain KW - Sjorgens-syndrome KW - reflex KW - afferents KW - neuralgia KW - pathways KW - humans KW - fibers Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-114249 SN - 1471-2377 VL - 14 ER - TY - JOUR A1 - Gessler, Florian A1 - Lehmann, Felix A1 - Bösel, Julian A1 - Fuhrer, Hannah A1 - Neugebauer, Hermann A1 - Wartenberg, Katja E. A1 - Wolf, Stefan A1 - Bernstock, Joshua D. A1 - Niesen, Wolf-Dirk A1 - Schuss, Patrick T1 - Triage and Allocation of Neurocritical Care Resources During the COVID 19 Pandemic - A National Survey JF - Frontiers in Neurology N2 - Objective: In light of the ongoing COVID-19 pandemic and the associated hospitalization of an overwhelming number of ventilator-dependent patients, medical and/or ethical patient triage paradigms have become essential. While guidelines on the allocation of scarce resources do exist, such work within the subdisciplines of intensive care (e.g., neurocritical care) remains limited. Methods: A 16-item questionnaire was developed that sought to explore/quantify the expert opinions of German neurointensivists with regard to triage decisions. The anonymous survey was conducted via a web-based platform and in total, 96 members of the Initiative of German Neurointensive Trial Engagement (IGNITE)-study group were contacted via e-mail. The IGNITE consortium consists of an interdisciplinary panel of specialists with expertise in neuro-critical care (i.e., anesthetists, neurologists and neurosurgeons). Results: Fifty members of the IGNITE consortium responded to the questionnaire; in total the respondents were in charge of more than 500 Neuro ICU beds throughout Germany. Common determinants reported which affected triage decisions included known patient wishes (98%), the state of health before admission (96%), SOFA-score (85%) and patient age (69%). Interestingly, other principles of allocation, such as a treatment of “youngest first” (61%) and members of the healthcare sector (50%) were also noted. While these were the most accepted parameters affecting the triage of patients, a “first-come, first-served” principle appeared to be more accepted than a lottery for the allocation of ICU beds which contradicts much of what has been reported within the literature. The respondents also felt that at least one neurointensivist should serve on any interdisciplinary triage team. Conclusions: The data gathered in the context of this survey reveal the estimation/perception of triage algorithms among neurointensive care specialists facing COVID-19. Further, it is apparent that German neurointensivists strongly feel that they should be involved in any triage decisions at an institutional level given the unique resources needed to treat patients within the Neuro ICU. KW - COVID-19 KW - SARS-CoV KW - pandemic KW - patient triage KW - neurocritical care Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-221593 SN - 1664-2295 VL - 11 ER - TY - JOUR A1 - Baum, Petra A1 - Koj, Severin A1 - Klöting, Nora A1 - Blüher, Matthias A1 - Classen, Joseph A1 - Paeschke, Sabine A1 - Gericke, Martin A1 - Toyka, Klaus V. A1 - Nowicki, Marcin A1 - Kosacka, Joanna T1 - Treatment-induced neuropathy in diabetes (TIND) — Developing a disease model in type 1 diabetic rats JF - International Journal of Molecular Sciences N2 - Treatment-induced neuropathy in diabetes (TIND) is defined by the occurrence of an acute neuropathy within 8 weeks of an abrupt decrease in glycated hemoglobin-A1c (HbA1c). The underlying pathogenic mechanisms are still incompletely understood with only one mouse model being explored to date. The aim of this study was to further explore the hypothesis that an abrupt insulin-induced fall in HbA1c may be the prime causal factor of developing TIND. BB/OKL (bio breeding/OKL, Ottawa Karlsburg Leipzig) diabetic rats were randomized in three groups, receiving insulin treatment by implanted subcutaneous osmotic insulin pumps for 3 months, as follows: Group one received 2 units per day; group two 1 unit per day: and group three 1 unit per day in the first month, followed by 2 units per day in the last two months. We serially examined blood glucose and HbA1c levels, motor- and sensory/mixed afferent conduction velocities (mNCV and csNCV) and peripheral nerve morphology, including intraepidermal nerve fiber density and numbers of Iba-1 (ionized calcium binding adaptor molecule 1) positive macrophages in the sciatic nerve. Only in BB/OKL rats of group three, with a rapid decrease in HbA1c of more than 2%, did we find a significant decrease in mNCV in sciatic nerves (81% of initial values) after three months of treatment as compared to those group three rats with a less marked decrease in HbA1c <2% (mNCV 106% of initial values, p ≤ 0.01). A similar trend was observed for sensory/mixed afferent nerve conduction velocities: csNCV were reduced in BB/OKL rats with a rapid decrease in HbA1c >2% (csNCV 90% of initial values), compared to those rats with a mild decrease <2% (csNCV 112% of initial values, p ≤ 0.01). Moreover, BB/OKL rats of group three with a decrease in HbA1c >2% showed significantly greater infiltration of macrophages by about 50% (p ≤ 0.01) and a decreased amount of calcitonin gene related peptide (CGRP) positive nerve fibers as compared to the animals with a milder decrease in HbA1c. We conclude that a mild acute neuropathy with inflammatory components was induced in BB/OKL rats as a consequence of an abrupt decrease in HbA1c caused by high-dose insulin treatment. This experimentally induced neuropathy shares some features with TIND in humans and may be further explored in studies into the pathogenesis and treatment of TIND. KW - BB/OKL rats KW - peripheral neuropathy KW - sciatic nerve KW - TIND KW - Type 1 diabetes Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-285793 SN - 1422-0067 VL - 22 IS - 4 ER - TY - JOUR A1 - Bieber, Michael A1 - Foerster, Kathrin I. A1 - Haefeli, Walter E. A1 - Pham, Mirko A1 - Schuhmann, Michael K. A1 - Kraft, Peter T1 - Treatment with edoxaban attenuates acute stroke severity in mice by reducing blood–brain barrier damage and inflammation JF - International Journal of Molecular Sciences N2 - Patients with atrial fibrillation and previous ischemic stroke (IS) are at increased risk of cerebrovascular events despite anticoagulation. In these patients, treatment with non-vitamin K oral anticoagulants (NOAC) such as edoxaban reduced the probability and severity of further IS without increasing the risk of major bleeding. However, the detailed protective mechanism of edoxaban has not yet been investigated in a model of ischemia/reperfusion injury. Therefore, in the current study we aimed to assess in a clinically relevant setting whether treatment with edoxaban attenuates stroke severity, and whether edoxaban has an impact on the local cerebral inflammatory response and blood–brain barrier (BBB) function after experimental IS in mice. Focal cerebral ischemia was induced by transient middle cerebral artery occlusion in male mice receiving edoxaban, phenprocoumon or vehicle. Infarct volumes, functional outcome and the occurrence of intracerebral hemorrhage were assessed. BBB damage and the extent of local inflammatory response were determined. Treatment with edoxaban significantly reduced infarct volumes and improved neurological outcome and BBB function on day 1 and attenuated brain tissue inflammation. In summary, our study provides evidence that edoxaban might exert its protective effect in human IS by modulating different key steps of IS pathophysiology, but further studies are warranted. KW - edoxaban KW - thrombo-inflammation KW - blood–brain barrier KW - tMCAO KW - experimental stroke KW - hemorrhagic transformation KW - NOAC Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-284481 SN - 1422-0067 VL - 22 IS - 18 ER - TY - JOUR A1 - Ablin, Jacob A1 - Fitzcharles, Mary-Ann A1 - Buskila, Dan A1 - Shir, Yoram A1 - Sommer, Claudia A1 - Häuser, Winfried T1 - Treatment of Fibromyalgia Syndrome: Recommendations of Recent Evidence-Based Interdisciplinary Guidelines with Special Emphasis on Complementary and Alternative Therapies JF - Evidence-Bayed Complementary and Alternative Medicine N2 - Objective. Current evidence indicates that there is no single ideal treatment for fibromyalgia syndrome (FMS). First choice treatment options remain debatable, especially concerning the importance of complementary and alternative medicine (CAM) treatments. Methods. Three evidence-based interdisciplinary guidelines on FMS in Canada, Germany, and Israel were compared for their first choice and CAM-recommendations. Results. All three guidelines emphasized a patient-tailored approach according to the key symptoms. Aerobic exercise, cognitive behavioral therapy, and multicomponent therapy were first choice treatments. The guidelines differed in the grade of recommendation for drug treatment. Anticonvulsants (gabapentin, pregabalin) and serotonin noradrenaline reuptake inhibitors (duloxetine, milnacipran) were strongly recommended by the Canadian and the Israeli guidelines. These drugs received only a weak recommendation by the German guideline. In consideration of CAM-treatments, acupuncture, hypnosis/guided imagery, and Tai Chi were recommended by the German and Israeli guidelines. The Canadian guidelines did not recommend any CAM therapy. Discussion. Recent evidence-based interdisciplinary guidelines concur on the importance of treatment tailored to the individual patient and further emphasize the need of self-management strategies (exercise, and psychological techniques). KW - metaanalysis KW - management KW - care Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-122235 SN - 1741-427X ER - TY - JOUR A1 - Walter, Maggie C. A1 - Reilich, Peter A1 - Thiele, Simone A1 - Schessl, Joachim A1 - Schreiber, Herbert A1 - Reiners, Karlheinz A1 - Kress, Wolfram A1 - Müller-Reible, Clemens A1 - Vorgerd, Matthias A1 - Urban, Peter A1 - Schrank, Bertold A1 - Deschauer, Marcus A1 - Schlotter-Weigel, Beate A1 - Kohnen, Ralf A1 - Lochmüller, Hans T1 - Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial JF - Orphanet Journal of Rare Diseases N2 - Background: Dysferlinopathies are autosomal recessive disorders caused by mutations in the dysferlin (DYSF) gene encoding the dysferlin protein. DYSF mutations lead to a wide range of muscular phenotypes, with the most prominent being Miyoshi myopathy (MM) and limb girdle muscular dystrophy type 2B (LGMD2B). Methods: We assessed the one-year-natural course of dysferlinopathy, and the safety and efficacy of deflazacort treatment in a double-blind, placebo-controlled cross-over trial. After one year of natural course without intervention, 25 patients with genetically defined dysferlinopathy were randomized to receive deflazacort and placebo for six months each (1 mg/kg/day in month one, 1 mg/kg every 2nd day during months two to six) in one of two treatment sequences. Results: During one year of natural course, muscle strength declined about 2% as measured by CIDD (Clinical Investigation of Duchenne Dystrophy) score, and 76 Newton as measured by hand-held dynamometry. Deflazacort did not improve muscle strength. In contrast, there is a trend of worsening muscle strength under deflazacort treatment, which recovers after discontinuation of the study drug. During deflazacort treatment, patients showed a broad spectrum of steroid side effects. Conclusion: Deflazacort is not an effective therapy for dysferlinopathies, and off-label use is not warranted. This is an important finding, since steroid treatment should not be administered in patients with dysferlinopathy, who may be often misdiagnosed as polymyositis. KW - Deflazacort KW - muscle strength KW - gridle muscular-dystrophy KW - Duchenne dystrphy KW - Miyoshi myopathy KW - mutation KW - prednisone KW - gene KW - 2B KW - children KW - design KW - steroids KW - therapy KW - dysferlinopathy KW - Limb girdle muscular dystrophy (LGMD) Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-125663 SN - 1750-1172 VL - 8 IS - 26 ER - TY - JOUR A1 - Lehrieder, Dominik A1 - Zapantis, Nikolaos A1 - Pham, Mirko A1 - Schuhmann, Michael Klaus A1 - Haarmann, Axel T1 - Treating seronegative neuromyelitis optica spectrum disorder with inebilizumab: a case report JF - Frontiers in Neurology N2 - Background Neuromyelitis optica spectrum disorder (NMOSD) is a devastating inflammatory disease of the central nervous system that is often severely disabling from the outset. The lack of pathognomonic aquaporin 4 (AQP4) antibodies in seronegative NMOSD not only hinders early diagnosis, but also limits therapeutic options, in contrast to AQP4 antibody-positive NMOSD, where the therapeutic landscape has recently evolved massively. Case presentation We report a 56-year-old woman with bilateral optic neuritis and longitudinally extensive myelitis as the index events of a seronegative NMOSD, who was successfully treated with inebilizumab. Conclusion Treatment with inebilizumab may be considered in aggressive seronegative NMOSD. Whether broader CD19-directed B cell depletion is more effective than treatment with rituximab remains elusive. KW - NMOSD KW - inebilizumab KW - AQP4 KW - longitudinally extensive transverse myelitis KW - optic neuritis KW - case report KW - CD19 KW - seronegative Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-354031 VL - 14 ER - TY - JOUR A1 - Binder, Andreas A1 - May, Denisa A1 - Baron, Ralf A1 - Maier, Christoph A1 - Tölle, Thomas R. A1 - Treede, Rolf-Detlef A1 - Berthele, Achim A1 - Faltraco, Frank A1 - Flor, Herta A1 - Gierthmühlen, Janne A1 - Haenisch, Sierk A1 - Huge, Volker A1 - Magerl, Walter A1 - Maihöfner, Christian A1 - Richter, Helmut A1 - Rolke, Roman A1 - Scherens, Andrea A1 - Üçeyler, Nurcan A1 - Ufer, Mike A1 - Wasner, Gunnar A1 - Zhu, Jihong A1 - Cascorbi, Ingolf T1 - Transient Receptor Potential Channel Polymorphisms Are Associated with the Somatosensory Function in Neuropathic Pain Patients JF - PLoS ONE N2 - Transient receptor potential channels are important mediators of thermal and mechanical stimuli and play an important role in neuropathic pain. The contribution of hereditary variants in the genes of transient receptor potential channels to neuropathic pain is unknown. We investigated the frequency of transient receptor potential ankyrin 1, transient receptor potential melastin 8 and transient receptor potential vanilloid 1 single nucleotide polymorphisms and their impact on somatosensory abnormalities in neuropathic pain patients. Within the German Research Network on Neuropathic Pain (Deutscher Forscbungsverbund Neuropathischer Schmerz) 371 neuropathic pain patients were phenotypically characterized using standardized quantitative sensory testing. Pyrosequencing was employed to determine a total of eleven single nucleotide polymorphisms in transient receptor potential channel genes of the neuropathic pain patients and a cohort of 253 German healthy volunteers. Associations of quantitative sensory testing parameters and single nucleotide polymorphisms between and within groups and subgroups, based on sensory phenotypes, were analyzed. Single nucleotide polymorphisms frequencies did not differ between both the cohorts. However, in neuropathic pain patients transient receptor potential ankyrin 1 710G>A (rs920829, E179K) was associated with the presence of paradoxical heat sensation (p=0.03), and transient receptor potential vanilloid 1 1911A>G (rs8065080, I585V) with cold hypoalgesia (p=0.0035). Two main subgroups characterized by preserved (1) and impaired (2) sensory function were identified. In subgroup 1 transient receptor potential vanilloid 1 1911A>G led to significantly less heat hyperalgesia, pinprick hyperalgesia and mechanical hypaesthesia (p=0.006, p=0.005 and p<0.001) and transient receptor potential vanilloid 1 1103C>G (rs222747, M315I) to cold hypaesthesia (p=0.002), but there was absence of associations in subgroup 2. In this study we found no evidence that genetic variants of transient receptor potential channels are involved in the expression of neuropathic pain, but transient receptor potential channel polymorphisms contributed significantly to the somatosensory abnormalities of neuropathic pain patients. KW - Paradoxical heat sensation KW - Neurogenic inflammation KW - Capsaicin receptor KW - TRP Channels KW - Cold KW - Mechanisms KW - Hyperalgesia KW - Sensitivity KW - Expression KW - Stimuli Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-142782 VL - 6 IS - 3 ER - TY - JOUR A1 - Hartmannsberger, Beate A1 - Scriba, Sabrina A1 - Guidolin, Carolina A1 - Becker, Juliane A1 - Mehling, Katharina A1 - Doppler, Kathrin A1 - Sommer, Claudia A1 - Rittner, Heike L. T1 - Transient immune activation without loss of intraepidermal innervation and associated Schwann cells in patients with complex regional pain syndrome JF - Journal of Neuroinflammation N2 - Background Complex regional pain syndrome (CRPS) develops after injury and is characterized by disproportionate pain, oedema, and functional loss. CRPS has clinical signs of neuropathy as well as neurogenic inflammation. Here, we asked whether skin biopsies could be used to differentiate the contribution of these two systems to ultimately guide therapy. To this end, the cutaneous sensory system including nerve fibres and the recently described nociceptive Schwann cells as well as the cutaneous immune system were analysed. Methods We systematically deep-phenotyped CRPS patients and immunolabelled glabrous skin biopsies from the affected ipsilateral and non-affected contralateral finger of 19 acute (< 12 months) and 6 chronic (> 12 months after trauma) CRPS patients as well as 25 sex- and age-matched healthy controls (HC). Murine foot pads harvested one week after sham or chronic constriction injury were immunolabelled to assess intraepidermal Schwann cells. Results Intraepidermal Schwann cells were detected in human skin of the finger—but their density was much lower compared to mice. Acute and chronic CRPS patients suffered from moderate to severe CRPS symptoms and corresponding pain. Most patients had CRPS type I in the warm category. Their cutaneous neuroglial complex was completely unaffected despite sensory plus signs, e.g. allodynia and hyperalgesia. Cutaneous innate sentinel immune cells, e.g. mast cells and Langerhans cells, infiltrated or proliferated ipsilaterally independently of each other—but only in acute CRPS. No additional adaptive immune cells, e.g. T cells and plasma cells, infiltrated the skin. Conclusions Diagnostic skin punch biopsies could be used to diagnose individual pathophysiology in a very heterogenous disease like acute CRPS to guide tailored treatment in the future. Since numbers of inflammatory cells and pain did not necessarily correlate, more in-depth analysis of individual patients is necessary. KW - complex regional pain syndrome KW - IENFD KW - nociceptive Schwann cells KW - mast cells KW - Langerhans cells KW - tissue resident T cells KW - dermal B cells KW - skin punch biopsy KW - chronic constriction nerve injury Y1 - 2024 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-357164 VL - 21 ER - TY - JOUR A1 - Ip, Chi Wang A1 - Isaias, Ioannis U. A1 - Kusche-Tekin, Burak B. A1 - Klein, Dennis A1 - Groh, Janos A1 - O´Leary, Aet A1 - Knorr, Susanne A1 - Higuchi, Takahiro A1 - Koprich, James B. A1 - Brotchie, Jonathan M. A1 - Toyka, Klaus V. A1 - Reif, Andreas A1 - Volkmann, Jens T1 - Tor1a+/- mice develop dystonia-like movements via a striatal dopaminergic dysregulation triggered by peripheral nerve injury JF - Acta Neuropathologica Communications N2 - Isolated generalized dystonia is a central motor network disorder characterized by twisted movements or postures. The most frequent genetic cause is a GAG deletion in the Tor1a (DYT1) gene encoding torsinA with a reduced penetrance of 30-40 % suggesting additional genetic or environmental modifiers. Development of dystonia-like movements after a standardized peripheral nerve crush lesion in wild type (wt) and Tor1a+/- mice, that express 50 % torsinA only, was assessed by scoring of hindlimb movements during tail suspension, by rotarod testing and by computer-assisted gait analysis. Western blot analysis was performed for dopamine transporter (DAT), D1 and D2 receptors from striatal and quantitative RT-PCR analysis for DAT from midbrain dissections. Autoradiography was used to assess the functional DAT binding in striatum. Striatal dopamine and its metabolites were analyzed by high performance liquid chromatography. After nerve crush injury, we found abnormal posturing in the lesioned hindlimb of both mutant and wt mice indicating the profound influence of the nerve lesion (15x vs. 12x relative to control) resembling human peripheral pseudodystonia. In mutant mice the phenotypic abnormalities were increased by about 40 % (p < 0.05). This was accompanied by complex alterations of striatal dopamine homeostasis. Pharmacological blockade of dopamine synthesis reduced severity of dystonia-like movements, whereas treatment with L-Dopa aggravated these but only in mutant mice suggesting a DYT1 related central component relevant to the development of abnormal involuntary movements. Our findings suggest that upon peripheral nerve injury reduced torsinA concentration and environmental stressors may act in concert in causing the central motor network dysfunction of DYT1 dystonia. KW - Dystonia KW - DYT1 KW - dopamine KW - peripheral injury KW - second hit Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-147839 VL - 4 IS - 108 ER - TY - JOUR A1 - Odorfer, Thorsten M. A1 - Yabe, Marie A1 - Hiew, Shawn A1 - Volkmann, Jens A1 - Zeller, Daniel T1 - Topological differences and confounders of mental rotation in cervical dystonia and blepharospasm JF - Scientific Reports N2 - Mental rotation (mR) bases on imagination of actual movements. It remains unclear whether there is a specific pattern of mR impairment in focal dystonia. We aimed to investigate mR in patients with cervical dystonia (CD) and blepharospasm (BS) and to assess potential confounders. 23 CD patients and 23 healthy controls (HC) as well as 21 BS and 19 hemifacial spasm (HS) patients were matched for sex, age, and education level. Handedness, finger dexterity, general reaction time, and cognitive status were assessed. Disease severity was evaluated by clinical scales. During mR, photographs of body parts (head, hand, or foot) and a non-corporal object (car) were displayed at different angles rotated within their plane. Subjects were asked to judge laterality of the presented image by keystroke. Both speed and correctness were evaluated. Compared to HC, CD and HS patients performed worse in mR of hands, whereas BS group showed comparable performance. There was a significant association of prolonged mR reaction time (RT) with reduced MoCA scores and with increased RT in an unspecific reaction speed task. After exclusion of cognitively impaired patients, increased RT in the mR of hands was confined to CD group, but not HS. While the question of whether specific patterns of mR impairment reliably define a dystonic endophenotype remains elusive, our findings point to mR as a useful tool, when used carefully with control measures and tasks, which may be capable of identifying specific deficits that distinguish between subtypes of dystonia. KW - neurology KW - neuroscience Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-357713 VL - 13 ER - TY - JOUR A1 - Langhauser, Friederike L. A1 - Heiler, Patrick M. A1 - Grudzenski, Saskia A1 - Lemke, Andreas A1 - Alonso, Angelika A1 - Schad, Lothar R. A1 - Hennerici, Michael G. A1 - Meairs, Stephen A1 - Fata, Marc T1 - Thromboembolic stroke in C57BL/6 mice monitored by 9.4 T MRI using a 1H cryo probe JF - Experimental and Translational Stroke Medicine N2 - Background A new thromboembolic animal model showed beneficial effects of t-PA with an infarct volume reduction of 36.8% in swiss mice. Because knock-out animal experiments for stroke frequently used C57BL76 mice we evaluated t-PA effects in this mouse strain and measured infarct volume and vascular recanalisation in-vivo by using high-field 9.4 T MRI and a 1H surface cryo coil. Methods Clot formation was triggered by microinjection of murine thrombin into the right middle cerebral artery (MCA). Animals (n = 28) were treated with 10 mg/kg, 5 mg/kg or no tissue plasminogen activator (t-PA) 40 min after MCA occlusion. For MR-imaging a Bruker 9.4 T animal system with a 1H surface cryo probe was used and a T2-weighted RARE sequence, a diffusion weighted multishot EPI sequence and a 3D flow-compensated gradient echo TOF angiography were performed. Results The infarct volume in animals treated with t-PA was significantly reduced (0.67 ± 1.38 mm3 for 10 mg/kg and 10.9 ± 8.79 mm3 for 5 mg/kg vs. 19.76 ± 2.72 mm3 ; p < 0.001) compared to untreated mice. An additional group was reperfused with t-PA inside the MRI. Already ten minutes after beginning of t-PA treatment, reperfusion flow was re-established in the right MCA. However, signal intensity was lower than in the contralateral MCA. This reduction in cerebral blood flow was attenuated during the first 60 minutes after reperfusion. 24 h after MCA occlusion and reperfusion, no difference in signal intensity of the contralateral and ipsilateral MCAs was observed. Conclusions We confirm a t-Pa effect using this stroke model in the C57BL76 mouse strain and demonstrate a chronological sequence MRI imaging after t-PA using a 1H surface cryo coil in a 9.4 T MRI. This setting will allow testing of new thrombolytic strategies for stroke treatment in-vivo in C57BL76 knock-out mice. KW - animal models KW - MRI KW - experimental KW - embolic stroke KW - T-PA Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-124218 VL - 4 IS - 18 ER - TY - JOUR A1 - Kraft, Peter A1 - Schwarz, Tobias A1 - Meijers, Joost C. M. A1 - Stoll, Guido A1 - Kleinschnitz, Christoph T1 - Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) Deficient Mice Are Susceptible to Intracerebral Thrombosis and Ischemic Stroke N2 - Background: Thrombus formation is a key step in the pathophysiology of acute ischemic stroke and results from the activation of the coagulation cascade. Thrombin plays a central role in this coagulation system and contributes to thrombus stability via activation of thrombin-activatable fibrinolysis inhibitor (TAFIa). TAFIa counteracts endogenous fibrinolysis at different stages and elevated TAFI levels are a risk factor for thrombotic events including ischemic stroke. Although substantial in vitro data on the influence of TAFI on the coagulation-fibrinolysis-system exist, investigations on the consequences of TAFI inhibition in animal models of cerebral ischemia are still lacking. In the present study we analyzed stroke development and post stroke functional outcome in TAFI-/- mice. Methodology/Principal Findings: TAFI-/- mice and wild-type controls were subjected to 60 min transient middle cerebral artery occlusion (tMCAO) using the intraluminal filament method. After 24 hours, functional outcome scores were assessed and infarct volumes weremeasured from 2,3,5-Triphenyltetrazoliumchloride (TTC)-stained brain slices. Hematoxylin and eosin (H&E) staining was used to estimate the extent of neuronal cell damage. Thrombus formation within the infarcted brain areas was analyzed by immunoblot. Infarct volumes and functional outcomes did not significantly differ between TAFI-/- mice and controls (p.0.05). Histology revealed extensive ischemic neuronal damage regularly including the cortex and the basal ganglia in both groups. TAFI deficiency also had no influence on intracerebral fibrin(ogen) formation after tMCAO. Conclusion: Our study shows that TAFI does not play a major role for thrombus formation and neuronal degeneration after ischemic brain challenge. KW - Thrombus Y1 - 2010 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-68519 ER - TY - THES A1 - Töppner, Verena T1 - Therapie und Outcome von Patienten mit aneurysmatischer Subarachnoidalblutung am Universitätsklinikum Würzburg T1 - Therapy and outcome of patients with aneurysmal subarachnoid haemorrhage at the university hospital Würzburg N2 - Die aneurysmatische SAB ist trotz etablierter Therapieverfahren (Coiling und Clipping) weiterhin ein Krankheitsbild mit hoher Mortalität. In unserer Arbeit haben wir retrospektiv die Patientenakten der Patienten, die mit der Diagnose aneurysmatische SAB am Universitätsklinikum Würzburg zwischen dem 01.01.1999 und dem 31.12.2009 aufgenommen wurden, ausgewertet. Es konnte dargestellt werden das als Hauptrisikofaktoren für ein schlechtes Therapieergebnis ein schlechter Aufnahmestatus des Patienten und das Auftreten von Komplikationen im Verlauf verantwortlich sind. N2 - The aneurysmal SAH is still, despite well-established therapeutic methods (Coiling and Clipping), a disease with a high rate of mortality. Our study did a retrospective research on the data of patients who have been hospitalized with the diagnosis of aneurysmal subarachnoid haemorrhage between 01.01.1999 and. 31.12.2009 at the university hospital Würzburg. We could define a bad neurological status at admission and the occurrence of complications as the major risk factors for a bad neurological outcome. KW - Subarachnoidalblutung KW - Aneurysma Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-209129 ER - TY - THES A1 - Ramthor, Mathias T1 - Therapeutischer Einfluß von zwei Antidepressiva auf das Schmerzverhalten von Ratten mit einer chronischen Konstriktionsläsion des N. ischiadicus T1 - Therapeutic Effect of Two Antidepressants on Pain-Related Behaviour of Rats With a Chronic Constriction Injury of The Sciatic Nerve N2 - In dieser Arbeit sollte an weiblichen Sprague Dawley Ratten untersucht werden, ob sich durch die Antidepressiva Amitriptylin und Venlafaxin Schmerzverhalten nach Nervenläsion verringern läßt und wenn ja, welche Mechanismen dieser Wirkung zugrunde liegen. Den Tieren wurde einseitig der N. ischiadicus nach dem Nervenläsionsmodell der Chronic-Constriction-Injury (CCI) operiert. Das Schmerzverhalten der mit Antidepressiva behandelten Tiere wurde über zwei bis drei Wochen verblindet im Vergleich mit plazebobehandelten Tieren untersucht. Das Ausmaß von Hitzehyperalgesie und taktiler Allodynie wurde durch die Anwendung etablierter Testverfahren quantifiziert. Amitriptylin hatte in der Dosis von zweimal täglich 10 mg/kg KG i.p. keinen relevanten Effekt auf das Schmerzverhalten der Tiere. Eine akute Gabe von Amitriptylin bei Tieren, die zuvor über 19 Tage chronisch mit Amitriptylin behandelt worden waren, reduzierte die taktile Allodynie geringgradig und hatte keinen Einfluß auf die Hitzehyperalgesie. Venlafaxin in der Dosis von zweimal täglich 25 mg/kg KG p.o. reduzierte in einigen Teilversuchen mäßiggradig die Hitzehyperalgesie und die taktile Allodynie nach CCI. Auf diesen Ergebnissen aufbauend wurde versucht, die Wirkung der chronischen Venlafaxin-Medikation durch Kombination mit zusätzlich akut verabreichten alpha-adrenergen- bzw. µ-Opiat-Rezeptor-agonistischen Substanzen zu verstärken. Die Kombination von Venlafaxin mit dem alpha-2A-Rezeptoragonisten Clonidin ergab eine Wirkungsverstärkung in Bezug auf die Reduktion der Hitzehyperalgesie, wobei sich zusätzlich eine Eigenwirkung von Clonidin nachweisen ließ. Der µ-Opiat-Rezeptor-Agonist Morphin führte hingegen zu keiner signifikanten Wirkungsverstärkung in Kombination mit Venlafaxin. Im Anschluß an die jeweilige Testreihe wurde den Tieren Nervengewebe entnommen, welches nach immunhistochemischer Färbung für alpha-2A- und µ-Rezeptoren morphometrisch evaluiert wurde. Dies diente der Untersuchung der Hypothese, daß den o.g. Wirkungen eine Vermehrung der entsprechenden Rezeptoren bei Venlafaxin-behandelten Tieren zugrunde lag. Die chronische postoperative Gabe von Venlafaxin hatte keinen Einfluß auf die Anzahl von alpha-2A-Rezeptor-immunreaktiven Neuronen im Spinalganglion CCI-operierter Ratten. Allerdings ließ sich unter der Medikation die Immunreaktivität für alpha-2A-Rezeptoren vermehrt in großkalibrigen Spinalganglienneuronen nachweisen. Die chronische postoperative Gabe von Venlafaxin führte zudem zu einer Zunahme von µ-Opiat-Rezeptoren im ipsilateralen N. ischiadicus CCI-operierter Ratten. Im Spinalganglion ergab sich nach Venlafaxinbehandlung keine Veränderung der Anzahl der µ-Rezeptor-immunreaktiven Neurone. Allerdings konnte durch chronische Venlafaxin-Medikation eine Phänotyp-Verschiebung mit Auftreten von µ-Rezeptor-Immunreaktivität in großkalibrigen Neuronen, wie sie nach CCI ohne Venlafaxinbehandlung auftrat, verhindert werden. Die Ergebnisse der Arbeit zeigen, daß die chronische, zweimal tägliche Anwendung der Antidepressiva Amitriptylin und Venlafaxin das Schmerz-assoziierte Verhalten von Ratten nach einer peripheren Nervenläsion inkonstant und nur in unzureichendem Ausmaß beeinflussen. Unabhängig davon wurden in den immunhistochemischen Untersuchungen Veränderungen in der Verteilung µ- und alpha-adrenerger Rezeptoren in Spinalganglionzellen und Ischiasnerv beobachtet, die auf eine kontinuierliche Venlafaxin-Medikation zurückzuführen zu sein scheinen. Berücksichtigt man vor diesem Hintergrund die Tatsache, daß sich die Venlafaxinwirkung durch den alpha-2A-Agonisten Clonidin verstärken ließ, so bieten diese Zusammenhänge eine mögliche Erklärung für die zugrundeliegenden Mechanismen der Wirkungsvermittlung von Antidepressiva in der Behandlung einer schmerzhaften Mononeuropathie. N2 - The main intention of the present study was to show if administration of the antidepressants amitriptyline and venlafaxine possibly alters pain-related behaviour of Sprague-Dawley rats with an experimental peripheral mononeuropathy. The possible underlying mechanisms of such action were of further interest and therefore investigated. All animals were inflicted an experimental mononeuropathy on sciatic nerve according to the Chronic-Constriction-Injury-Model (CCI) as described by Bennett and Xie. The resulting pain-related behaviour - such as allodynia and hyperalgesia - was quantified by established test-procedures with antidepressant-treated rats tested against placebo-treated animals over a time-course of two to three weeks. Chronic administration of amitriptyline, at a dose of 10 mg/kg bodyweight i.p. twice daily, showed no effect on pain-related behaviour of rats; whereas an additional acute booster-dose on postoperative day 19 reduced tactile allodynia in a significant manner in this setup. Chronic distribution of venlafaxine - at 25 mg/kg bodyweight, p.o. twice daily - reduced heat-hyperalgesia and tactile allodynia in the CCI-model moderately in a few of the carried out experiments. Expecting enhanced effectiveness chronic therapy with venlafaxine was combined with acute administration of alpha-adrenergic- or µ-opiate-receptor-agonists. Combination of venlafaxine with clonidine – an alpha-2A-receptor-agonist – showed an enhanced reduction of heat-hyperalgesia in CCI-operated rats compared to monotherapy as well as an effectiveness of clonidine alone. Contrarily, combination of venlafaxine with µ-opiate-receptor-agonist morphine showed no enhancement of analgesia. Following each experimental setup nerve-tissue of the used animals was obtained and microscopically evaluated after immunhistochemical staining for alpha-2A- and µ-opiate-receptors. This approach was meant to verify the hypothesis that attenuation of neuropathic-pain by venlafaxine may be due to mechanisms including quantitative alterations in alpha-adrenergic- or opiate-receptor-quantity. Chronic administration of venlafaxine showed no quantitative impact on alpha-2A-receptor-immunoreactivity in neurons of the dorsal-root-ganglion (DRG) of CCI-operated rats, but immunoreactivity showed an remarkable shift towards neurons with a wider caliber. Furthermore chronic administration of venlafaxine led to a quantitative increase in µ-opiate-receptor-immunoreactivity in ipsilateral sciatic nerve of CCI-operated rats. Also no such quantitative alterations in receptor-immunoreactivity could be shown for DRG-neurons, phenotype-switch towards neurons of wide caliber - as seen in ipsilateral DRG of untreated CCI-rats – was apparently prevented by chronic administration of venlafaxine. In total this experimental study showed that the chronic, twice daily administration of the antidepressant drugs amitriptyline and venlafaxine has an inconstant and dissatifying effect on attenuating pain-related behaviour of CCI-operated rats. Irrespective from these results immunhistochemical staining of peripheral nerve-tissue and DRG showed alterations in the allocation of µ- and alpha-adrenergic-receptor-immunoreactivity which tended to be dependent on precedent venlafaxine-administration. Bearing in mind aforementioned enhancement of venlafaxine-effectiveness by coadministration of clonidine, one could presume that said implications may be a possible explanation for a mechanism of antidepressant action in alleviating pain in an experimental peripheral mononeuropathy. KW - Neuropathie KW - Schmerz KW - CCI KW - Amitriptylin KW - Venlafaxin KW - Neuropathy KW - pain KW - CCI KW - amitriptyline KW - venlafaxine Y1 - 2007 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-23739 ER - TY - THES A1 - Karl, Franziska T1 - The role of miR-21 in the pathophysiology of neuropathic pain using the model of B7-H1 knockout mice T1 - Die Rolle von miR-21 in der Pathophysiologie von neuropathischem Schmerz am Model der B7-H1 defizienten Maus N2 - The impact of microRNA (miRNA) as key players in the regulation of immune and neuronal gene expression and their role as master switches in the pathophysiology of neuropathic pain is increasingly recognized. miR-21 is a promising candidate that could be linked to the immune and the nociceptive system. To further investigate the pathophysiological role of miR-21 in neuropathic pain, we assesed mice deficient of B7 homolog 1 (B7-H1 ko), a protein with suppressive effect on inflammatory responses. B7-H1 ko mice and wildtype littermates (WT) of three different age-groups, young (8 weeks), middle-aged (6 months), and old (12 months) received a spared nerve injury (SNI). Thermal withdrawal latencies and mechanical withdrawal thresholds were determined. Further, we investigated anxiety-, depression-like and cognitive behavior. Quantitative real time PCR was used to determine miR-21 relative expression in peripheral nerves, dorsal root ganglia and white blood cells (WBC) at distinct time points after SNI. Naïve B7-H1 ko mice showed mechanical hyposensitivity with increasing age. Young and middle-aged B7-H1 ko mice displayed lower mechanical withdrawal thresholds compared to WT mice. From day three after SNI both genotypes developed mechanical and heat hypersensitivity, without intergroup differences. As supported by the results of three behavioral tests, no relevant differences were found for anxiety-like behavior after SNI in B7-H1 ko and WT mice. Also, there was no indication of depression-like behavior after SNI or any effect of SNI on cognition in both genotypes. The injured nerves of B7-H1 ko and WT mice showed higher miR-21 expression and invasion of macrophages and T cells 7 days after SNI without intergroup differences. Perineurial miR-21 inhibitor injection reversed SNI-induced mechanical and heat hypersensitivity in old B7-H1 ko and WT mice. This study reveals that reduced mechanical thresholds and heat withdrawal latencies are associated with miR-21 induction in the tibial and common peroneal nerve after SNI, which can be reversed by perineurial injection of a miR-21 inhibitor. Contrary to expectations, miR-21 expression levels were not higher in B7-H1 ko compared to WT mice. Thus, the B7-H1 ko mouse may be of minor importance for the study of miR-21 related pain. However, these results spot the contribution of miR-21 in the pathophysiology of neuropathic pain and emphasize the crucial role of miRNA in the regulation of neuronal and immune circuits that contribute to neuropathic pain. N2 - Die Beteiligung von microRNA (miRNA) an der Genregulation immunologischer und neuronaler Prozesse und deren Rolle als Schlüsselelement in der Pathophysiologie von neuropathischem Schmerz gewinnt zunehmend an Bedeutung. miR-21 ist ein vielversprechender Kandidat, der sowohl das Immunsystem, als auch das nozizeptive System beeinflusst. Um die pathophysiologische Rolle von miR-21 bei neuropathischem Schmerz besser zu verstehen wurden Mäuse mit B7 homolog 1 Defizienz (B7-H1 ko), einem immunsupprimierendem Protein, untersucht. Eine frühere Studie zeigte eine Hochregulierung von miR-21 in murinen Lymphozyten. Junge (8 Wochen), mittelalte (6 Monate) und alte (12 Monate) B7-H1 ko Mäuse und Wildtypwurfgeschwister (WT) erhielten eine spared nerve injury (SNI) als neuropathischem Schmerzmodell. Es wurden thermische Rückzugslatenzen und mechanische Rückzugsschwellen bestimmt. Des weiteren wurde sowohl das Angstverhalten, das depressive Verhalten, als auch das kognitive Verhalten untersucht. Um die relative Expression von miR-21 in den peripheren Nerven, den Spinalganglien und in den weißen Blutzellen zu verschiedenen Zeitpunkten zu bestimmen, wurde die quantitative real time PCR angewandt. Naive B7-H1 ko Mäuse zeigten mit zunehmendem Alter eine mechanische Hyposensitivität. Bereits 3 Tage nach SNI entwickelten beide Genotypen eine Überempfindlichkeit gegenüber Hitze und mechanischer Stimulation. In drei durchgeführten Verhaltenstests konnten keine relevanten Unterschiede im Angstverhalten nach SNI von B7-H1 ko und WT Mäusen festgestellt werden. Bei beiden Genotypen gab es weder Hinweise auf depressives Verhalten nach SNI, noch wurde das kognitive Verhalten durch SNI beeinträchtigt. Die verletzen Nerven der B7-H1 ko und WT Mäuse zeigten 7 Tage nach SNI eine höhere miR-21 Expression und eine Invasion durch Makrophagen und T-Zellen ohne Gruppenunterschiede. Die perineurale Injektion eines miR-21 Inhibitors konnte die durch SNI induzierte mechanische und thermische Hypersensitivität lindern. Diese Studie zeigt, dass der Anstieg von miR-21 im N. tibialis und N. peroneus communis mit reduzierten Rückzugsschwellen gegen mechanische Reize und verkürzten Wegzugslatenzen bei Hitzestimulation einhergeht, welche durch perineurale Injektion eines miR-21 Inhibitors verringert werden können. Entgegen der Erwartungen zeigten B7-H1 ko Mäuse im Vergleich zu WT Mäusen keine erhöhte miR-21 Expression und sind daher möglicherweise von geringer Bedeutung für die Untersuchung von miR-21 assoziiertem Schmerz. Jedoch bekräftigen diese Ergebnisse eine Beteiligung von miR-21 an der Pathophysiologie von neuropathischem Schmerz und bestätigen die wichtige Rolle von miRNA bei der Regulation von neuronalen und immunologischen Prozessen, die zu neuropathischem Schmerz beitragen. KW - neuropathic pain KW - inflammation KW - B7-H1 KW - immune system KW - neuropathic pain KW - miRNA KW - miR-21 Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-156004 ER - TY - JOUR A1 - Ding, Hao A1 - Seusing, Nelly A1 - Nasseroleslami, Bahman A1 - Anwar, Abdul Rauf A1 - Strauss, Sebastian A1 - Lotze, Martin A1 - Grothe, Matthias A1 - Groppa, Sergiu A1 - Muthuraman, Muthuraman T1 - The role of ipsilateral motor network in upper limb movement JF - Frontiers in Physiology N2 - The execution of voluntary movements is primarily governed by the cerebral hemisphere contralateral to the moving limb. Previous research indicates that the ipsilateral motor network, comprising the primary motor cortex (M1), supplementary motor area (SMA), and premotor cortex (PM), plays a crucial role in the planning and execution of limb movements. However, the precise functions of this network and its interplay in different task contexts have yet to be fully understood. Twenty healthy right-handed participants (10 females, mean age 26.1 ± 4.6 years) underwent functional MRI scans while performing biceps brachii representations such as bilateral, unilateral flexion, and bilateral flexion-extension. Ipsilateral motor evoked potentials (iMEPs) were obtained from the identical set of participants in a prior study using transcranial magnetic stimulation (TMS) targeting M1 while employing the same motor tasks. The voxel time series was extracted based on the region of interest (M1, SMA, ventral PM and dorsal PM). Directed functinal connectivity was derived from the extracted time series using time-resolved partial directed coherence. We found increased connectivity from left-PMv to both sides M1, as well as right-PMv to both sides SMA, in unilateral flexion compared to bilateral flexion. Connectivity from left M1 to left-PMv, and left-SMA to right-PMd, also increased in both unilateral flexion and bilateral flexion-extension compared to bilateral flexion. However, connectivity between PMv and right-M1 to left-PMd decreased during bilateral flexion-extension compared to unilateral flexion. Additionally, during bilateral flexion-extension, the connectivity from right-M1 to right-SMA had a negative relationship with the area ratio of iMEP in the dominant side. Our results provide corroborating evidence for prior research suggesting that the ipsilateral motor network is implicated in the voluntary movements and underscores its involvement in cognitive processes such as movement planning and coordination. Moreover, ipsilateral connectivity from M1 to SMA on the dominant side can modulate the degree of ipsilateral M1 activation during bilateral antagonistic contraction. KW - ipsilateral motor network KW - upper limb KW - ipsilateral motor evoked potential KW - voluntary movement KW - bilateral motor network Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-321805 SN - 1664-042X VL - 14 ER - TY - THES A1 - Hörner, Michaela T1 - The role of inflammation in hereditary spastic paraplegia type 11 T1 - Die Rolle von Entzündungsreaktionen bei hereditärer spastischer Paraplegie Typ 11 N2 - Hereditary spastic paraplegias (HSPs) are genetically-determined, neurodegenerative disorders characterized by progressive weakness and spasticity of the lower limbs. Spastic paraplegia type 11 (SPG11) is a complicated form of HSP, which is caused by mutations in the SPG11 gene encoding spatacsin, a protein possibly involved in lysosomal reformation. Based on our previous studies demonstrating that secondary neuroinflammation can be a robust amplifier of various genetically-mediated diseases of both the central and peripheral nervous system, we here test the possibility that neuroinflammation may modify the disease outcome also in a mouse model for SPG11. Spg11-knockout (Spg11-/-) mice develop early walking pattern and behavioral abnormalities, at least partially reflecting motor, and behavioral changes typical for patients. Furthermore, we detected a progressive increase in axonal damage and axonal spheroid formation in the white and grey matter compartments of the central nervous system of Spg11-/- mice. This was accompanied by a concomitant substantial increase of secondary inflammation by cytotoxic CD8+ and CD4+ T-lymphocytes. We here provide evidence that disease-related changes can be ameliorated/delayed by the genetic deletion of the adaptive immune system. Accordingly, we provide evidence that repurposing clinically approved immunomodulators (fingolimod/FTY720 or teriflunomide), that are in use for treatment of multiple sclerosis (MS), also improve disease symptoms in mice, when administered in an early (before neural damage) or late (after/during neural damage) treatment regime. This work provides strong evidence that immunomodulation can be a therapeutic option for the still untreatable SPG11, including its typical neuropsychological features. This poses the question if inflammation is not only a disease amplifier in SPG11 but can act as a unifying factor also for other genetically mediated disorders of the CNS. If true, this may pave the way to therapeutic options in a wide range of still untreatable, primarily genetic, neurological disorders by repurposing approved immunomodulators. N2 - Hereditäre spastische Paraplegien (HSPs) sind genetisch-determinierte, neurodegenerative Erkrankungen, die durch eine progressive Schwäche und Spastizität der unteren Extremitäten charakterisiert sind. Die spastische Paraplegie Typ 11 (SPG11) ist eine komplizierte Form der HSP, die durch eine Mutation des SPG11 Gens hervorgerufen wird. Dieses Gen kodiert Spatacsin, ein Protein, das wahrscheinlich in der lysosomalen Reformation eine Rolle spielt. Frühere Studien unserer Arbeitsgruppe konnten zeigen, dass sekundäre Entzündungsreaktionen verschiedene genetisch-determinierte Krankheiten des zentralen und peripheren Nervensystems verstärken können. Daher haben wir hier untersucht, ob neuroinflammatorische Reaktionen auch in einem Mausmodell für SPG11 den Krankheitsverlauf beeinflussen. Spg11-knockout (Spg11-/-) Mäuse entwickeln frühzeitige Gangveränderungen und Verhaltensauffälligkeiten, welche die Veränderungen der Patienten, zumindest teilweise, abbilden. Außerdem konnten wir eine progressive Zunahme von axonalem Schaden und die Bildung von axonalen Schwellungen in der weißen und grauen Substanz des zentralen Nervensystems von Spg11-/- Mäusen feststellen. Dies wurde von einer deutlichen Zunahme einer sekundären Entzündungsreaktion in der weißen und grauen Substanz durch zytotoxische CD8+ und CD4+ T-Lymphozyten begleitet. Wir zeigen hier, dass diese krankheitsbedingten Veränderungen durch eine genetische Deletion von Teilen des adaptiven Immunsystems verbessert bzw. ihr Auftreten hinausgezögert werden können. Entsprechend zeigen wir, dass eine Behandlung mit klinisch etablierten Immunomodulatoren (Fingolimod/FTY720 oder Teriflunomid), die zu der Behandlung der Multiplen Sklerose (MS) eingesetzt werden, den Krankheitsverlauf positiv beeinflusst, wenn sie in einem frühzeitigen (Gabe vor neuronalem Schaden) oder späten (Gabe nach/während neuronalem Schaden) Behandlungsversuch appliziert werden. Diese Arbeit deutet stark darauf hin, dass Immunomodulation eine Therapiemöglichkeit für die noch nicht behandelbare Krankheit SPG11 sein könnte, inklusive der typischen neuropsychologischen Auffälligkeiten. Das wirft die Frage auf, ob sekundäre Entzündungsreaktionen nicht nur einen krankheitsverstärkenden Effekt in SPG11 haben, sondern als ein vereinender Faktor für andere genetisch determinierte Krankheiten des ZNS fungieren können. Dies könnte den Weg dahin ebnen das Fortschreiten anderer unheilbarer, primär genetisch bedingter, neurologischer Erkrankungen durch eine individuelle Behandlung mit auf dem Markt verfügbaren immunomodulatorischen Medikamenten zu verlangsamen. KW - Entzündung KW - Immunmodulation KW - Hereditary spastic paraplegia KW - Hereditäre spastsiche Paraplegie KW - Approved immunomodulators KW - Nervendegeneration KW - Neurodegenerative Erkrankung KW - Entzündungsreaktion KW - Inflammation Y1 - 2024 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-303368 ER - TY - THES A1 - Yu-Hwa, Huang T1 - The Role of HLA-G-expressing Regulatory T cells in Multiple Sclerosis: A Perspective of Beneficial Inflammation in the Central Nervous System Inflammation T1 - Die Rolle HLA-G-exprimierender regulatorischer T-Zellen in multipler Sklerose: Möglichkeit einer hilfreichen Entzündung bei Entzündungserkrankung des zentralen Nervensystems N2 - Die Regulation von Effektor-T-Zellen ist ein wichtiger Mechanismus zur Kontrolle organspezifischer Entzündungen. Dabei sind regulatorische T-Zellen (Treg) maßgeblich an der Aufrechterhaltung peripherer Immuntoleranz und parenchymaler Immunhomöostase beteiligt. Eine neue Population von humanen, natürlich vorkommenden Treg Zellen wurde durch ihre konstitutive Expression des immuntolerogenen Moleküls HLA-G identifiziert. Im ersten Teil dieser Arbeit wurden die Mechanismen, durch die CD4+ HLA-Gpos Treg Zellen ihre Zielzellen (autologe HLA-Gneg T-Zellen) modulieren, aufgeklärt. Unter Verwendung eines Suppressionsansatzes in Abwesenheit von antigenpräsentierenden Zellen (APC) wurden T-T-Zell-Interaktionen, die die Proliferation von HLA-Gneg T-Zellen hemmen, demonstriert. Diese Suppression, die durch die Stimulierung des T-Zell-Rezeptors auf HLA-Gpos Treg Zellen verstärkt wurde, war unabhängig vom Zell-Zell-Kontakt. Die HLA-Gneg T-Zellen erlangten nach Entfernung der HLA-Gpos Treg Zellen und einer erneuten Stimulierung ihrer T-Zell- Rezeptoren ihre Fähigkeit zur Proliferation wieder. Dies wies auf die Umkehrbarkeit dieser Suppression hin. Darüber hinaus war die HLA-Gpos Treg-vermittelte Suppression entscheidend von der IL-10- Sekretion, nicht jedoch von TGF-β abhängig. Zusammengefasst beschreibt dieser Teil der Arbeit eine detaillierte Charakterisierung der Mechanismen, wie HLA-Gpos Treg HLA-Gneg TZellen supprimieren. Das tiefere Verständnis der Wirkmechanismen von HLA-Gpos Treg könnte in therapeutischen Strategien verwendet werden, in denen die regulatorische Funktion der T-Zell-Suppression verstärkt oder moduliert werden soll. Im zweiten Teil dieser Arbeit wurde die potenzielle Rolle von HLA-Gpos Treg bei der Multiplen Sklerose (MS) untersucht, einer klassischen Autoimmunerkrankung des Zentralnervensystems (ZNS). Im Gegensatz zu Vergleichspatienten mit nicht-entzündlichen Erkrankungen konnte im Liquor von MS Patienten eine erhöhte Anzahl von HLA-Gpos Treg gefunden werden. Diese aus dem Liquor isolierten HLA-Gpos Treg wiesen phänotypische Merkmale von zentralen Gedächtnis-T-Zellen (CD45RA- CD27+) auf, exprimierten den Aktivierungsmarker ICOS sowie deutlich höhere Level des Chemokinrezeptors (CCR) CCR5 und agierten als starke Suppressoren der autologen CD4+ T-Zellproliferation. Durch Verwendung eines in vitro Modells der humanen Bluthirnschranke konnte demonstriert werden, dass HLA-Gpos Treg eine starke Neigung zur Migration haben, die durch die CCR5- Liganden MIP1α und RANTES, nicht jedoch durch MIP3β (Ligand von CCR7) unterstützt wird. Diese Chemokin-induzierte Migration von HLA-Gpos Treg war auch mit einer Steigerung der suppressiven Kapazität nach Zelltransmigration assoziiert. Im Gegensatz zu CD4+CD25+, FoxP3-exprimierenden Treg zeigten HLA-Gpos Treg von MS-Patienten keine beeinträchtigte Funktionalität. Dies deutet auf eine selektive Rekrutierung von HLA-Gpos Treg zu Entzündungsherden im ZNS und ihre Beteiligung an der Bekämpfung der destruktiven Entzündung hin. Die Ergebnisse dieser Studien tragen zum weitergehenden Verständnis der Rolle und Funktion HLA-Gpos Treg Zellen bei und stellen somit ein wichtiges pathophysiologisches Beispiel „gutartiger“ T-Zell-Entzündung während der ZNS Autoimmunität dar, das sowohl aus pathophysiologischer als auch therapeutischer Sicht interessant ist. N2 - Regulation of effector T cells is an important mechanism to control organ-specific inflammation. Thereby regulatory T cells (Treg cells) are essential for maintaining peripheral immune tolerance and for establishing parenchyma immune homeostasis. A novel population of natural human Treg characterized by the constitutive expression of the immune-tolerogenic human HLA-G molecule has been identified. In the first part of the study, we elucidated the mechanism(s) by which CD4+ HLA-Gpos Treg modulates their cellular targets namely autologous HLA-G negative responder T cells (HLAGneg Tresp). Using a suppression system free of antigen-presenting cells (APC), we demonstrate a T-T cell interaction resulting in suppression of HLA-Gneg Tresp. We could also show that this suppression was independent of cell-cell contact. Importantly, stimulus of T cell receptor (TCR) on HLA-Gpos Treg facilitated their suppressive capacity. We also observed that removal of HLA-Gpos Treg from the established co-cultures could restore the ability of HLA-Gneg Tresp to proliferate upon TCR re-stimulation, indicating that the suppression was reversible. Further, HLA-Gpos Treg–mediated suppression was critically depending on the secretion of IL-10 but not TGF-β. Taken together, this part of the work provides an in-depth characterization of the mechanisms of how HLA-Gpos Treg suppresses T responder cells in direct T-T interactions. Understanding the suppressive mechanism used by HLA-Gpos Treg may help to develop therapeutic strategies to modulate regulatory arms of T-cell suppression. In the second part of this study, the potential role of HLA-Gpos Treg in the pathophysiological process of Multiple Sclerosis (MS), a prototypic autoimmune inflammatory central nervous system (CNS), has been investigated. We found that HLA-Gpos Treg are enriched in the cerebrospinal fluid (CSF) from MS patients, but not in non-inflammatory controls. CSFderived HLA-Gpos Treg showed predominance of central memory (CD45RA-CD27+) phenotype, exhibited markers of activation (ICOS), and had significantly higher expression of the inflammatory chemokine receptor CCR5. Importantly, these cells demonstrated as potent suppressors to autologous CD4+ T-cell proliferation. Using an in vitro model of human blood brain barrier, we showed that HLA-Gpos Treg have a strong propensity to migrate, which could be facilitated by MIP1α and RANTES (ligands of CCR5) but not MIP3β (a ligand of CCR7). The HLA-Gpos Treg migration triggered by chemokines was also associated with a gain of suppressive capacity upon cellular transmigration. In contrast to CD4+CD25+ naturally occurring FoxP3-expressing Treg, HLA-Gpos Treg from patients with MS did not exhibit impaired function, suggesting that HLA-Gpos Treg are selectively recruited to the sites of CNS inflammation in an effort to combat destructive inflammation during MS. Our results contribute to the understanding of the role and function of HLA-Gpos Treg and provide an important example of “beneficial” T-cell inflammation in CNS autoimmunity- interesting both from a patho/-physiological and a therapeutically point of view. KW - Regulatorische T-Zellen KW - Multiplen Sklerose KW - HLA-G KW - Zentralnervensystems KW - Chemokinrezeptors KW - Regulatory T cells KW - Multiple Sclerosis KW - HLA-G KW - Central Nervous System KW - Chemokine Receptor Y1 - 2009 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-39957 ER - TY - JOUR A1 - Gómez-Fernández, Paloma A1 - Lopez de Lapuente Portilla, Aitzkoa A1 - Astobiza, Ianire A1 - Mena, Jorge A1 - Urtasun, Andoni A1 - Altmann, Vivian A1 - Matesanz, Fuencisla A1 - Otaegui, David A1 - Urcelay, Elena A1 - Antigüedad, Alfredo A1 - Malhotra, Sunny A1 - Montalban, Xavier A1 - Castillo-Triviño, Tamara A1 - Espino-Paisán, Laura A1 - Aktas, Orhan A1 - Buttmann, Mathias A1 - Chan, Andrew A1 - Fontaine, Bertrand A1 - Gourraud, Pierre-Antoine A1 - Hecker, Michael A1 - Hoffjan, Sabine A1 - Kubisch, Christian A1 - Kümpfel, Tania A1 - Luessi, Felix A1 - Zettl, Uwe K. A1 - Zipp, Frauke A1 - Alloza, Iraide A1 - Comabella, Manuel A1 - Lill, Christina M. A1 - Vandenbroeck, Koen T1 - The rare IL22RA2 signal peptide coding variant rs28385692 decreases secretion of IL-22BP isoform-1, -2 and -3 and is associated with risk for multiple sclerosis JF - Cells N2 - The IL22RA2 locus is associated with risk for multiple sclerosis (MS) but causative variants are yet to be determined. In a single nucleotide polymorphism (SNP) screen of this locus in a Basque population, rs28385692, a rare coding variant substituting Leu for Pro at position 16 emerged significantly (p = 0.02). This variant is located in the signal peptide (SP) shared by the three secreted protein isoforms produced by IL22RA2 (IL-22 binding protein-1(IL-22BPi1), IL-22BPi2 and IL-22BPi3). Genotyping was extended to a Europe-wide case-control dataset and yielded high significance in the full dataset (p = 3.17 × 10\(^{-4}\)). Importantly, logistic regression analyses conditioning on the main known MS-associated SNP at this locus, rs17066096, revealed that this association was independent from the primary association signal in the full case-control dataset. In silico analysis predicted both disruption of the alpha helix of the H-region of the SP and decreased hydrophobicity of this region, ultimately affecting the SP cleavage site. We tested the effect of the p.Leu16Pro variant on the secretion of IL-22BPi1, IL-22BPi2 and IL-22BPi3 and observed that the Pro16 risk allele significantly lowers secretion levels of each of the isoforms to around 50%–60% in comparison to the Leu16 reference allele. Thus, our study suggests that genetically coded decreased levels of IL-22BP isoforms are associated with augmented risk for MS. KW - IL22RA2 KW - IL-22 binding protein isoform KW - mutation KW - signal peptide KW - multiple sclerosis KW - autoimmune Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-200769 SN - 2073-4409 VL - 9 IS - 1 ER - TY - THES A1 - Dreykluft, Angela T1 - The PD-1/B7-H1 Pathway in a Transgenic Mouse Model for Spontaneous Autoimmune Neuroinflammation: Immunological Studies on Devic B7-H1-/- Mice T1 - Der PD-1/B7-H1 Signalweg in einem transgenen Mausmodell für spontane autoimmune Neuroinflammation: Immunologische Studien an Devic B7-H1-/- Mäusen N2 - Multiple sclerosis is an autoimmune disease of the central nervous system characterized by inflammatory, demyelinating lesions and neuronal death. Formerly regarded as a variant of MS, neuromyelitis optica (NMO)/Devic’s disease is now recognized as a distinct neurological disorder exhibiting characteristic inflammatory and demyelinated foci in the optic nerves and the spinal cord sparing the brain. With the introduction of the double-transgenic “Devic mouse” model featuring spontaneous, adjuvant-free incidence of autoimmune neuroinflammation due to the interaction of transgenic MOG-specific T and B cells, a promising tool was found for the analysis of factors triggering or preventing autoimmunity. The co-inhibitory molecule B7-H1 has been proposed to contribute to the maintenance of peripheral tolerance and to confine autoimmune inflammatory damage via the PD-1/B7-H1 pathway. Compared to Devic B7-H1+/+ mice, Devic B7-H1-/- mice developed clinical symptoms with a remarkably higher incidence rate and faster kinetics emphasized by deteriorated disease courses and a nearly quadrupled mortality rate. Remarkably enlarged immune-cell accumulation in the CNS of Devic B7-H1-/- mice, in particular of activated MOG-specific CD4+ T cells, correlated with the more severe clinical features. Our studies showed that the CNS not only was the major site of myelin-specific CD4+ T-cell activation but also that B7-H1 expression within the target organ significantly influenced T-cell activation and differentiation levels. Analysis at disease maximum revealed augmented accumulation of MOG-specific CD4+ T cells in the peripheral lymphoid organs of Devic B7-H1-/- mice partly due to increased T-cell proliferation rates. Transgenic MOG-specific B cells of Devic B7-H1-/- mice activated MOG-specific CD4+ T cells more efficiently than B cells of Devic B7-H1+/+ mice. This observation indicated a relevant immune-modulating role of B7-H1 on APCs (antigen-presenting cells) in this mouse model. We also assumed altered thymic selection processes to be involved in increased peripheral CD4+ T-cell numbers of Devic B7-H1-/- mice as we found more thymocytes expressing the transgenic MOG-specific T-cell receptor (TCR). Moreover, preliminary in vitro experiments hinted on an enhanced survival of TCRMOG-transgenic CD4+ T cells of Devic B7-H1-/- mice; a mechanism that might as well have led to higher peripheral T-cell accumulation. Elevated levels of MOG-specific CD4+ T cells in the periphery of Devic B7-H1-/- mice could have entailed the higher quantities in the CNS. However, mechanisms such as CNS-specific proliferation and/or apoptosis/survival could also have contributed. This should be addressed in future investigations. Judging from in vitro migration assays and adoptive transfer experiments on RAG-1-/- recipient mice, migratory behavior of MOG-specific CD4+ T cells of Devic B7-H1+/+ and Devic B7-H1-/- mice seemed not to differ. However, enhanced expression of the transmigration-relevant integrin LFA-1 on CD4+ T cells in young symptom-free Devic B7-H1-/- mice might hint on temporally differently pronounced transmigration capacities during the disease course. Moreover, we attributed the earlier conversion of CD4+ T cells into Th1 effector cells in Devic B7-H1-/- mice during the initiation phase to the lack of co-inhibitory signaling via PD-1/B7-H1 possibly leading to an accelerated disease onset. Full blown autoimmune inflammatory processes could have masked these slight effects of B7-H1 in the clinical phase. Accordingly, at peak of the disease, Th1 and Th17 effector functions of peripheral CD4+ T cells were comparable in both mouse groups. Moreover, judging from titers of MOG-specific IgG1 and IgM antibodies, alterations in humoral immunity were not detected. Therefore, clinical differences could not be explained by altered T-cell or B-cell effector functions at disease maximum. B7-H1 rather seemed to take inhibitory effect in the periphery during the initiation phase only and consistently within the target organ by parenchymal expression. Our observations indicate that B7-H1 plays a relevant role in the regulation of T-cell responses in this mouse model for spontaneous CNS autoimmunity. By exerting immune-modulating effects in the preclinical as well as the clinical phase of the disease, B7-H1 contributed to the confinement of the immunopathological tissue damage in Devic B7-H1+/+ mice mirrored by later disease onsets and lower disease scores. As a model for spontaneous autoimmunity featuring a close to 100 % incidence rate, the Devic B7-H1-/- mouse may prove instrumental in clarifying disease-triggering and -limiting factors and in validating novel therapeutic approaches in the field of autoimmune neuroinflammation, in particular the human Devic’s disease. N2 - Multiple Sklerose ist eine Autoimmunerkrankung des zentralen Nervensystems, die durch entzündliche, demyelinisierende Läsionen und neuronalen Tod gekennzeichnet ist. Einst als Variante der MS betrachtet, gilt die Neuromyelitis optica (NMO) / Devic-Krankheit heute als eigenständige neurologische Erkrankung, bei der charakteristische Läsionen in den Sehnerven und im Rückenmark jedoch nicht im Gehirn auftreten. Mit der Einführung des doppelt-transgenen "Devic Maus"-Modells, bei dem es zur spontanen, Adjuvans-freien Inzidenz von autoimmuner Neuroinflammation durch Expression transgener MOG-spezifischer T- und B-Zellen kommt, wurde ein vielversprechendes Werkzeug für die Analyse von Faktoren gefunden, die Autoimmunität auslösen bzw. hemmen können. Das ko-inhibitorische Molekül B7-H1 trägt über den PD-1/B7-H1 Signalweg vermeintlich zur Aufrechterhaltung peripherer Toleranz bei. Devic B7-H1-/ - Mäuse entwickelten im Vergleich zu Devic B7-H1+/ + Mäusen Symptome, die mit deutlich höherer Inzidenz und schnellerer Kinetik einhergingen, unterstrichen von verstärkten Krankheitsverläufen und einer nahezu vervierfachten Sterblichkeit. Die verstärkte Akkumulierung von Immunzellen im ZNS, insbesondere von aktivierten MOG-spezifischen CD4+ T-Zellen, korrelierte mit den schwerwiegenderen klinischen Merkmalen. Unsere Untersuchungen zeigten nicht nur, dass die Aktivierung von myelin-spezifischen CD4+ T-Zellen hauptsächlich im ZNS stattfand, sondern auch, dass im Zielorgan exprimiertes B7-H1 maßgeblich den T-Zell-Aktivierungs- und -Differenzierungsgrad beeinflusste. Analysen am Krankheitsmaximum zeigten eine verstärkte Akkumulierung von MOG-spezifischen CD4+ T-Zellen in den Lymphorganen von Devic B7-H1-/- Mäusen, die wir teils auf erhöhte T-Zell-Proliferation zurückzuführten. Transgene MOG-spezifische B-Zellen der Devic B7-H1-/- Mäuse aktivierten effizienter als B-Zellen der Devic B7-H1+/+ Mäuse MOG-spezifische CD4+ T-Zellen. Dies deutet auf eine wichtige immunmodulierende Rolle von B7-H1 auf Antigen-präsentierenden Zellen in diesem Mausmodell hin. Veränderte Selektionsprozesse im Thymus trugen wohlmöglich zu den höheren CD4+ T-Zellzahlen in der Peripherie bei. Vorläufige in vitro Experimente deuteten auf ein verbessertes Überleben von TCRMOG-transgenen CD4+ T-Zellen aus Devic B7-H1-/- Mäusen hin. Eine erhöhte Anzahl von peripheren MOG-spezifischen CD4+ T-Zellen könnte zu den größeren Mengen im ZNS von Devic B7-H1-/- Mäusen geführt haben. Jedoch sind zusätzliche Mechanismen wie ZNS-spezifische Proliferation und/oder Apoptose bzw. Überleben denkbar. Dies sollte in zukünftigen Untersuchungen genauer analysiert werden. Anhand von in vitro-Migrationsassays und Adoptiver Transfer-Experimenten in RAG-1-/- Mäusen schlossen wir, dass das Migrationsverhalten von MOG-spezifischen CD4+ T-Zellen von Devic B7-H1-/- Mäusen nicht verändert war. Allerdings deutet die verstärkte Expression des transmigrationsrelevanten Intergins LFA-1 auf CD4+ T-Zellen in jungen, symptomfreien Devic B7-H1-/- Mäusen auf im Krankheitsverlauf zeitlich verschieden ausgeprägte Transmigrationskapazitäten hin. Die frühere Differenzierung von peripheren CD4+ T-Zellen in Th1-Effektorzellen in Devic B7-H1-/- Mäusen während der Initiationsphase schrieben wir der fehlenden inhibierenden Wirkung des PD-1/B7-H1 Signalwegs zu, was den früheren Krankheitsbeginn bedingt haben könnte. Stark ausgeprägte autoimmune Entzündungsreaktionen am Krankheitsmaximum maskierten jedoch wahrscheinlich diese schwachen Effekte von B7-H1. Dies wurde durch die Tatsache untermauert, dass am Krankheitsmaximum Th1- und Th17-Effektorfunktionen von peripheren CD4+ T-Zellen in beiden Mausgruppen vergleichbar ausgeprägt waren. Des Weiteren bestanden am Krankheitsmaximum keine Unterschiede in der humoralen Immunität. Die beobachteten klinischen Unterschiede waren demnach nicht durch veränderte periphere T-Zell- oder B-Zell-Effektorfunktionen in dieser Krankheitsphase erklärbar. Vielmehr scheint B7-H1 in der Peripherie ausschließlich während der Initiationsphase der Krankheit und fortwährend im Zielorgan durch seine parenchymale Expression immuninhibierend zu wirken. Unsere Beobachtungen zeigen, dass B7-H1 eine relevante Rolle bei der Immunregulierung im vorliegenden Mausmodell für spontane ZNS-Autoimmunität spielt. Durch immunmodulierende Effekte in der präklinischen sowie der klinischen Phase der Krankheit trug B7-H1 zu der Begrenzung der immunpathologischen Gewebeschädigung in Devic B7-H1+/+ Mäusen bei, sichtbar an einem späteren Krankheitsbeginn und leichteren -verlauf. Als Tiermodell für spontane ZNS-Autoimmunität mit nahezu 100 %iger Inzidenz könnte sich die Devic B7-H1-/- Maus als hilfreich bei der Klärung krankheitsauslösender und -limitierender Faktoren erweisen sowie bei der Validierung neuer therapeutischer Ansätze im Bereich der autoimmunen Neuroinflammation, insbesondere der Devic-Krankheit im Menschen. KW - Autoimmunität KW - Zentralnervensystem KW - Neuroinflammation KW - B7-H1 KW - Ko-inhibitorischer Signalweg KW - Devic Maus KW - autoimmunity KW - neuroinflammation KW - B7-H1 KW - co-inhibitory signalling KW - Devic mice KW - Maus KW - Entzündung KW - Signaltransduktion Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-83288 ER - TY - THES A1 - Klein, Dennis T1 - The pathogenic role of endogenous antibodies in a mouse model for Charcot-Marie-Tooth 1B neuropathy T1 - Die pathogenetische Funktion von endogenen Antikörpern in einem Maus-Modell der Charcot-Marie-Tooth 1B Neuropathie N2 - Charcot-Marie-Tooth (CMT) type 1 neuropathies are a genetically heterogeneous group of non-treatable inherited disorders affecting the peripheral nervous system that lead to sensory and motor dysfunction. Secondary low grade inflammation, implicating the innate and adaptive immune system, could previously be identified as a substantial disease modifier in two mouse models for CMT1, CMT1B and 1X, respectively. However, the exact mechanism how the adaptive immune system contributes to disease pathogenesis is not completely understood. Based on observations that the accumulation of endogenous antibodies to myelin components is important for rapid myelin clearance after nerve injury during Wallerian degeneration, a possibly similar mechanism was considered for endogenous antibodies as disease amplifier in mice heterozygously deficient for P0 (P0het), mimicking some typical features of CMT1B. In this study an increased antibody deposition was detected in the affected peripheral nerves of P0het myelin mutant mice. By crossbreeding P0het mutants with mice specifically lacking B-lymphocytes, and therefore antibodies (JHD-/-), a decline of endoneurial macrophages together with a substantially ameliorated demyelination could be demonstrated in 6-month-old mutant mice. Moreover, reconstitution with murine IgGs reverted the neuropathic phenotype, substantiating that endogenous antibodies are potentially pathogenic at this early stage of disease. Unexpectedly, in 12-months-old P0het mutants, JHD deficiency resulted in disease aggravation accompanied by an increased inflammatory reaction and M2-polarized macrophage response. These observations suggest that in a mouse model for CMT1B, the lack of endogenous antibodies has a dichotomous effect: ameliorating early macrophage-mediated demyelination, as opposed to increasing inflammatory reactions leading to disease aggravation at older ages. N2 - Als Charcot-Marie-Tooth (CMT) Typ 1 Erkrankungen bezeichnet man eine genetisch heterogene Gruppe von nicht behandelbaren, erblichen Neuropathien, die das periphere Nervensystem betreffen und letztendlich zu starken motorischen und sensorischen Defiziten führen. Anhand verschiedener Studien konnte gezeigt werden, dass sekundäre Entzündungsreaktionen, insbesondere des angeborenen und adaptiven Immunsystems, eine entscheidende Rolle bei der Pathogenese von zwei verschiedenen CMT1-Mausmodellen (CMT1B und CMT1X) spielen. Jedoch ist der genaue Mechanismus, in dem das adaptive Immunsystem zur Pathogenese beiträgt, nicht komplett bekannt. In einer veröffentlichten Studie wurden gebundenen endogenen Antiköpern eine wichtige Rolle beim raschen Myelinabbau nach Nervläsion während der Waller´schen Degeneration zugeschrieben. In Mäusen, die heterozygot defizient für P0 (P0het) sind und einige typische Merkmale der CMT1B Neuropathie aufweisen, sollte ein möglicherweise ähnlicher Mechanismus von endogenen Antikörpern untersucht werden, der zur Verstärkung der Krankheitsentwicklung führt. In dieser Studie konnte eine vermehrte Antikörperbindung in den betroffenen peripheren Nerven von P0het Myelinmutanten beobachtet werden. Anhand von Verkreuzungs-Experimenten von P0het Mutanten mit Mäusen, die keine B-Lymphozyten besitzen und daher keine Antikörper bilden können (JHD-/-), konnte zudem in den untersuchten 6 Monate alten Doppelmutanten eine verringerte Anzahl endoneuraler Makrophagen und eine deutliche Verbesserung der Demyelinisierung aufgezeigt werden. Zusätzlich konnte anhand von Rekonstitutions-Experimenten mit mausspezifischen-IgGs der neuropathische Phänotyp in peripheren Nerven wiederhergestellt werden, was die mögliche pathogenetische Rolle endogener Antikörper im frühen Stadium der Erkrankung bekräftigt. Unerwarteterweise führte die JHD-Defizienz jedoch in 12 Monate alten P0het Mausmutanten eher zu einer Verschlechterung der Neuropathie, zusammen mit einer verstärkten Entzündungsreaktion und M2-polarisierten Makrophagen-Aktivierung. Diese Beobachtungen deuten darauf hin, dass das Fehlen von Antikörpern in einem etablierten Mausmodell für CMT1B unterschiedliche Folgen hat, da dies zu einer verringerten Makrophagen-vermittelten Demyelinisierung im frühen Erkrankungsverlauf führt, gleichzeitig aber im späteren Alter in einer verstärkten Entzündungsreaktion und einem vermehrten Nervschaden resultiert. KW - Charcot-Marie-Tooth KW - Demyelinisierung KW - Adaptives Immunsystem KW - Antikörper KW - Makrophagen KW - B-Lymphocyten KW - Fc-Rezeptor KW - Komplement KW - demyelination KW - antibodies KW - macrophages KW - adaptive immune system KW - B-lymphocytes KW - Fc-receptor KW - complement KW - Maus KW - Charcot-Marie-Syndrom KW - Immunsystem KW - Antikörper Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-121941 ER - TY - JOUR A1 - Frerichs, K. A1 - Sirèn, Anna-Leena A1 - Feuerstein, G. A1 - Hallenbeck, JM T1 - The onset of postischemic hypoperfusion in rats is precipitous and may be controlled by local neurons N2 - Background and Purpose: Reperfusion following transient global cerebral ischemia is characterized by an initial hyperemic phase, which precedes hypo perfusion. The pathogenesis of these flow derangements remains obscure. Our study investigates the dynamics of postischemic cerebral blood flow changes, with particular attention to the role of local neurons. Metho(Js: We assessed local cortical blood flow continuously by laser Doppler flowmetry to permit observation of any rapid flow changes after forebrain ischemia induced by four-vessel occlusion for 20 minutes in rats. To investigate the role of local cortical neurons in the regulation of any blood flow fluctuations, five rats received intracortical microinjections of a neurotoxin (10 p,g ibotenic acid in 1 p,1; 1.5-mm-depth parietal cortex) 24 hours before ischemia to induce selective and localized neuronal depletion in an area corresponding to the sampie volume of the laser Doppler probe (1 mm3 ). Local cerebral blood flow was measured within the injection site and at an adjacent control site. Results: Ischemia was followed by marked hyperemia (235 ±23% of control, n =7), followed by secondary hypoperfusion (45±3% of control, n=7). The transition from hyperemia to hypoperfusioo occurred not gradually but precipitously (maximal slope of flow decay: 66±6%/min; n=7). In ibotenic acid-injected rats, hyperemia was preserved at the injection site, but the sudden decline of blood flow was abolished (maximal slope of flow decay: 5±3%/min compared with 53±8%/min at the control site; n=5, p47%. A significant correlation was described between the asymmetry indices of the swinging of the two arms and dopaminergic striatal innervation. When arm ROM was reduced, we found a positive correlation between upper-lower limb phase shift modulation ( at different gait velocities) and striatal dopaminergic innervation. These findings are preliminary evidence that dopaminergic striatal tone plays a modulatory role in upper-limb locomotor synergies and upper-lower limb coupling while walking at different velocities. KW - pet KW - Parkinsons disease KW - basal ganglia KW - spinal-cord KW - walking KW - gait KW - arm KW - coordination KW - movements Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-133976 VL - 7 IS - 12 ER - TY - JOUR A1 - Hiew, Shawn A1 - Eibeck, Leila A1 - Nguemeni, Carine A1 - Zeller, Daniel T1 - The influence of age and physical activity on locomotor adaptation JF - Brain Sciences N2 - Background: Aging increases individual susceptibility to falls and injuries, suggesting poorer adaptation of balance responses to perturbation during locomotion, which can be measured with the locomotor adaptation task (LAT). However, it is unclear how aging and lifestyle factors affect these responses during walking. Hence, the present study investigates the relationship between balance and lifestyle factors during the LAT in healthy individuals across the adult lifespan using a correlational design. Methods: Thirty participants aged 20–78 years performed an LAT on a split-belt treadmill (SBT). We evaluated the magnitude and rate of adaptation and deadaptation during the LAT. Participants reported their lifelong physical and cognitive activity. Results: Age positively correlated with gait-line length asymmetry at the late post-adaptation phase (p = 0.007). These age-related effects were mediated by recent physical activity levels (p = 0.040). Conclusion: Our results confirm that locomotor adaptive responses are preserved in aging, but the ability to deadapt newly learnt balance responses is compromised with age. Physical activity mediates these age-related effects. Therefore, gait symmetry post-adaptation could effectively measure the risk of falling, and maintaining physical activity could protect against declines in balance. KW - locomotor adaptation KW - walking KW - physical activity KW - exercise KW - aging KW - balance Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-362478 SN - 2076-3425 VL - 13 IS - 9 ER - TY - THES A1 - Schwab, Nicholas T1 - The importance of CD8\(^+\) T cells and antigen-presenting cells in the immune reaction of primary inflammatory versus degenerative diseases T1 - Die Bedeutung CD8\(^+\) T-Zellen und Antigen-präsentierender Zellen in der Immunreaktion primär inflammatorischer gegenüber degenerativen Erkrankungen N2 - The bidirectional influence of parenchymal cells and cells of the immune system, especially of antigen-presenting and CD8\(^+\) T cells, in situations of putative auto- immune pathogenicity and degeneration was the main topic of this thesis. In the first part, the influence of human muscle cells on antigen-presenting cells was investigated. In inflammatory myopathies prominent infiltrates of immune cells containing T cells and antigen-presenting cells like macrophages and dendritic cells are present. The hypothesis was that human myoblasts have an inhibiting influence on these antigen-presenting cells under homeostatic conditions. A dysfunction or impairment under inflammatory circumstances might contribute to the development of myopathic conditions. The surface analysis of dendritic cells cocultured with myoblasts showed that immature dendritic cells could be driven into a reversible semi- mature state with significantly elevated levels of CD80. These dendritic cells were additionally characterized by their inhibiting function on T-cell proliferation. It was also shown that the lysates of healthy myoblasts could strongly enhance the phagocytic ability of macrophages, which could help with muscle regeneration and which might be disturbed in myositis patients. The second part of this thesis was about the clonal specificity of CD8\(^+\) T cells in a mouse model with genetically induced over-expression of PLP in oligodendrocytes. Here, we could show that the cytotoxic T lymphocytes, which had previously been shown to be pathogenic, were clonally expanded in the CNS of the transgenic mice. The amino acid sequences of the corresponding receptor chains were not identical, yet showed some similarities, which could mean that these clones recognize similar antigens (or epitopes of the same antigen). The knockout of PD-1 in this setting allowed for an analysis of the importance of tissue immune regulation. It became evident that the absence of PD-1 induced a larger number of clonal expansions in the CNS, hinting towards a reduced threshold for clonal disturbance and activation in these T cells. The expansions were, however, not pathogenic by themselves. Only in the presence of tissue damage and an antigenic stimulus (in our case the overexpression of PLP), the PD-1 limitation exacerbated the immune pathogenicity. Therefore, only in the presence of a “tissue damage signal”, the dyshomeostasis of T cells lacking PD-1 achieved high pathogenetic relevance. Finally, we investigated the pathogenetic role of CD8 T cells in Rasmussen encephalitis, a rare and chronic neurological disease mainly affecting children. The analysis of the T-cell receptor repertoire in Rasmussen encephalitis patients in the peripheral CD4\(^+\) and CD8\(^+\) T-cell compartments as well as the brain revealed the involvement of T cells in the pathogenicity of this disease. Many clonal expansions in the brain matched CD8\(^+\) T-cell expansions in the periphery on the sequence level. These putatively pathogenic clones could be visualized by immunohistochemistry in the brain and were found in close proximity to astrocytes and neurons. Additionally, the expanded clones could be found in the periphery of patients for at least one year. N2 - Der Einfluss von Parenchymzellen auf Immunzellen und umgekehrt, im Besonderen von Antigen-präsentierenden Zellen und CD8\(^+\) T-Zellen, im Zusammenhang von auto- immuner Pathogenese und Degeneration war das Hauptthema dieser Dissertation. Im ersten Teil wurde der Einfluss menschlicher Muskelzellen auf Antigen- präsentierende Zellen untersucht. In entzündlichen Myopathien kommt es zu massiven Infiltraten von Immunzellen, die T-Zellen und auch Antigen-präsentierende Zellen wie Makrophagen und dendritische Zellen enthalten. Die Hypothese war, dass menschliche Myoblasten einen hemmenden Einfluss auf die Antigen-präsentierenden Zellen unter homöostatischen Bedingungen haben. Eine Störung dieses Einflusses oder eine Beeinträchtigung unter entzündlichen Rahmenbedingungen könnte eventuell zur Entwicklung eines myopathischen Zustands beitragen. In der Oberflächenanalyse der dendritischen Zellen, die mit Myoblasten kultiviert wurden, zeigte sich, dass unreife dendritische Zellen in einen halb-reifen Zustand versetzt werden konnten, der sich beispielsweise durch stark erhöhte CD80 Expression kennzeichnet. Diese dendritischen Zellen wurden weiterhin charakterisiert über ihre hemmende Funktion auf die T-Zell Proliferation. Außerdem wurde gezeigt, dass Zelllysate gesunder Myoblasten die Phagozytoserate von Makrophagen enorm verstärken, was die Regeneration des Muskelgewebes erhöhen und möglicherweise in Myositispatienten gestört sein könnte. Im zweiten Teil der Dissertation ging es um die klonale Spezifität von CD8\(^+\) T-Zellen in einem Mausmodell mit genetisch induzierter Überexpression von PLP in Oligodendrozyten. Hier konnte gezeigt werden, dass die zytotoxischen T-Zellen, deren Pathogenität Gegenstand früherer Arbeiten war, im ZNS der transgenen Mäuse klonal expandiert waren. Die Aminosäuresequenzen der TCRβ Kette der expandierten Klone waren nicht identisch, zeigten jedoch einige Ähnlichkeiten, die darauf hinweisen könnten, dass diese Klone ähnliche Antigene (oder Epitope des gleichen Antigens) erkennen. Die genetisch induzierte Abwesenheit von PD-1 ermöglichte es, in diesem Zusammenhang den Einfluss von spezifischer Immunregulation im Gewebe zu untersuchen. Es zeigte sich, dass die Deletion von PD-1 eine erhöhte Anzahl von klonalen Expansionen im ZNS der Mäuse erzeugte, was auf eine herabgesetzte Schwelle für klonale Störungen und Aktivierung schließen lässt. Diese Expansionen 
 waren jedoch für sich genommen nicht pathogen. Nur in der Anwesenheit eines Gewebeschadens und eines zusätzlicher Antigenstimulus (in unserem Fall in Form der PLP Überexpression) konnte man die erhöhte Pathogenität durch die PD-1 Deletion erkennen. Deswegen erreichten die PD-1 deletierten T-Zellen nur in der Gegenwart eines „Gewebeschaden-Signals“ hohe pathogenetische Relevanz. Schließlich untersuchten wir die pathogenetische Rolle von CD8\(^+\) T-Zellen in der Rasmussen Enzephalitis, einer seltenen, chronischen Erkrankung des Gehirns, die hauptsächlich in Kindern vorkommt. Die Analyse des T-Zell-Rezeptor Repertoires in Rasmussen Enzephalitis Patienten in peripheren CD4\(^+\) und CD8\(^+\) T-Zell Populationen und im Gehirn zeigte die Beteiligung von T-Zellen in der Pathogenese dieser Krankheit auf. Viele klonale Expansionen waren zwischen Gehirn und der peripheren CD8\(^+\) Population bis hin zur Aminosäuresequenz identisch. Diese vermutlich pathogenen Klone konnten in Gehirnbiopsien von Rasmussenpatienten histochemisch nachgewiesen werden und wurden in enger Nachbarschaft zu Astrozyten und Neuronen gefunden. Zusätzlich konnten diese expandierten Kone in der Peripherie von Patienten für die beobachteten Zeiträume (mindestens ein Jahr) nachgewiesen werden. KW - T-Lymphozyt KW - Entzündung KW - Degeneration KW - Immunsystem KW - Rasmussen-Syndrom KW - T lymphocyte KW - inflammation KW - degeneration KW - immune system KW - rasmussen encephalitis Y1 - 2009 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-37330 ER - TY - THES A1 - Spitzel, Marlene T1 - The impact of inflammation, hypoxia, and vasculopathy on pain development in the α-galactosidase A mouse model of Morbus Fabry T1 - Der Einfluss von Inflammation, Hypoxie und Vaskulopathie auf die Schmerzentwicklung des Morbus Fabry-spezifischen α-Galaktosidase A Mausmodells N2 - Fabry disease (FD), an X-linked lysosomal storage disorder, is caused by variants in the gene α-galactosidase A (GLA). As a consequence, the encoded homonymous enzyme GLA is not produced in sufficient amount or does not function properly. Subsequently, globotriaosylceradmide (Gb3), the target substrate of GLA, starts accumulating in several cell types, especially neurons and endothelial cells. FD patients suffer from multiorgan symptoms including cardiomyopathy, nephropathy, stroke, and acral burning pain. It is suggested that the impact of pathological Gb3 accumulation, inflammatory and hypoxic processes, and vasculopathy are contributing to the specific FD pain phenotype. Thus, we investigated the role of inflammation, hypoxia, and vasculopathy on molecular level in dorsal root ganglia (DRG) of the GLA knockout (KO) mouse model. Further, we investigated pain-like characteristics of GLA KO mice at baseline (BS), after capsaicin administration, and after repeated enzyme replacement therapy (ERT) administration for a period of 1.5 years. Acquired data showed disturbances in immune response markers represented by downregulated inflammation-associated genes and lower numbers of CD206+ macrophages in DRG of GLA KO mice. Hypoxic mechanisms were active in DRG of GLA KO mice reflected by increased gene expression of hypoxia- and DNA damage-associated targets, higher numbers of hypoxia-inducible factor 1α-positive (HIF1α+) and carbonic anhydrase 9-positive (CA9+) neurons in DRG of GLA KO mice, and DRG neuronal HIF1α cytosolic-nuclear translocation in GLA KO mice. Vascularization in DRG of GLA KO mice was reduced including lower numbers of blood vessel branches and reduced total blood vessel length. Pain-like behavior of the GLA KO mouse model revealed no mechanical hypersensitivity at BS but age-dependent heat hyposensitivity, which developed also age-matched wild type (WT) mice. Capsaicin administration under isoflurane anesthesia did not elicit the development of nocifensive behavior in GLA KO mice after mechanical or heat stimulation. Repeated ERT administration did not show a clear effect in GLA KO mice in terms of restored heat hyposensitivity to BS paw withdrawal latencies. In summary, we demonstrated the impact of disturbed immune response markers, active hypoxic mechanisms, and reduced vascularization on molecular FD pathophysiology. N2 - Morbus Fabry (M. Fabry oder Fabry disease, FD) ist eine X-chromosomal vererbte, lysosomale Speichererkrankung, die durch Varianten im Gen α-Galaktosidase A (GLA) verursacht wird. Das durch GLA kodierte gleichnamige Enzym GLA kann somit nicht in ausreichender Menge produziert werden oder erhält nicht die volle Funktionalität. Als Folge akkumuliert das Glykosphingolipid Globotriaosylceramid (Gb3), welches das Zielsubstrat von GLA ist und durch dieses Enzym normalerweise abgebaut wird. Gb3 Akkumulationen sind in verschiedenen Zelltypen zu finden, jedoch bevorzugt in Neurone und Endothelzellen. FD-Patienten leiden unter Symptome, die verschiedene Organe betreffen, insbesondere Kardiomyopathien, Nephropathien, Schlaganfälle, und brennende Schmerzen in den Extremitäten. Es wird vermutet, dass neben dem pathologischen Einfluss der Gb3 Ablagerungen auch inflammatorische und hypoxische Prozesse und Vaskulopathien zum spezifischen FD-Schmerzphänotyps beitragen. Daher wurde die Rolle der Inflammation, Hypoxie und Vaskulopathie auf molekularer Ebene in Spinalganglien (dorsal root ganglion, DRG) eines FD-spezifischen GLA knockout (KO) Mausmodells untersucht. Des Weiteren wurde der Schmerz-ähnliche Phänotyp in GLA KO Mäusen unter nativen Bedingungen, nach Capsaicingabe und unter Enzymersatztherapie (enzyme replacement therapy, ERT) während einer Dauer von 1,5 Jahren untersucht. Unsere erhobenen Daten zeigten eine Beeinträchtigung von Faktoren der Immunantwort, die sich durch herunterregulierter Genexpression Inflammations-assoziierter Gene und einer geringeren Anzahl an CD206+ Makrophagen in DRG von GLA KO Mäusen nachweisen ließ. Zu aktiven Hypoxiemechanismen trugen eine hochregulierte Genexpression Hypoxie- und DNA-Schäden-assoziierter Gene, eine höhere Anzahl an hypoxia-inducible factor 1α-positiver (HIF1α+) und carbonic anhydrase 9-positiver (CA9+) Neurone in DRG von GLA KO Mäusen, und die DRG neuronale HIF1α Translokation zwischen Zytosol und Nukleus bei. Die Vaskularisierung der DRG in GLA KO Mäusen war reduziert zusätzlich zu der geringeren Anzahl an Blutgefäßverzweigungen und einer Reduzierung der gesamten Blutgefäßlänge. Die Untersuchungen des nativen Schmerz-ähnlichen Verhaltens der GLA KO Mäuse zeigte keine Entwicklung mechanischer Hypersensitivität, während sich eine Hitzehyposensitivität mit steigendem Alter der Tiere entwickelte, die sich auch in altersangepassten Wildtyp (WT) Mäusen zeigte. Eine Capsaicingabe unter Isoflurannarkose zeigte keine erhöhte Sensitivität der GLA KO Mäuse nach mechanischer oder Hitzestimulation. Wiederholte ERT-Gaben zeigten keine Verbesserung der Hitzehyposensitivität auf ein natives Niveau der Pfotenrückzuglatenz. Wir konnten den Einfluss beeinträchtigter Faktoren der Immunantwort, aktiver Hypoxieprozesse und reduzierter Vaskularisierung in DRG von GLA KO Mäusen auf die molekulare FD-Pathophysiologie zeigen. KW - Fabry disease KW - GLA KO mouse model KW - molecular mechanism KW - Fabry-Krankheit KW - Morbus Fabry Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-345794 ER - TY - JOUR A1 - Niemann, Axel A1 - Huber, Nina A1 - Wagner, Konstanze M. A1 - Somandin, Christian A1 - Horn, Michael A1 - Lebrun-Julien, Frédéric A1 - Angst, Brigitte A1 - Pereira, Jorge A. A1 - Halfter, Hartmut A1 - Welzl, Hans A1 - Feltri, M. Laura A1 - Wrabetz, Lawrence A1 - Young, Peter A1 - Wessig, Carsten A1 - Toyka, Klaus V. A1 - Suter, Ueli T1 - The Gdap1 knockout mouse mechanistically links redox control to Charcot–Marie–Tooth disease JF - Brain N2 - The ganglioside-induced differentiation-associated protein 1 (GDAP1) is a mitochondrial fission factor and mutations in GDAP1 cause Charcot–Marie–Tooth disease. We found that Gdap1 knockout mice (\(Gdap1^{−/−}\)), mimicking genetic alterations of patients suffering from severe forms of Charcot–Marie–Tooth disease, develop an age-related, hypomyelinating peripheral neuropathy. Ablation of Gdap1 expression in Schwann cells recapitulates this phenotype. Additionally, intra-axonal mitochondria of peripheral neurons are larger in \(Gdap1^{−/−}\) mice and mitochondrial transport is impaired in cultured sensory neurons of \(Gdap1^{−/−}\) mice compared with controls. These changes in mitochondrial morphology and dynamics also influence mitochondrial biogenesis. We demonstrate that mitochondrial DNA biogenesis and content is increased in the peripheral nervous system but not in the central nervous system of \(Gdap1^{−/−}\) mice compared with control littermates. In search for a molecular mechanism we turned to the paralogue of GDAP1, GDAP1L1, which is mainly expressed in the unaffected central nervous system. GDAP1L1 responds to elevated levels of oxidized glutathione by translocating from the cytosol to mitochondria, where it inserts into the mitochondrial outer membrane. This translocation is necessary to substitute for loss of GDAP1 expression. Accordingly, more GDAP1L1 was associated with mitochondria in the spinal cord of aged \(Gdap1^{−/−}\) mice compared with controls. Our findings demonstrate that Charcot–Marie–Tooth disease caused by mutations in GDAP1 leads to mild, persistent oxidative stress in the peripheral nervous system, which can be compensated by GDAP1L1 in the unaffected central nervous system. We conclude that members of the GDAP1 family are responsive and protective against stress associated with increased levels of oxidized glutathione. KW - animal models KW - Charcot-Marie-Tooth disease KW - mitochondria KW - axonal transport KW - demyelinating disease Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-120731 VL - 137 IS - 3 ER - TY - JOUR A1 - Krupka, Jennifer A1 - May, Frauke A1 - Weimer, Thomas A1 - Pragst, Ingo A1 - Kleinschnitz, Christoph A1 - Stoll, Guido A1 - Panousis, Con A1 - Dickneite, Gerhard A1 - Nolte, Marc W. T1 - The Coagulation Factor XIIa Inhibitor rHA-Infestin-4 Improves Outcome after Cerebral Ischemia/Reperfusion Injury in Rats JF - PLoS ONE N2 - Background and Purpose Ischemic stroke provokes severe brain damage and remains a predominant disease in industrialized countries. The coagulation factor XII (FXII)-driven contact activation system plays a central, but not yet fully defined pathogenic role in stroke development. Here, we investigated the efficacy of the FXIIa inhibitor rHA-Infestin-4 in a rat model of ischemic stroke using both a prophylactic and a therapeutic approach. Methods For prophylactic treatment, animals were treated intravenously with 100 mg/kg rHA-Infestin-4 or an equal volume of saline 15 min prior to transient middle cerebral artery occlusion (tMCAO) of 90 min. For therapeutic treatment, 100 mg/kg rHA-Infestin-4, or an equal volume of saline, was administered directly after the start of reperfusion. At 24 h after tMCAO, rats were tested for neurological deficits and blood was drawn for coagulation assays. Finally, brains were removed and analyzed for infarct area and edema formation. Results Within prophylactic rHA-Infestin-4 treatment, infarct areas and brain edema formation were reduced accompanied by better neurological scores and survival compared to controls. Following therapeutic treatment, neurological outcome and survival were still improved although overall effects were less pronounced compared to prophylaxis. Conclusions With regard to the central role of the FXII-driven contact activation system in ischemic stroke, inhibition of FXIIa may represent a new and promising treatment approach to prevent cerebral ischemia/reperfusion injury. KW - coagulation factor XIIa KW - ischemic stroke KW - contact activation system KW - FXIIa inhibitor rHA-Infestin Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-167370 VL - 11 IS - 1 ER - TY - JOUR A1 - Mirza, Myriam A1 - Vainshtein, Anna A1 - DiRonza, Alberto A1 - Chandrachud, Uma A1 - Haslett, Luke J. A1 - Palmieri, Michela A1 - Storch, Stephan A1 - Groh, Janos A1 - Dobzinski, Niv A1 - Napolitano, Gennaro A1 - Schmidtke, Carolin A1 - Kerkovich, Danielle M. T1 - The CLN3 gene and protein: What we know JF - Molecular Genetics & Genomic Medicine N2 - Background One of the most important steps taken by Beyond Batten Disease Foundation in our quest to cure juvenile Batten (CLN3) disease is to understand the State of the Science. We believe that a strong understanding of where we are in our experimental understanding of the CLN3 gene, its regulation, gene product, protein structure, tissue distribution, biomarker use, and pathological responses to its deficiency, lays the groundwork for determining therapeutic action plans. Objectives To present an unbiased comprehensive reference tool of the experimental understanding of the CLN3 gene and gene product of the same name. Methods BBDF compiled all of the available CLN3 gene and protein data from biological databases, repositories of federally and privately funded projects, patent and trademark offices, science and technology journals, industrial drug and pipeline reports as well as clinical trial reports and with painstaking precision, validated the information together with experts in Batten disease, lysosomal storage disease, lysosome/endosome biology. Results The finished product is an indexed review of the CLN3 gene and protein which is not limited in page size or number of references, references all available primary experiments, and does not draw conclusions for the reader. Conclusions Revisiting the experimental history of a target gene and its product ensures that inaccuracies and contradictions come to light, long-held beliefs and assumptions continue to be challenged, and information that was previously deemed inconsequential gets a second look. Compiling the information into one manuscript with all appropriate primary references provides quick clues to which studies have been completed under which conditions and what information has been reported. This compendium does not seek to replace original articles or subtopic reviews but provides an historical roadmap to completed works. KW - Batten KW - CLN3 KW - JNCL KW - juvenile Batten KW - neuronal ceroid lipofuscinosis Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-224138 VL - 7 ER - TY - JOUR A1 - Rovituso, Damiano M. A1 - Duffy, Catharina E. A1 - Schroeter, Michael A1 - Kaiser, Claudia C. A1 - Kleinschnitz, Christoph A1 - Bayas, Antonios A1 - Elsner, Rebecca A1 - Kuerten, Stefanie T1 - The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients JF - Scientific Reports N2 - B cells have only recently begun to attract attention in the immunopathology of multiple sclerosis (MS). Suitable markers for the prediction of treatment success with immunomodulatory drugs are still missing. Here we evaluated the B cell response to brain antigens in n = 34 relapsing-remitting MS (RRMS) patients treated with glatiramer acetate (GA) using the enzyme-linked immunospot technique (ELISPOT). Our data demonstrate that patients can be subdivided into responders that show brain-specific B cell reactivity in the blood and patients without this reactivity. Only in patients that classified as B cell responders, there was a significant positive correlation between treatment duration and the time since last relapse in our study. This correlation was GA-specific because it was absent in a control group that consisted of interferon-\(\beta\) (IFN-\(\beta\))-treated RRMS patients (n = 23). These data suggest that GA has an effect on brain-reactive B cells in a subset of patients and that only this subset benefits from treatment. The detection of brain-reactive B cells is likely to be a suitable tool to identify drug responders. KW - cortical pathology KW - natural history KW - disability KW - expression KW - antibodies KW - disease KW - lesions KW - trial KW - multiple sclerosis Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-148172 VL - 5 IS - 14265 ER - TY - JOUR A1 - Groh, Janos A1 - Hörner, Michaela A1 - Martini, Rudolf T1 - Teriflunomide attenuates neuroinflammation-related neural damage in mice carrying human PLP1 mutations JF - Journal of Neuroinflammation N2 - Background: Genetically caused neurological disorders of the central nervous system (CNS) are mostly characterized by poor or even fatal clinical outcome and few or no causative treatments are available. Often, these disorders are associated with low-grade, disease-promoting inflammation, another feature shared by progressive forms of multiple sclerosis (PMS). We previously generated two mouse lines carrying distinct mutations in the oligodendrocytic PLP1 gene that have initially been identified in patients diagnosed with MS. These mutations cause a loss of PLP function leading to a histopathological and clinical phenotype common to both PMS and genetic CNS disorders, like hereditary spastic paraplegias. Importantly, neuroinflammation promotes disease progression in these models, suggesting that pharmacological modulation of inflammation might ameliorate disease outcome. Methods: We applied teriflunomide, an approved medication for relapsing-remitting MS targeting activated T-lymphocytes, in the drinking water (10 mg/kg body weight/day). Experimental long-term treatment of PLP mutant mice was non-invasively monitored by longitudinal optical coherence tomography and by rotarod analysis. Immunomodulatory effects were subsequently analyzed by flow cytometry and immunohistochemistry and treatment effects regarding neural damage, and neurodegeneration were assessed by histology and immunohistochemistry. Results: Preventive treatment with teriflunomide attenuated the increase in number of CD8+ cytotoxic effector T cells and fostered the proliferation of CD8+ CD122+ PD-1+ regulatory T cells in the CNS. This led to an amelioration of axonopathic features and neuron loss in the retinotectal system, also reflected by reduced thinning of the innermost retinal composite layer in longitudinal studies and ameliorated clinical outcome upon preventive long-term treatment. Treatment of immune-incompetent PLP mutants did not provide evidence for a direct, neuroprotective effect of the medication. When treatment was terminated, no rebound of neuroinflammation occurred and histopathological improvement was preserved for at least 75 days without treatment. After disease onset, teriflunomide halted ongoing axonal perturbation and enabled a recovery of dendritic arborization by surviving ganglion cells. However, neither neuron loss nor clinical features were ameliorated, likely due to already advanced neurodegeneration before treatment onset. Conclusions: We identify teriflunomide as a possible medication not only for PMS but also for inflammation-related genetic diseases of the nervous system for which causal treatment options are presently lacking. KW - axonal degeneration KW - inflammation KW - proteolipid protein KW - T-lymphocytes KW - teriflunomide Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-176524 VL - 15 IS - 194 ER - TY - JOUR A1 - Doerck, Sebastian A1 - Goebel, Kerstin A1 - Weise, Gesa A1 - Schneider-Hohendorf, Tilman A1 - Reinhardt, Michael A1 - Hauff, Peter A1 - Schwab, Nicholas A1 - Linker, Ralf A1 - Maeurer, Mathias A1 - Meuth, Sven G. A1 - Wiendl, Heinz T1 - Temporal Pattern of ICAM-I Mediated Regulatory T Cell Recruitment to Sites of Inflammation in Adoptive Transfer Model of Multiple Sclerosis N2 - Migration of immune cells to the target organ plays a key role in autoimmune disorders like multiple sclerosis (MS). However, the exact underlying mechanisms of this active process during autoimmune lesion pathogenesis remain elusive. To test if pro-inflammatory and regulatory T cells migrate via a similar molecular mechanism, we analyzed the expression of different adhesion molecules, as well as the composition of infiltrating T cells in an in vivo model of MS, adoptive transfer experimental autoimmune encephalomyelitis in rats. We found that the upregulation of ICAM-I and VCAM-I parallels the development of clinical disease onset, but persists on elevated levels also in the phase of clinical remission. However, the composition of infiltrating T cells found in the developing versus resolving lesion phase changed over time, containing increased numbers of regulatory T cells (FoxP3) only in the phase of clinical remission. In order to test the relevance of the expression of cell adhesion molecules, animals were treated with purified antibodies to ICAM-I and VCAM-I either in the phase of active disease or in early remission. Treatment with a blocking ICAM-I antibody in the phase of disease progression led to a milder disease course. However, administration during early clinical remission aggravates clinical symptoms. Treatment with anti-VCAM-I at different timepoints had no significant effect on the disease course. In summary, our results indicate that adhesion molecules are not only important for capture and migration of pro-inflammatory T cells into the central nervous system, but also permit access of anti-inflammatory cells, such as regulatory T cells. Therefore it is likely to assume that intervention at the blood brain barrier is time dependent and could result in different therapeutic outcomes depending on the phase of CNS lesion development. KW - Multiple Sklerose Y1 - 2010 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-68565 ER - TY - JOUR A1 - Odorfer, Thorsten M. A1 - Wind, Teresa A1 - Zeller, Daniel T1 - Temporal discrimination thresholds and proprioceptive performance: impact of age and nerve conduction JF - Frontiers in Neuroscience N2 - Background Increasing attention is payed to the contribution of somatosensory processing in motor control. In particular, temporal somatosensory discrimination has been found to be altered differentially in common movement disorders. To date, there have only been speculations as to how impaired temporal discrimination and clinical motor signs may relate to each other. Prior to disentangling this relationship, potential confounders of temporal discrimination, in particular age and peripheral nerve conduction, should be assessed, and a quantifiable measure of proprioceptive performance should be established. ObjectiveTo assess the influence of age and polyneuropathy (PNP) on somatosensory temporal discrimination threshold (STDT), temporal discrimination movement threshold (TDMT), and behavioral measures of proprioception of upper and lower limbs. Methods STDT and TDMT were assessed in 79 subjects (54 healthy, 25 with PNP; age 30–79 years). STDT was tested with surface electrodes over the thenar or dorsal foot region. TDMT was probed with needle electrodes in flexor carpi radialis (FCR) and tibialis anterior (TA) muscle. Goniometer-based devices were used to assess limb proprioception during (i) active pointing to LED markers, (ii) active movements in response to variable visual cues, and (iii) estimation of limb position following passive movements. Pointing (or estimation) error was taken as a measure of proprioceptive performance. Results In healthy subjects, higher age was associated with higher STDT and TDMT at upper and lower extremities, while age did not correlate with proprioceptive performance. Patients with PNP showed higher STDT and TDMT values and decreased proprioceptive performance in active pointing tasks compared to matched healthy subjects. As an additional finding, there was a significant correlation between performance in active pointing tasks and temporal discrimination thresholds. Conclusion Given their notable impact on measures of temporal discrimination, age and peripheral nerve conduction need to be accounted for if STDT and TDMT are applied in patients with movement disorders. As a side observation, the correlation between measures of proprioception and temporal discrimination may prompt further studies on the presumptive link between these two domains. KW - pointing task KW - position estimation KW - aging KW - kinesthesia KW - somatosensory temporal discrimination KW - TDMT KW - temporal discrimination threshold Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-195648 SN - 1662-453X VL - 13 IS - 1241 ER - TY - JOUR A1 - Barlinn, J. A1 - Winzer, S. A1 - Worthmann, H. A1 - Urbanek, C. A1 - Häusler, K. G. A1 - Günther, A. A1 - Erdur, H. A1 - Görtler, M. A1 - Busetto, L. A1 - Wojciechowski, C. A1 - Schmitt, J. A1 - Shah, Y. A1 - Büchele, B. A1 - Sokolowski, P. A1 - Kraya, T. A1 - Merkelbach, S. A1 - Rosengarten, B. A1 - Stangenberg-Gliss, K. A1 - Weber, J. A1 - Schlachetzki, F. A1 - Abu-Mugheisib, M. A1 - Petersen, M. A1 - Schwartz, A. A1 - Palm, F. A1 - Jowaed, A. A1 - Volbers, B. A1 - Zickler, P. A1 - Remi, J. A1 - Bardutzky, J. A1 - Bösel, J. A1 - Audebert, H. J. A1 - Hubert, G. J. A1 - Gumbinger, C. T1 - Telemedizin in der Schlaganfallversorgung – versorgungsrelevant für Deutschland T1 - Telemedicine in stroke—pertinent to stroke care in Germany JF - Der Nervenarzt N2 - Hintergrund und Ziel Telemedizinische Schlaganfall-Netzwerke tragen dazu bei, die Schlaganfallversorgung und insbesondere den Zugang zu zeitkritischen Schlaganfalltherapien in vorrangig strukturschwachen, ländlichen Regionen zu gewährleisten. Ziel ist eine Darstellung der Nutzungsfrequenz und regionalen Verteilung dieser Versorgungsstruktur. Methoden Die Kommission „Telemedizinische Schlaganfallversorgung“ der Deutschen Schlaganfall-Gesellschaft führte eine Umfragestudie in allen Schlaganfall-Netzwerken durch. Ergebnisse In Deutschland sind 22 telemedizinische Schlaganfall-Netzwerke aktiv, welche insgesamt 43 Zentren (pro Netzwerk: Median 1,5, Interquartilsabstand [IQA] 1–3) sowie 225 Kooperationskliniken (pro Netzwerk: Median 9, IQA 4–17) umfassen und an einem unmittelbaren Zugang zur Schlaganfallversorgung für 48 Mio. Menschen teilhaben. Im Jahr 2018 wurden 38.211 Telekonsile (pro Netzwerk: Median 1340, IQA 319–2758) durchgeführt. Die Thrombolyserate betrug 14,1 % (95 %-Konfidenzintervall 13,6–14,7 %), eine Verlegung zur Thrombektomie wurde bei 7,9 % (95 %-Konfidenzintervall 7,5–8,4 %) der ischämischen Schlaganfallpatienten initiiert. Das Finanzierungssystem ist uneinheitlich mit einem Vergütungssystem für die Zentrumsleistungen in nur drei Bundesländern. Diskussion Etwa jeder 10. Schlaganfallpatient wird telemedizinisch behandelt. Die telemedizinischen Schlaganfall-Netzwerke erreichen vergleichbar hohe Lyseraten und Verlegungen zur Thrombektomie wie neurologische Stroke-Units und tragen zur Sicherstellung einer flächendeckenden Schlaganfallversorgung bei. Eine netzwerkübergreifende Sicherstellung der Finanzierung und einheitliche Erhebung von Qualitätssicherungsdaten haben das Potenzial diese Versorgungsstruktur zukünftig weiter zu stärken. N2 - Background and objective Telemedical stroke networks improve stroke care and provide access to time-dependent acute stroke treatment in predominantly rural regions. The aim is a presentation of data on its utility and regional distribution. Methods The working group on telemedical stroke care of the German Stroke Society performed a survey study among all telestroke networks. Results Currently, 22 telemedical stroke networks including 43 centers (per network: median 1.5, interquartile range, IQR, 1–3) as well as 225 cooperating hospitals (per network: median 9, IQR 4–17) operate in Germany and contribute to acute stroke care delivery to 48 million people. In 2018, 38,211 teleconsultations (per network: median 1340, IQR 319–2758) were performed. The thrombolysis rate was 14.1% (95% confidence interval 13.6–14.7%) and transfer for thrombectomy was initiated in 7.9% (95% confidence interval 7.5–8.4%) of ischemic stroke patients. Financial reimbursement differs regionally with compensation for telemedical stroke care in only three federal states. Conclusion Telemedical stroke care is utilized in about 1 out of 10 stroke patients in Germany. Telemedical stroke networks achieve similar rates of thrombolysis and transfer for thrombectomy compared with neurological stroke units and contribute to stroke care in rural regions. Standardization of network structures, financial assurance and uniform quality measurements may further strengthen the importance of telestroke networks in the future. KW - Schlaganfall KW - Stroke-Unit KW - Telemedizin KW - Schlaganfall-Netzwerk KW - Umfragestudie KW - stroke KW - stroke unit KW - telemedicine KW - stroke networks KW - survey Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-307752 SN - 0028-2804 SN - 1433-0407 VL - 92 IS - 6 ER - TY - JOUR A1 - Schuhmann, Michael K. A1 - Kraft, Peter A1 - Bieber, Michael A1 - Kollikowski, Alexander M. A1 - Schulze, Harald A1 - Nieswandt, Bernhard A1 - Pham, Mirko A1 - Stegner, David A1 - Stoll, Guido T1 - Targeting platelet GPVI plus rt-PA administration but not α2β1-mediated collagen binding protects against ischemic brain damage in mice JF - International Journal of Molecular Science N2 - Platelet collagen interactions at sites of vascular injuries predominantly involve glycoprotein VI (GPVI) and the integrin α2β1. Both proteins are primarily expressed on platelets and megakaryocytes whereas GPVI expression is also shown on endothelial and integrin α2β1 expression on epithelial cells. We recently showed that depletion of GPVI improves stroke outcome without increasing the risk of cerebral hemorrhage. Genetic variants associated with higher platelet surface integrin α2 (ITGA2) receptor levels have frequently been found to correlate with an increased risk of ischemic stroke in patients. However until now, no preclinical stroke study has addressed whether platelet integrin α2β1 contributes to the pathophysiology of ischemia/reperfusion (I/R) injury. Focal cerebral ischemia was induced in C57BL/6 and Itga2\(^{−/−}\) mice by a 60 min transient middle cerebral artery occlusion (tMCAO). Additionally, wild-type animals were pretreated with anti-GPVI antibody (JAQ1) or Fab fragments of a function blocking antibody against integrin α2β1 (LEN/B). In anti-GPVI treated animals, intravenous (IV) recombinant tissue plasminogen activator (rt-PA) treatment was applied immediately prior to reperfusion. Stroke outcome, including infarct size and neurological scoring was determined on day 1 after tMCAO. We demonstrate that targeting the integrin α2β1 (pharmacologic; genetic) did neither reduce stroke size nor improve functional outcome on day 1 after tMCAO. In contrast, depletion of platelet GPVI prior to stroke was safe and effective, even when combined with rt-PA treatment. Our results underscore that GPVI, but not ITGA2, is a promising and safe target in the setting of ischemic stroke. KW - ischemic stroke KW - integrin α2 KW - glycoprotein VI KW - recombinant tissue-type plasminogen activator KW - intracranial bleeding KW - transient middle cerebral artery occlusion Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-201700 SN - 1422-0067 VL - 20 IS - 8 ER - TY - JOUR A1 - Hopp, Sarah A1 - Albert-Weissenberger, Christiane A1 - Mencl, Stine A1 - Bieber, Michael A1 - Schuhmann, Michael K. A1 - Stetter, Christian A1 - Nieswandt, Bernhard A1 - Schmidt, Peter M. A1 - Monoranu, Camelia-Maria A1 - Alafuzoff, Irina A1 - Marklund, Niklas A1 - Nolte, Marc W. A1 - Sirén, Anna-Leena A1 - Kleinschnitz, Christoph T1 - Targeting coagulation factor XII as a novel therapeutic option in brain trauma JF - Annals of Neurology N2 - Objective: Traumatic brain injury is a major global public health problem for which specific therapeutic interventions are lacking. There is, therefore, a pressing need to identify innovative pathomechanism-based effective therapies for this condition. Thrombus formation in the cerebral microcirculation has been proposed to contribute to secondary brain damage by causing pericontusional ischemia, but previous studies have failed to harness this finding for therapeutic use. The aim of this study was to obtain preclinical evidence supporting the hypothesis that targeting factor XII prevents thrombus formation and has a beneficial effect on outcome after traumatic brain injury. Methods: We investigated the impact of genetic deficiency of factor XII and acute inhibition of activated factor XII with a single bolus injection of recombinant human albumin-fused infestin-4 (rHA-Infestin-4) on trauma-induced microvascular thrombus formation and the subsequent outcome in 2 mouse models of traumatic brain injury. Results: Our study showed that both genetic deficiency of factor XII and an inhibition of activated factor XII in mice minimize trauma-induced microvascular thrombus formation and improve outcome, as reflected by better motor function, reduced brain lesion volume, and diminished neurodegeneration. Administration of human factor XII in factor XII-deficient mice fully restored injury-induced microvascular thrombus formation and brain damage. Interpretation: The robust protective effect of rHA-Infestin-4 points to a novel treatment option that can decrease ischemic injury after traumatic brain injury without increasing bleeding tendencies. KW - Molecular-weight heparin KW - Thrombus formation KW - Cerebral-ischemia KW - in-vivo KW - Intravascular coagulation KW - Hemodynamic depression KW - Head-injury KW - Rats KW - Model KW - Mice Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-188800 VL - 79 IS - 6 ER - TY - THES A1 - Langjahr [verh. Held], Melissa T1 - Systemische Expression von Zytokinen bei schmerzhaften und schmerzlosen Polyneuropathien T1 - Systemic expression of cytokines in painful and painless polyneuropathies N2 - Die Pathophysiologie der PNP wie auch die Entstehung der oft assoziierten neuropathischen Schmerzen ist unklar. Gleichzeitig gibt es bislang keine geeigneten Biomarker, die die oft komplizierte Differentialdiagnose vereinfachen können. Einige Tiermodelle und klinische Studien lieferten bereits Hinweise auf die entscheidende Rolle pro- und anti-inflammatorischer Zytokine in diesen Prozessen. Ziel unserer Studie war es, die systemische Genexpression pro- und anti-inflammatorischer Zytokine in einer großen Kohorte von Patienten mit PNP verschiedener Ätiologie zu charakterisieren. Insgesamt konnten 111 PNP-Patienten und 38 gesunde Kontrollpersonen prospektiv rekrutiert werden. Nach Isolation von PBMC aus Blutproben von 97 Patienten wurde die Genexpression der pro-inflammatorischen Zytokine TNF, IL1, IL2, IL6, IL8 und der anti-inflammatorischen Zytokine IL4 und IL10 mittels qRT-PCR bestimmt. Bei 47 Patienten und 12 Kontrollen wurde zudem die IL6-, IL-8- und TNF-Zytokinproduktion von PBMC in vitro nach Stimulation durch LPS mittels ELISA untersucht. Hauptbefund war ein pro-inflammatorisches Zytokinprofil der PNP-Patienten mit höherer Genexpression von IL1, IL2, IL8 und TNF im Vergleich zu den gesunden Kontrollen. Im Falle der entzündlichen Neuropathien konnte zudem eine niedrigere Genexpression von IL10 im Vergleich zu Gesunden nachgewiesen werden. Sowohl schmerzhafte als auch schmerzlose Verlaufsformen wiesen ein pro-inflammatorisches Zytokingenexpressionsprofil im Vergleich zu Gesunden auf, das bei schmerzhaften PNP deutlich mehr beteiligte pro-inflammatorische Zytokine umfasste; relevante Unterschiede zwischen den PNP-Patienten mit und ohne Schmerz sowie der diagnostischen Subgruppen fanden sich nicht. Eine niedrigere Stimulationsschwelle der PBMC lag bei PNP-Patienten im Vergleich zu Gesunden nicht vor. Insgesamt erscheint die Rolle einzelner Zytokine als systemische Biomarker für die Differenzierung verschiedener PNP-Formen bzw. bezüglich neuropathischen Schmerzes aufgrund einer niedrigen Spezifität deutlich eingeschränkt. Dennoch sprechen unsere Ergebnisse für eine mögliche Rolle eines pro-inflammatorischen Milieus bei der Entstehung bzw. des Verlaufes verschiedener entzündlicher und nicht-entzündlicher Neuropathien und neuropathischen Schmerzes. N2 - Distinct cytokine expression patterns have been reported in biomaterial of patients with polyneuropathies (PNP). We investigated gene expression profiles of pro- and anti-inflammatory cytokines in peripheral blood mononuclear cells (PBMC) of patients with neuropathies of different etiologies. We prospectively studied 111 patients with neuropathies and compared data between diagnostic subgroups and healthy controls. Gene expression of a panel of pro- and anti-inflammatory cytokines was analyzed (interleukin-1 [IL-1], IL-2, IL-6, IL-8, and tumor necrosis factor-alpha [TNF], IL-4 and IL-10) in PBMC samples of 97 patients and 38 healthy controls. Furthermore, protein levels of IL-6, IL-8, and TNF were measured in supernatant of PBMC stimulated with lipopolysaccharide (LPS). PNP were associated with higher PBMC gene expression of IL-1 (p<0.05), IL-2 (p<0.05), IL-8 (p<0.001), and TNF (p<0.01) compared to healthy controls. Inflammatory neuropathies were associated with higher gene expression of IL-8 (p<0.001) and TNF (p<0.05) and lower gene expression of IL-10 (p<0.05) compared to healthy controls. More pro-inflammatory cytokines were elevated in painful neuropathy (IL-1, IL-2 [p<0.05], IL-8 [p<0.001] and TNF [p<0.05]) than in painless neuropathy (IL-8 [p<0.01] and TNF [p<0.01]) compared to healthy controls. Disease duration positively correlated with IL-6 gene expression (p<0.01). Supernatant protein levels of IL-6, IL-8, and TNF did not differ between groups. Conclusion: Systemic gene expression of pro-inflammatory cytokines is increased in patients with neuropathies and may be influenced by the presence of neuropathic pain. KW - Polyneuropathie KW - Cytokine KW - Genexpression KW - peripheral neuropathy KW - neuropathic pain KW - cytokine KW - gene expression KW - peripheral blood mononuclear cells KW - Neuropathischer Schmerz KW - Zytokine KW - Periphere mononukleäre Zellen Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-154445 ER - TY - JOUR A1 - García-Fernández, Patricia A1 - Höfflin, Klemens A1 - Rausch, Antonia A1 - Strommer, Katharina A1 - Neumann, Astrid A1 - Cebulla, Nadine A1 - Reinhold, Ann-Kristin A1 - Rittner, Heike A1 - Üçeyler, Nurcan A1 - Sommer, Claudia T1 - Systemic inflammatory markers in patients with polyneuropathies JF - Frontiers in Immunology N2 - Introduction In patients with peripheral neuropathies (PNP), neuropathic pain is present in 50% of the cases, independent of the etiology. The pathophysiology of pain is poorly understood, and inflammatory processes have been found to be involved in neuro-degeneration, -regeneration and pain. While previous studies have found a local upregulation of inflammatory mediators in patients with PNP, there is a high variability described in the cytokines present systemically in sera and cerebrospinal fluid (CSF). We hypothesized that the development of PNP and neuropathic pain is associated with enhanced systemic inflammation. Methods To test our hypothesis, we performed a comprehensive analysis of the protein, lipid and gene expression of different pro- and anti-inflammatory markers in blood and CSF from patients with PNP and controls. Results While we found differences between PNP and controls in specific cytokines or lipids, such as CCL2 or oleoylcarnitine, PNP patients and controls did not present major differences in systemic inflammatory markers in general. IL-10 and CCL2 levels were related to measures of axonal damage and neuropathic pain. Lastly, we describe a strong interaction between inflammation and neurodegeneration at the nerve roots in a specific subgroup of PNP patients with blood-CSF barrier dysfunction. Conclusion In patients with PNP systemic inflammatory, markers in blood or CSF do not differ from controls in general, but specific cytokines or lipids do. Our findings further highlight the importance of CSF analysis in patients with peripheral neuropathies. KW - cytokines KW - polyneuropathy KW - cerebrospinal fluid KW - neurofilament light chain KW - blood CSF barrier Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-304217 VL - 14 ER - TY - JOUR A1 - Üceyler, Nurcan A1 - Häuser, Winfried A1 - Sommer, Claudia T1 - Systematic review with meta-analysis: Cytokines in fibromyalgia syndrome N2 - Background: To perform a systematic review and meta-analysis on cytokine levels in patients with fibromyalgia syndrome (FMS). Methods: Through December 2010 we systematically reviewed the databases PubMed, MEDLINE, and PsycINFO and screened the reference lists of 22 review articles for suitable original articles. Original articles investigating cytokines in patients with FMS were included. Data were extracted by two independent authors. Differences of the cytokine levels of FMS patients and controls were summarized by standardized mean differences (SMD) using a random effects model. Study quality was assessed applying methodological scores: modified Center of Evidence Based Medicine, Newcastle-Ottawa-Scale, and Würzburg Methodological Quality Score. Results: Twenty-five articles were included investigating 1255 FMS patients and 800 healthy controls. Data of 13/25 studies entered meta-analysis. The overall methodological quality of studies was low. The results of the majority of studies were not comparable because methods, investigated material, and investigated target cytokines differed. Systematic review of the selected 25 articles revealed that FMS patients had higher serum levels of interleukin (IL)-1 receptor antagonist, IL-6, and IL-8, and higher plasma levels of IL-8. Meta-analysis of eligible studies showed that FMS patients had higher plasma IL-6 levels compared to controls (SMD = -0.34 [-0.64, -0.03] 95% CI; p = 0.03). The majority of investigated cytokines were not different between patients and controls. Conclusions: The pathophysiological role of cytokines in FMS is still unclear. Studies of higher quality and with higher numbers of subjects are needed. KW - Fibromyalgie Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-69189 ER - TY - JOUR A1 - Elhfnawy, Ahmed Mohamed A1 - Volkmann, Jens A1 - Schliesser, Mira A1 - Fluri, Felix T1 - Symptomatic vs. asymptomatic 20–40% internal carotid artery stenosis: Does the plaque size matter? JF - Frontiers in Neurology N2 - Background: Around 9–15% of ischemic strokes are related to internal carotid artery (ICA)-stenosis ≥50%. However, the extent to which ICA-stenosis <50% causes ischemic cerebrovascular events is uncertain. We examined the relation between plaque cross-sectional area and length and the risk of ischemic stroke or TIA among patients with ICA-stenosis of 20–40%. Methods: We retrospectively identified patients admitted to the Department of Neurology, University Hospital of Würzburg, from January 2011 until September 2016 with ischemic stroke or TIA and concomitant ICA-stenosis of 20–40%, either symptomatic or asymptomatic. Plaque length and cross-sectional area were assessed on ultrasound scans. Results: We identified 41 patients with ischemic stroke or TIA and ICA-stenosis of 20–40%; 14 symptomatic and 27 asymptomatic. The plaque cross-sectional area was significantly larger among symptomatic than asymptomatic ICA-stenosis; median values (IQR) were 0.45 (0.21–0.69) cm2 and 0.27 (0.21–0.38) cm2, p = 0.03, respectively. A plaque cross-sectional area ≥0.36 cm2 had a sensitivity of 71% and a specificity of 76% for symptomatic compared with asymptomatic ICA-stenosis. In a sex-adjusted multivariate logistic regression, a plaque cross-sectional area ≥0.36 cm2 and a plaque length ≥1.65 cm were associated with an OR (95% CI) of 5.54 (1.2–25.6), p = 0.028 and 1.78 (0.36–8.73), p = 0.48, respectively, for symptomatic ICA-stenosis. Conclusion: Large plaques might increase the risk of ischemic stroke or TIA among patients with low-grade ICA-stenosis of 20–40%. Sufficiently powered prospective longitudinal cohort studies are needed to definitively test the stroke risk stratification value of carotid plaque length and cross-sectional area in the setting of current optimal medical treatment. KW - ischemic stroke KW - carotid atherosclerosis KW - carotid stenosis KW - plaque cross-sectional area KW - length of stenosis KW - carotid ultrasound Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-201262 VL - 10 IS - 960 ER - TY - JOUR A1 - Pham, Mirko A1 - Helluy, Xavier A1 - Kleinschnitz, Christoph A1 - Kraft, Peter A1 - Bartsch, Andreas J. A1 - Jakob, Peter A1 - Nieswandt, Bernhard A1 - Bendszus, Martin A1 - Guido, Stoll T1 - Sustained Reperfusion after Blockade of Glycoprotein-Receptor-Ib in Focal Cerebral Ischemia: An MRI Study at 17.6 Tesla JF - PLoS ONE N2 - Background: Inhibition of early platelet adhesion by blockade of glycoprotein-IB (GPIb) protects mice from ischemic stroke. To elucidate underlying mechanisms in-vivo, infarct development was followed by ultra-high field MRI at 17.6 Tesla. Methods: Cerebral infarction was induced by transient-middle-cerebral-artery-occlusion (tMCAO) for 1 hour in C57/BL6 control mice (N = 10) and mice treated with 100 mg Fab-fragments of the GPIb blocking antibody p0p/B 1 h after tMCAO (N = 10). To control for the effect of reperfusion, additional mice underwent permanent occlusion and received anti-GPIb treatment (N = 6; pMCAO) or remained without treatment (N = 3; pMCAO). MRI 2 h and 24 h after MCAO measured cerebral-blood-flow (CBF) by continuous arterial-spin labelling, the apparent-diffusion-coefficient (ADC), quantitative-T2 and T2-weighted imaging. All images were registered to a standard mouse brain MRI atlas and statistically analysed voxel-wise, and by cortico-subcortical ROI analysis. Results: Anti-GPIb treatment led to a relative increase of postischemic CBF vs. controls in the cortical territory of the MCA (2 h: 44.2 +/- 6.9 ml/100g/min versus 24 h: 60.5 +/- 8.4; p = 0.0012, F((1,18)) = 14.63) after tMCAO. Subcortical CBF 2 h after tMCAO was higher in anti-GPIb treated animals (45.3 +/- 5.9 vs. controls: 33.6 +/- 4.3; p = 0.04). In both regions, CBF findings were clearly related to a lower probability of infarction (Cortex/Subcortex of treated group: 35%/65% vs. controls: 95%/100%) and improved quantitative-T2 and ADC. After pMCAO, anti-GPIb treated mice developed similar infarcts preceded by severe irreversible hypoperfusion as controls after tMCAO indicating dependency of stroke protection on reperfusion. Conclusion: Blockade of platelet adhesion by anti-GPIb-Fab-fragments results in substantially improved CBF early during reperfusion. This finding was in exact spatial correspondence with the prevention of cerebral infarction and indicates in-vivo an increased patency of the microcirculation. Thus, progression of infarction during early ischemia and reperfusion can be mitigated by anti-platelet treatment. KW - Von-Willebrand-factor KW - Experimental stroke KW - Magnetic-resonance KW - Arterial water KW - Brain KW - Perfusion KW - Mice KW - Inflammation KW - Coefficient KW - mechanisms Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-142608 VL - 6 IS - 4 ER - TY - JOUR A1 - Traub, Jan A1 - Grondey, Katja A1 - Gassenmaier, Tobias A1 - Schmitt, Dominik A1 - Fette, Georg A1 - Frantz, Stefan A1 - Boivin-Jahns, Valérie A1 - Jahns, Roland A1 - Störk, Stefan A1 - Stoll, Guido A1 - Reiter, Theresa A1 - Hofmann, Ulrich A1 - Weber, Martin S. A1 - Frey, Anna T1 - Sustained increase in serum glial fibrillary acidic protein after first ST-elevation myocardial infarction JF - International Journal of Molecular Sciences N2 - Acute ischemic cardiac injury predisposes one to cognitive impairment, dementia, and depression. Pathophysiologically, recent positron emission tomography data suggest astroglial activation after experimental myocardial infarction (MI). We analyzed peripheral surrogate markers of glial (and neuronal) damage serially within 12 months after the first ST-elevation MI (STEMI). Serum levels of glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) were quantified using ultra-sensitive molecular immunoassays. Sufficient biomaterial was available from 45 STEMI patients (aged 28 to 78 years, median 56 years, 11% female). The median (quartiles) of GFAP was 63.8 (47.0, 89.9) pg/mL and of NfL 10.6 (7.2, 14.8) pg/mL at study entry 0–4 days after STEMI. GFAP after STEMI increased in the first 3 months, with a median change of +7.8 (0.4, 19.4) pg/mL (p = 0.007). It remained elevated without further relevant increases after 6 months (+11.7 (0.6, 23.5) pg/mL; p = 0.015), and 12 months (+10.3 (1.5, 22.7) pg/mL; p = 0.010) compared to the baseline. Larger relative infarction size was associated with a higher increase in GFAP (ρ = 0.41; p = 0.009). In contrast, NfL remained unaltered in the course of one year. Our findings support the idea of central nervous system involvement after MI, with GFAP as a potential peripheral biomarker of chronic glial damage as one pathophysiologic pathway. KW - myocardial infarction KW - STEMI KW - glial fibrillary acidic protein KW - GFAP KW - neurofilament light chain KW - NfL KW - glial damage KW - cardiac magnetic resonance imaging KW - MRI KW - infarction size Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-288261 SN - 1422-0067 VL - 23 IS - 18 ER - TY - THES A1 - Palmisano, Chiara T1 - Supraspinal Locomotor Network Derangements: A Multimodal Approach T1 - Störungen des Supraspinalen Lokomotorischen Netzwerks: ein Multimodaler Ansatz N2 - Parkinson’s Disease (PD) constitutes a major healthcare burden in Europe. Accounting for aging alone, ~700,000 PD cases are predicted by 2040. This represents an approximately 56% increase in the PD population between 2005 and 2040, with a consequent rise in annual disease‐related medical costs. Gait and balance disorders are a major problem for patients with PD and their caregivers, mainly because to their correlation with falls. Falls occur as a result of a complex interaction of risk factors. Among them, Freezing of Gait (FoG) is a peculiar gait derangement characterized by a sudden and episodic inability to produce effective stepping, causing falls, mobility restrictions, poor quality of life, and increased morbidity and mortality. Between 50–70% of PD patients have FoG and/or falls after a disease duration of 10 years, only partially and inconsistently improved by dopaminergic treatment and Deep Brain Stimulation (DBS). Treatment-induced worsening has been also observed under certain conditions. Effective treatments for gait disturbances in PD are lacking, probably because of the still poor understanding of the supraspinal locomotor network. In my thesis, I wanted to expand our knowledge of the supraspinal locomotor network and in particular the contribution of the basal ganglia to the control of locomotion. I believe this is a key step towards new preventive and personalized therapies for postural and gait problems in patients with PD and related disorders. In addition to patients with PD, my studies also included people affected by Progressive Supranuclear Palsy (PSP). PSP is a rare primary progressive parkinsonism characterized at a very early disease stage by poor balance control and frequent backwards falls, thus providing an in vivo model of dysfunctional locomotor control. I focused my attention on one of the most common motor transitions in daily living, the initiation of gait (GI). GI is an interesting motor task and a relevant paradigm to address balance and gait impairments in patients with movement disorders, as it is associated with FoG and high risk of falls. It combines a preparatory (i.e., the Anticipatory Postural Adjustments [APA]) and execution phase (the stepping) and allows the study of movement scaling and timing as an expression of muscular synergies, which follow precise and online feedback information processing and integration into established feedforward patterns of motor control. By applying a multimodal approach that combines biomechanical assessments and neuroimaging investigations, my work unveiled the fundamental contribution of striatal dopamine to GI in patients with PD. Results in patients with PSP further supported the fundamental role of the striatum in GI execution, revealing correlations between the metabolic intake of the left caudate nucleus with diverse GI measurements. This study also unveiled the interplay of additional brain areas in the motor control of GI, namely the Thalamus, the Supplementary Motor Area (SMA), and the Cingulate cortex. Involvement of cortical areas was also suggested by the analysis of GI in patients with PD and FoG. Indeed, I found major alterations in the preparatory phase of GI in these patients, possibly resulting from FoG-related deficits of the SMA. Alterations of the weight shifting preceding the stepping phase were also particularly important in PD patients with FoG, thus suggesting specific difficulties in the integration of somatosensory information at a cortical level. Of note, all patients with PD showed preserved movement timing of GI, possibly suggesting preserved and compensatory activity of the cerebellum. Postural abnormalities (i.e., increased trunk and thigh flexion) showed no relationship with GI, ruling out an adaptation of the motor pattern to the altered postural condition. In a group of PD patients implanted with DBS, I further explored the pathophysiological functioning of the locomotor network by analysing the timely activity of the Subthalamic Nucleus (STN) during static and dynamic balance control (i.e., standing and walking). For this study, I used novel DBS devices capable of delivering stimulation and simultaneously recording Local Field Potentials (LFP) of the implanted nucleus months and years after surgery. I showed a gait-related frequency shift in the STN activity of PD patients, possibly conveying cortical (feedforward) and cerebellar (feedback) information to mesencephalic locomotor areas. Based on this result, I identified for each patient a Maximally Informative Frequency (MIF) whose power changes can reliably classify standing and walking conditions. The MIF is a promising input signal for new DBS devices that can monitor LFP power modulations to timely adjust the stimulation delivery based on the ongoing motor task (e.g., gait) performed by the patient (adaptive DBS). Altogether my achievements allowed to define the role of different cortical and subcortical brain areas in locomotor control, paving the way for a better understanding of the pathophysiological dynamics of the supraspinal locomotor network and the development of tailored therapies for gait disturbances and falls prevention in PD and related disorders. N2 - Die Parkinson-Krankheit (PD) stellt in Europa eine große Belastung für das Gesundheitswesen dar. Allein unter Berücksichtigung der Alterung werden bis zum Jahr 2040 etwa 700 000 Fälle von Parkinson prognostiziert. Dies entspricht einer Zunahme der Parkinson-Population um etwa 56 % zwischen 2005 und 2040, was zu einem Anstieg der jährlichen krankheitsbedingten medizinischen Kosten führt. Gang- und Gleichgewichtsstörungen sind ein großes Problem für Morbus-Parkinson-Patienten und ihre Betreuer, vor allem, weil sie mit Stürzen zusammenhängen. Stürze sind das Ergebnis einer komplexen Interaktion von Risikofaktoren. Zu diesen Faktoren gehört das Freezing of Gait (FoG), eine besondere Gangstörung, die durch eine plötzliche und episodische Unfähigkeit gekennzeichnet ist, einen effektiven Schritt zu machen, was zu Stürzen, Mobilitätseinschränkungen, schlechter Lebensqualität und erhöhter Morbidität und Mortalität führt. Zwischen 50 und 70 % der Morbus-Parkinson-Patienten haben nach einer Krankheitsdauer von 10 Jahren FoG und/oder Stürze, die sich durch dopaminerge Behandlung und Tiefe Hirnstimulation (DBS) nur teilweise und uneinheitlich verbessern. Unter bestimmten Bedingungen wurde auch eine behandlungsbedingte Verschlechterung beobachtet. Es gibt keine wirksamen Behandlungen für Gangstörungen bei Morbus Parkinson, was wahrscheinlich auf das noch immer unzureichende Verständnis des supraspinalen lokomotorischen Netzwerks zurückzuführen ist. In meiner Dissertation wollte ich unser Wissen über das supraspinale Bewegungsnetzwerk und insbesondere den Beitrag der Basalganglien zur Steuerung der Fortbewegung erweitern. Ich glaube, dass dies ein wichtiger Schritt auf dem Weg zu neuen präventiven und personalisierten Therapien für Haltungs- und Gangprobleme bei Patienten mit Parkinson und verwandten Erkrankungen ist. Neben Morbus-Parkinson-Patienten wurden in meine Studien auch Menschen mit progressiver supranukleärer Lähmung (PSP) einbezogen. PSP ist ein seltener primär progressiver Parkinsonismus, der in einem sehr frühen Krankheitsstadium durch eine schlechte Gleichgewichtskontrolle und häufige Rückwärtsstürze gekennzeichnet ist und somit ein In-vivo-Modell für eine gestörte Bewegungskontrolle darstellt. Ich habe mich auf einen der häufigsten motorischen Übergänge im täglichen Leben konzentriert, die Initiierung des Gangs (GI). GI ist eine interessante motorische Aufgabe und ein relevantes Paradigma zur Untersuchung von Gleichgewichts- und Gangstörungen bei Patienten mit Bewegungsstörungen, da sie mit FoG und einem hohen Sturzrisiko verbunden ist. Sie kombiniert eine Vorbereitungsphase (d. h. die antizipatorischen posturalen Anpassungen [APA]) und eine Ausführungsphase (den Schritt) und ermöglicht die Untersuchung der Bewegungsskalierung und des Timings als Ausdruck muskulärer Synergien, die einer präzisen und online erfolgenden Verarbeitung von Feedback-Informationen und der Integration in etablierte Feedforward-Muster der motorischen Kontrolle folgen. Durch Anwendung eines multimodalen Ansatzes, der biomechanische Bewertungen und bildgebende Untersuchungen kombiniert, hat meine Arbeit den grundlegenden Einfluss des striatalen Dopamins auf GI bei Patienten mit Parkinson enthüllt. Die Ergebnisse bei Patienten mit PSP untermauerten die grundlegende Rolle des Striatums bei der Ausführung von GI, indem sie Korrelationen zwischen der metabolischen Aufnahme des linken Nucleus caudatus und verschiedenen GI-Parametern aufzeigten. Diese Studie enthüllte auch das Zusammenspiel weiterer Hirnareale bei der motorischen Kontrolle von GI, nämlich des Thalamus, der Supplementary Motor Area (SMA) und des Cingulum-Kortex. Die Beteiligung kortikaler Areale wurde auch durch die Analyse der GI bei Patienten mit Parkinson und FoG nahegelegt. In der Tat fand ich bei diesen Patienten erhebliche Veränderungen in der Vorbereitungsphase des GI, die möglicherweise auf FoG-bedingte Defizite der SMA zurückzuführen sind. Veränderungen der Gewichtsverlagerung, die der Schrittphase vorausgeht, waren bei Morbus-Parkinson-Patienten mit FoG ebenfalls besonders ausgeprägt, was auf spezifische Schwierigkeiten bei der Integration somatosensorischer Informationen auf kortikaler Ebene schließen lässt. Bemerkenswert ist, dass alle Morbus-Parkinson-Patienten ein gut erhaltenes Bewegungs-Timing von GI aufwiesen, was möglicherweise auf eine ebenfalls gut erhaltene und kompensatorische Aktivität des Kleinhirns hindeutet. Haltungsanomalien (d. h. verstärkte Rumpf- und Oberschenkelflexion) standen in keinem Zusammenhang mit GI, was eine Anpassung des motorischen Musters an die veränderten Haltungsbedingungen ausschließt. Bei einer Gruppe von Morbus-Parkinson-Patienten, denen eine DBS implantiert wurde, untersuchte ich die pathophysiologische Funktionsweise des lokomotorischen Netzwerks weiter, indem ich die rechtzeitige Aktivität des subthalamischen Nucleus (STN) während der statischen und dynamischen Gleichgewichtskontrolle (d. h. Stehen und Gehen) analysierte. Für diese Studie habe ich neuartige DBS-Geräte verwendet, die in der Lage sind, Stimulationen abzugeben und gleichzeitig lokale Feldpotentiale (LFP) des implantierten Nucleus Monate und Jahre nach der Operation aufzuzeichnen. Ich konnte eine gehbezogene Frequenzverschiebung in der STN-Aktivität von Morbus-Parkinson-Patienten nachweisen, die möglicherweise kortikale (feedforward) und zerebelläre (feedback) Informationen an mesenzephale Bewegungsbereiche weiterleitet. Auf der Grundlage dieses Ergebnisses habe ich für jeden Patienten eine maximal informative Frequenz (MIF) identifiziert, deren Leistungsänderungen eine zuverlässige Klassifizierung von Steh- und Gehzuständen ermöglichen. Die MIF ist ein vielversprechendes Eingangssignal für neue DBS-Geräte, die LFP-Leistungsmodulationen überwachen können, um die Stimulationsabgabe zeitnah an die laufende motorische Aufgabe (z. B. Gehen) des Patienten anzupassen (adaptive DBS). Insgesamt ist es mir gelungen, die Rolle verschiedener kortikaler und subkortikaler Hirnareale bei der Bewegungskontrolle zu definieren. Dies ebnet den Weg für ein besseres Verständnis der pathophysiologischen Dynamik des supraspinalen Bewegungsnetzwerks und die Entwicklung maßgeschneiderter Therapien für Gangstörungen und Sturzprävention bei Morbus Parkinson und verwandten Erkrankungen. KW - locomotor network KW - gait initiation KW - deep brain stimulation KW - gait analysis KW - movement disorders KW - neural biomarkers KW - parkinson's disease Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-266442 ER - TY - THES A1 - Ramirez Pasos, Uri Eduardo T1 - Subthalamic Nucleus Neural Synchronization and Connectivity during Limbic Processing of Emotional Pictures: Evidence from Invasive Recordings in Patients with Parkinson's Disease T1 - Synchronisierung und Konnektivität des Nucleus subthalamicus während limbischer Bearbeitung affektiver Bilder: Evidenz aus invasiven Aufzeichnungen in Patienten mit Morbus Parkinson N2 - In addition to bradykinesia and tremor, patients with Parkinson’s disease (PD) are known to exhibit non-motor symptoms such as apathy and hypomimia but also impulsivity in response to dopaminergic replacement therapy. Moreover, a plethora of studies observe differences in electrocortical and autonomic responses to both visual and acoustic affective stimuli in PD subjects compared to healthy controls. This suggests that the basal ganglia (BG), as well as the hyperdirect pathway and BG thalamocortical circuits, are involved in affective processing. Recent studies have shown valence and dopamine-dependent changes in synchronization in the subthalamic nucleus (STN) in PD patients during affective tasks. This thesis investigates the role of dopamine, valence, and laterality in STN electrophysiology by analyzing event-related potentials (ERP), synchronization, and inter-hemispheric STN connectivity. STN recordings were obtained from PD patients with chronically implanted electrodes for deep brain stimulation during a passive affective picture presentation task. The STN exhibited valence-dependent ERP latencies and lateralized ‘high beta’ (28–40 Hz) event-related desynchronization. This thesis also examines the role of dopamine, valence, and laterality on STN functional connectivity with the anterior cingulate cortex (ACC) and the amygdala. The activity of these limbic structures was reconstructed using simultaneously recorded electroencephalographic signals. While the STN was found to establish early coupling with both structures, STN-ACC coupling in the ‘alpha’ range (7–11 Hz) and uncoupling in the ‘low beta’ range (14–21 Hz) were lateralized. Lateralization was also observed at the level of synchrony in both reconstructed sources and for ACC ERP amplitude, whereas dopamine modulated ERP latency in the amygdala. These results may deepen our current understanding of the STN as a limbic node within larger emotional-motor networks in the brain.
 N2 - Neben Bradykinese und Tremor weisen Patienten mit Morbus Parkinson (PD) bekannterweise nicht-motorische Symptome auf wie Apathie und Hypomimie, aber auch Impulsivität, welche durch Dopaminersatztherapien bedingt ist. Viele Studien belegen außerdem Unterschiede von kortikalen und autonomen Reaktionen auf sowohl visuelle als auch akustische Reize bei Patienten mit PD im Vergleich zu gesunden Kontrollgruppen. Dies legt nahe, dass sich die Basalganglien (BG), und auch die hyperdirekte Verbindung sowie die BG-thalamokortikalen Schleifen, an der Affektbearbeitung beteiligen. Jüngere Studien haben Valenz- und Dopamin-bedingte Veränderungen der Synchronisierung im Nucleus subthalamicus (STN) von Parkinson-Patienten bei affektiven Aufgaben belegt. Diese Promotionsarbeit untersucht die Rolle von Dopamin, Valenz und Lateralität in der STN-Elektrophysiologie mittels Analysen von ereigniskorrelierten Potentialen (ERP), Synchronisierung und interhemisphärischer funktioneller Konnektivität. STN-Aufzeichnungen wurden von Patienten mit dauerhaft implantierten Elektroden für die Tiefenhirnstimulation während einer passiven Aufgabe abgeleitet, bei den ihnen Bilder mit emotionalen Inhalten gezeigt wurden. Der STN wies Valenz-bedingte ERP-Latenz und lateralisierte ereigniskorrelierte Desynchronisierung in ‘hohem Beta’ (28–40 Hz) auf. Diese Dissertation untersucht auch die Rolle von Dopamin, Valenz und Lateralität bezüglich der funktionellen Konnektivität zwischen dem STN und dem Gyrus cinguli pars anterior (ACC) sowie der Amygdala. Die Aktivität dieser Strukturen wurde aus simultanen elektroenzephalographischen Aufzeichnungen rekonstruiert. Obwohl eine STN-Kopplung mit beiden Strukturen auftritt, war die STN-ACC-Kopplung im ‘Alpha’- Bereich (7–11 Hz) und die Entkopplung im ‘niedrigen Beta’-Bereich (14–21 Hz) lateralisiert. Lateralisierung wurde auch an der Synchronisierung in beiden rekonstruierten Quellen und an der ACC-ERP-Amplitude festgestellt, wohingegen Dopamin die ERP-Latenz in der Amygdala modulierte. Diese Ergebnisse mögen das gegenwärtige Wissen vom STN als limbischem Knoten innerhalb größerer affektiv-motorischer Schleifen im Gehirn vertiefen. KW - Nucleus subthalamicus KW - subthalamic nucleus KW - Emotionales Verhalten KW - functional connectivity KW - oscillations KW - emotion KW - Affekt KW - Elektrophysiologie Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-169850 ER - TY - JOUR A1 - Özdağ Acarlı, Ayşe Nur A1 - Klein, Thomas A1 - Egenolf, Nadine A1 - Sommer, Claudia A1 - Üçeyler, Nurcan T1 - Subepidermal Schwann cell counts correlate with skin innervation - an exploratory study JF - Muscle & Nerve N2 - Introduction/Aims Schwann cell clusters have been described at the murine dermis-epidermis border. We quantified dermal Schwann cells in the skin of patients with small-fiber neuropathy (SFN) compared with healthy controls to correlate with the clinical phenotype. Methods Skin punch biopsies from the lower legs of 28 patients with SFN (11 men, 17 women; median age, 54 [range, 19-73] years) and 9 healthy controls (five men, four women, median age, 34 [range, 25-69] years) were immunoreacted for S100 calcium-binding protein B as a Schwann cell marker, protein-gene product 9.5 as a pan-neuronal marker, and CD207 as a Langerhans cell marker. Intraepidermal nerve fiber density (IENFD) and subepidermal Schwann cell counts were determined. Results Skin samples of patients with SFN showed lower IENFD (P < .05), fewer Schwann cells per millimeter (P < .01), and fewer Schwann cell clusters per millimeter (P < .05) than controls. When comparing SFN patients with reduced (n = 13; median age, 53 [range, 19-73] years) and normal distal (n = 15, median age, 54 [range, 43-68] years) IENFD, the number of solitary Schwann cells per millimeter (p < .01) and subepidermal nerve fibers associated with Schwann cell branches (P < .05) were lower in patients with reduced IENFD. All three parameters correlated positively with distal IENFD (P < .05 to P < .01), whereas no correlation was found between Schwann cell counts and clinical pain characteristics. Discussion Our data raise questions about the mechanisms underlying the interdependence of dermal Schwann cells and skin innervation in SFN. The temporal course and functional impact of Schwann cell presence and kinetics need further investigation. KW - intraepidermal nerve fiber density KW - small-fiber neuropathy KW - skin punch biopsy KW - Schwann cell KW - neuropathic pain KW - innervation Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-318726 VL - 65 IS - 4 SP - 471 EP - 479 ER - TY - JOUR A1 - Wutzler, Alexander A1 - Krogias, Christos A1 - Grau, Anna A1 - Veltkamp, Roland A1 - Heuschmann, Peter U. A1 - Haeusler, Karl Georg T1 - Stroke prevention in patients with acute ischemic stroke and atrial fibrillation in Germany - a cross sectional survey JF - BMC Neurology N2 - Background Atrial fibrillation (AF) is present in 15–20% of patients with acute ischemic stroke. Oral anticoagulation reduces the risk of AF-related recurrent stroke but clinical guideline recommendations are rather vague regarding its use in the acute phase of stroke. We aimed to assess the current clinical practice of medical stroke prevention in AF patients during the acute phase of ischemic stroke. Methods In April 2017, a standardized anonymous questionnaire was sent to clinical leads of all 298 certified stroke units in Germany. Results Overall, 154 stroke unit leads participated (response rate 52%). Anticoagulation in the acute phase of stroke is considered feasible in more than 90% of AF patients with ischemic stroke. Clinicians assume that about two thirds of all AF patients (range 20–100%) are discharged on oral anticoagulation. According to local preferences, acetylsalicylic acid is given orally in the majority of patients with delayed initiation of oral anticoagulation. A non-vitamin K-dependent oral anticoagulant (NOAC) is more often prescribed than a vitamin K-dependent oral anticoagulant (VKA). VKA is more often chosen in patients with previous VKA intake than in VKA naive patients. In the minority of patients, stroke unit leads discuss the prescription of a specific oral anticoagulant with the treating general practitioner. Adherence to medical stroke prevention after hospital discharge is not assessed on a regular basis in any patient by the majority of participating stroke centers. Conclusions Early secondary stroke prevention in AF patients in German stroke units is based on OAC use but prescription modalities vary in clinical practice. KW - Ischemic stroke KW - Secondary stroke prevention KW - Atrial fibrillation KW - Survey KW - Oral anticoagulation KW - Stroke unit Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-201078 VL - 19 ER - TY - JOUR A1 - Canessa, Andrea A1 - Pozzi, Nicolò G. A1 - Arnulfo, Gabriele A1 - Brumberg, Joachim A1 - Reich, Martin M. A1 - Pezzoli, Gianni A1 - Ghilardi, Maria F. A1 - Matthies, Cordula A1 - Steigerwald, Frank A1 - Volkmann, Jens A1 - Isaias, Ioannis U. T1 - Striatal Dopaminergic Innervation Regulates Subthalamic Beta-Oscillations and Cortical-Subcortical Coupling during Movements: Preliminary Evidence in Subjects with Parkinson's Disease JF - Frontiers in Human Neuroscience N2 - Activation of the basal ganglia has been shown during the preparation and execution of movement. However, the functional interaction of cortical and subcortical brain areas during movement and the relative contribution of dopaminergic striatal innervation remains unclear. We recorded local field potential (LFP) activity from the subthalamic nucleus (STN) and high-density electroencephalography (EEG) signals in four patients with Parkinson’s disease (PD) off dopaminergic medication during a multi-joint motor task performed with their dominant and non-dominant hand. Recordings were performed by means of a fully-implantable deep brain stimulation (DBS) device at 4 months after surgery. Three patients also performed a single-photon computed tomography (SPECT) with [123I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane (FP-CIT) to assess striatal dopaminergic innervation. Unilateral movement execution led to event-related desynchronization (ERD) followed by a rebound after movement termination event-related synchronization (ERS) of oscillatory beta activity in the STN and primary sensorimotor cortex of both hemispheres. Dopamine deficiency directly influenced movement-related beta-modulation, with greater beta-suppression in the most dopamine-depleted hemisphere for both ipsi- and contralateral hand movements. Cortical-subcortical, but not interhemispheric subcortical coherencies were modulated by movement and influenced by striatal dopaminergic innervation, being stronger in the most dopamine-depleted hemisphere. The data are consistent with a role of dopamine in shielding subcortical structures from an excessive cortical entrapment and cross-hemispheric coupling, thus allowing fine-tuning of movement. KW - beta oscillations KW - Parkinson’s disease KW - motor control KW - movement disorders KW - imaging KW - subthalamic nucleus KW - coherence analysis Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-164061 VL - 10 IS - 611 ER - TY - JOUR A1 - Rickert, V. A1 - Wagenhäuser, L. A1 - Nordbeck, P. A1 - Wanner, C. A1 - Sommer, C. A1 - Rost, S. A1 - Üçeyler, N. T1 - Stratification of Fabry mutations in clinical practice: a closer look at α‐galactosidase A‐3D structure JF - Journal of Internal Medicine N2 - Background Fabry disease (FD) is an X‐linked lysosomal storage and multi‐system disorder due to mutations in the α‐galactosidase A (α‐GalA) gene. We investigated the impact of individual amino acid exchanges in the α‐GalA 3D‐structure on the clinical phenotype of FD patients. Patients and methods We enrolled 80 adult FD patients with α‐GalA missense mutations and stratified them into three groups based on the amino acid exchange location in the α‐GalA 3D‐structure: patients with active site mutations, buried mutations and other mutations. Patient subgroups were deep phenotyped for clinical and laboratory parameters and FD‐specific treatment. Results Patients with active site or buried mutations showed a severe phenotype with multi‐organ involvement and early disease manifestation. Patients with other mutations had a milder phenotype with less organ impairment and later disease onset. α‐GalA activity was lower in patients with active site or buried mutations than in those with other mutations (P < 0.01 in men; P < 0.05 in women) whilst lyso‐Gb3 levels were higher (P < 0.01 in men; <0.05 in women). Conclusions The type of amino acid exchange location in the α‐GalA 3D‐structure determines disease severity and temporal course of symptom onset. Patient stratification using this parameter may become a useful tool in the management of FD patients. KW - Fabry disease KW - Fabry genotype KW - Fabry phenotype KW - lyso‐Gb3 KW - α‐GalA 3D‐structure Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-218125 VL - 288 IS - 5 SP - 593 EP - 604 ER - TY - THES A1 - Cheong, David T1 - Stereologische Untersuchung der Gesamtanzahl dopaminerger Neurone in der Substantia Nigra von C57BL/6 Mäusen unter Benutzung des „optical fractionator“ und einer Standard-Mikroskopieausrüstung T1 - Stereological estimation of dopaminergic Neurons in the substantia nigra of C57BL/6 mice by using the "optical fractionator" and a standard microscopy N2 - In pre-clinical Parkinson's disease research, analysis of the nigrostriatal tract, including quantification of dopaminergic neuron loss within the substantia nigra, is essential. To estimate the total dopaminergic neuron number, unbiased stereology using the optical fractionator method is currently considered the gold standard. Because the theory behind the optical fractionator method is complex and because stereology is difficult to achieve without specialized equipment, several commercially available complete stereology systems that include the necessary software do exist, purely for cell counting reasons. Since purchasing a specialized stereology setup is not always feasible, for many reasons, this report describes a method for the stereological estimation of dopaminergic neuronal cell counts using standard microscopy equipment, including a light microscope, a motorized object table (x, y, z plane) with imaging software, and a computer for analysis. A step-by-step explanation is given on how to perform stereological quantification using the optical fractionator method, and pre-programmed files for the calculation of estimated cell counts are provided. To assess the accuracy of this method, a comparison to data obtained from a commercially available stereology apparatus was performed. Comparable cell numbers were found using this protocol and the stereology device, thus demonstrating the precision of this protocol for unbiased stereology. Source: Ip, C. W., Cheong, D., Volkmann, J. Stereological Estimation of Dopaminergic Neuron Number in the Mouse Substantia Nigra Using the Optical Fractionator and Standard Microscopy Equipment. J. Vis. Exp. (127), e56103, doi:10.3791/56103 (2017) N2 - Schwerpunktmäßig befasst sich diese Arbeit mit den praktischen Vorgängen zur Zählung von Neuronen mit dem optischen Fraktionator unter dem Mikroskop, wobei zur Veranschaulichung die Neuronen in der Substantia Nigra an C57BL/6-Mäusen gezählt wurden. Es wurde erläutert, wie die Einstellungen der jeweiligen Methode vorzunehmen sind und auf die angestrebten Ziele angepasst werden können, um ein effizientes Zählen von Neuronen unter Berücksichtigung grundlegender Zählregeln zu gewährleisten. Gleichzeitig wurde gezeigt, wie die Methoden des optischen Fraktionators die gewünschten präzisen Ergebnisse anhand des CE-Wertes liefern können. Die in dieser Arbeit präsentierte Axiophot-2-Methode ist in der Lage, selbst mit einem einfachen, kommerziell erhältlichen Lichtmikroskop und einem Standbildaufnahmeprogramm die Gesamtanzahl von Zellen einer gegebenen Struktur unter Beachtung aller stereologischen Regeln zu zählen – und zwar genauso effizient und mit vergleichbaren Ergebnissen wie mit einem speziell für stereologische Untersuchungen vorgefertigtes Komplettsystem. Vergleiche beider Methoden zueinander ergeben folgende Schlussfolgerungen: bei dem Stereo Investigator, ist die Untersuchung zwar wesentlich schneller, da die Bildaufnahme und Auswertung mittels voreingestellten Programmes automatisch durchgeführt werden. Allerdings ist solch ein Komplettsystem sehr kostspielig (ca. 60.000 Euro Anschaffungskosten) und nicht flexibel auf andere Untersuchungsbereiche einsetzbar. Die Axiophot-2-Methode weist zwar einige Nachteile aufgrund der manuellen Vorarbeiten auf, ist aber dafür wesentlich günstiger und zugänglicher, da sie nur ein konventionelles Mikroskop mit einem Standardprogramm erfordert. KW - Stereologie KW - fractionator Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-162753 ER - TY - JOUR A1 - Elhfnawy, Ahmed Mohamed A1 - Heuschmann, Peter U. A1 - Pham, Mirko A1 - Volkmann, Jens A1 - Fluri, Felix T1 - Stenosis length and degree interact with the risk of cerebrovascular events related to internal carotid artery stenosis JF - Frontiers in Neurology N2 - Background and Purpose: Internal carotid artery stenosis (ICAS)≥70% is a leading cause of ischemic cerebrovascular events (ICVEs). However, a considerable percentage of stroke survivors with symptomatic ICAS (sICAS) have <70% stenosis with a vulnerable plaque. Whether the length of ICAS is associated with high risk of ICVEs is poorly investigated. Our main aim was to investigate the relation between the length of ICAS and the development of ICVEs. Methods: In a retrospective cross-sectional study, we identified 95 arteries with sICAS and another 64 with asymptomatic internal carotid artery stenosis (aICAS) among 121 patients with ICVEs. The degree and length of ICAS as well as plaque echolucency were assessed on ultrasound scans. Results: A statistically significant inverse correlation between the ultrasound-measured length and degree of ICAS was detected for sICAS≥70% (Spearman correlation coefficient ρ = –0.57, p < 0.001, n = 51) but neither for sICAS<70% (ρ = 0.15, p = 0.45, n = 27) nor for aICAS (ρ = 0.07, p = 0.64, n = 54). The median (IQR) length for sICAS<70% and ≥70% was 17 (15–20) and 15 (12–19) mm (p = 0.06), respectively, while that for sICAS<90% and sICAS 90% was 18 (15–21) and 13 (10–16) mm, respectively (p < 0.001). Among patients with ICAS <70%, a cut-off length of ≥16 mm was found for sICAS rather than aICAS with a sensitivity and specificity of 74.1% and 51.1%, respectively. Irrespective of the stenotic degree, plaques of the sICAS compared to aICAS were significantly more often echolucent (43.2 vs. 24.6%, p = 0.02). Conclusion: We found a statistically insignificant tendency for the ultrasound-measured length of sICAS<70% to be longer than that of sICAS≥70%. Moreover, the ultrasound-measured length of sICAS<90% was significantly longer than that of sICAS 90%. Among patients with sICAS≥70%, the degree and length of stenosis were inversely correlated. Larger studies are needed before a clinical implication can be drawn from these results. KW - ischemic stroke KW - carotid stenosis KW - carotid atherosclerosis KW - length of stenosis KW - degree of stenosis KW - carotid ultrasound KW - outcome Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-196225 SN - 1664-2295 VL - 10 IS - 317 ER - TY - JOUR A1 - Nguemeni, Carine A1 - Hiew, Shawn A1 - Kögler, Stefanie A1 - Homola, György A. A1 - Volkmann, Jens A1 - Zeller, Daniel T1 - Split-belt training but not cerebellar anodal tDCS improves stability control and reduces risk of fall in patients with multiple sclerosis JF - Brain Sciences N2 - The objective of this study was to examine the therapeutic potential of multiple sessions of training on a split-belt treadmill (SBT) combined with cerebellar anodal transcranial direct current stimulation (tDCS) on gait and balance in People with Multiple Sclerosis (PwMS). Twenty-two PwMS received six sessions of anodal (PwMS\(_{real}\), n = 12) or sham (PwMS\(_{sham}\), n = 10) tDCS to the cerebellum prior to performing the locomotor adaptation task on the SBT. To evaluate the effect of the intervention, functional gait assessment (FGA) scores and distance walked in 2 min (2MWT) were measured at the baseline (T0), day 6 (T5), and at the 4-week follow up (T6). Locomotor performance and changes of motor outcomes were similar in PwMS\(_{real}\) and PwMS\(_{sham}\) independently from tDCS mode applied to the cerebellum (anodal vs. sham, on FGA, p = 0.23; and 2MWT, p = 0.49). When the data were pooled across the groups to investigate the effects of multiple sessions of SBT training alone, significant improvement of gait and balance was found on T5 and T6, respectively, relative to baseline (FGA, p < 0.001 for both time points). The FGA change at T6 was significantly higher than at T5 (p = 0.01) underlining a long-lasting improvement. An improvement of the distance walked during the 2MWT was also observed on T5 and T6 relative to T0 (p = 0.002). Multiple sessions of SBT training resulted in a lasting improvement of gait stability and endurance, thus potentially reducing the risk of fall as measured by FGA and 2MWT. Application of cerebellar tDCS during SBT walking had no additional effect on locomotor outcomes. KW - multiple sclerosis KW - split-belt treadmill KW - cerebellar tDCS KW - gait KW - balance KW - risk of fall Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-252179 SN - 2076-3425 VL - 12 IS - 1 ER - TY - THES A1 - Graulich, Michael T1 - Spinale Effekte von TNF-α am Modell des tumorinduzierten Knochenschmerzes der Maus T1 - Spinal effects of TNF-α in a mouse model of bone cancer pain N2 - Am Modell des tumorinduzierten Schmerzes der Maus wurden sowohl das Schmerzverhalten der Tiere als auch spezifische morphologische Veränderungen im Hinterhorn des Rückenmarks (Aktivierung von Astrozyten) und im tumorbefallenen Knochen analysiert. Durch Analyse von Mäusen mit Defizienz für TNF-Rezeptor 1, TNF-Rezeptor 2 oder für beide Rezeptoren konnte die Rolle von TNF-α seiner Rezeptoren bei der Entstehung von tumorinduziertem Schmerz untersucht werden. Im Unterschied zu neuropathischen Schmerzmodellen konnte gezeigt werden, dass beide TNF-Rezeptoren ausgeschaltet werden müssen, um eine signifikante Schmerzreduktion zu erzielen. Die systemische Behandlung mit dem TNF-neutralisierenden Fusionsprotein Etanercept konnte die im genetischen Modell gezeigte Reduktion der mechanischen Allodynie teilweise, aber nicht vollständig reproduzieren. Eine Hemmung der Mikrogliaaktivierung mittels Minocyclin erbrachte im Tumor-schmerzmodell keinen Effekt auf das Schmerzverhalten der Tiere. Die histologische Analyse der tumoraffizierten Knochen zeigte eine signifikante Zunahme der Osteoklastenaktivität in tumortragenden Tieren. Die Behandlung mit Minocyclin war ohne erkennbaren Effekt auf die Differenzierung und die Aktivität der Osteoklasten. Es ergaben sich jedoch Hinweise, dass TNF-α einen hemmenden Einfluss auf die Osteoklastenaktivität im Knochentumormodell hat, da sowohl in den TNFR-KO-Tieren als auch unter Gabe von Etanercept eine Steigerung der Osteoklastenaktivität nachgewiesen werden konnte. Die Ergebnisse dieser Arbeit zeigen, dass TNF-α eine wichtige Rolle, sowohl in der Entstehung, als auch in der Aufrechterhaltung von tumorinduziertem Schmerz spielt. Hier liegt der Ansatzpunkt für weitere Studien mit dem Ziel, eine spezifische Pharmakotherapie zu entwickeln mit wirksamer TNF-α Blockade auch bei Patienten mit Tumorschmerzen. Nach den Erkenntnissen dieser Arbeit mit Etanercept sollte ein spezielles Augenmerk auf die ZNS-Gängigkeit dieser Substanzen gelegt werden und die Gefahr der Möglichkeit eines vermehrten Tumorwachstum bedacht werden. N2 - Bone-cancer-related pain is one of the most disabling factors in patients suffering from primary bone cancer or bone metastases. Recent studies point toward an important role of proinflammatory cytokines, example tumor necrosis factor-alpha (TNF), for tumor growth and bone-cancer-associated pain. Mechanisms by which TNF, through its receptor subtypes, TNF receptor 1 (TNFR1) and -2 (TNFR2), elicits altered sensation and pain behavior, are still incompletely understood. To look for a potential role of TNF in bone cancer pain, cancer-related pain was analyzed in fibrosarcoma-bearing C57Bl/6J wild type mice after systemic antagonism of TNF. To further clarify the role of TNF receptor (TNFR) in bone-cancer pain, naive and fibrosarcoma-bearing C57Bl/ 6J wild type and transgenic mice with a deficiency of TNFR1 (TNFR1ko), TNFR2 (TNFR2ko), and TNFR1+2 (TNFR1+2ko) were compared regarding cancer-related pain and hyperalgesia, tumor growth, osteoclast activation, and spinal astrogliosis. Systemic antagonism of TNF significantly alleviated tactile hypersensitivity and spontaneous bone-cancer-related pain behavior. Most interestingly, combined deletion of the TNFR1 and TNFR2, but not of either gene alone, almost completely inhibited the development of tactile hypersensitivity, whereas spontaneous pain behavior was transiently increased. Accordingly, spinal astrogliosis was markedly reduced, whereas tumor growth was significantly increased in TNFR1+2ko mice. In contrast, deletion of the TNFR1 or TNFR2 gene alone did not change tumor growth or spinal astrogliosis. Our findings suggest that the combined absence of TNFR1 and TNFR2 is necessary for the attenuation of cancer-related tactile hypersensitivity and concomitant spinal astrogliosis, whereas tumor growth seems to be inhibited by combined TNFR activation. These findings support the hypothesis of cytokine-dependent pain development in cancer pain. Differential targeting of TNFR activation could be an interesting strategy in bone-cancer-related pain conditions. KW - Neuralgie KW - Schmerz KW - Schmerzforschung KW - Tumor-Nekrose-Faktor KW - Tumor-Nekrose-Faktor -Inhibitor KW - Experimentaltumor KW - Knochentumor KW - pain KW - tumor KW - bone KW - neuropathy KW - tnf KW - glia KW - minocycline KW - etanercept Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-54439 ER - TY - JOUR A1 - Friedrich, Maximilian U. A1 - Schneider, Erich A1 - Buerklein, Miriam A1 - Taeger, Johannes A1 - Hartig, Johannes A1 - Volkmann, Jens A1 - Peach, Robert A1 - Zeller, Daniel T1 - Smartphone video nystagmography using convolutional neural networks: ConVNG JF - Journal of Neurology N2 - Background Eye movement abnormalities are commonplace in neurological disorders. However, unaided eye movement assessments lack granularity. Although videooculography (VOG) improves diagnostic accuracy, resource intensiveness precludes its broad use. To bridge this care gap, we here validate a framework for smartphone video-based nystagmography capitalizing on recent computer vision advances. Methods A convolutional neural network was fine-tuned for pupil tracking using > 550 annotated frames: ConVNG. In a cross-sectional approach, slow-phase velocity of optokinetic nystagmus was calculated in 10 subjects using ConVNG and VOG. Equivalence of accuracy and precision was assessed using the “two one-sample t-test” (TOST) and Bayesian interval-null approaches. ConVNG was systematically compared to OpenFace and MediaPipe as computer vision (CV) benchmarks for gaze estimation. Results ConVNG tracking accuracy reached 9–15% of an average pupil diameter. In a fully independent clinical video dataset, ConVNG robustly detected pupil keypoints (median prediction confidence 0.85). SPV measurement accuracy was equivalent to VOG (TOST p < 0.017; Bayes factors (BF) > 24). ConVNG, but not MediaPipe, achieved equivalence to VOG in all SPV calculations. Median precision was 0.30°/s for ConVNG, 0.7°/s for MediaPipe and 0.12°/s for VOG. ConVNG precision was significantly higher than MediaPipe in vertical planes, but both algorithms’ precision was inferior to VOG. Conclusions ConVNG enables offline smartphone video nystagmography with an accuracy comparable to VOG and significantly higher precision than MediaPipe, a benchmark computer vision application for gaze estimation. This serves as a blueprint for highly accessible tools with potential to accelerate progress toward precise and personalized Medicine. KW - digital medicine KW - nystagmus KW - eye movement disorders KW - videooculography KW - computer vision KW - telemedicine KW - precision medicine Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-324526 VL - 270 IS - 5 ER - TY - THES A1 - Ebert, Sönke T1 - Small- und Large-fiber-Beteiligung bei Morbus Parkinson T1 - Small- and large-fiber-neuropathy in Parkinson's disease N2 - Die hier vorliegende Forschungsarbeit überprüfte eine mögliche Beteiligung des peripheren Nervensystems bei M. Parkinson und den atypischen Parkinson-Syndromen. 31 Patienten mit einem idiopathischen Parkinson-Syndrom (IPD-Patienten) und neun Patienten mit einem atypischen Parkinson-Syndrom (APD-Patienten) sowie 35 altersentsprechende Kontrollprobanden wurden zwischen 2011 und 2012 für diese Studie rekrutiert. Neben der Eigenanamnese und der neurologischen Untersuchung erhielten die Patienten eine Suralisneurographie zur Überprüfung der large fibers und eine Quantitative sensorische Testung (QST) zur Detektion einer möglichen Small-fiber-Dysfunktion. Die Vitamin-Bestimmung diente der Untersuchung möglicher Zusammenhänge zwischen der Levodopa-Therapie, eventuell daraus resultierenden Vitamin-Mangelzuständen und einer reduzierten intraepidermalen Nervenfaser-Dichte (IENF-Dichte) beim M. Parkinson. Für die histologische Auswertung der IENF-Dichte und der dermalen, myelinisierten Nervenfaserbündel (PGP 9.5- / MBP- Doppelfärbung) sowie für die immunohistochemische Untersuchung der Nervenfasersubtypen (anti-alpha-CGRP- und anti-Substanz P-Antikörper) wurden bei jedem Probanden vier Hautbiopsien von den Extremitäten und dem Körperstamm entnommen. Sieben IPD-Patienten und ein Proband mit einem atypischen Parkinson-Syndrom wiesen ein vermindertes sensorisches Nervenaktionspotenzial (SNAP) in der Suralisneurographie auf. Dagegen war eine pathologisch reduzierte Nervenleitgeschwindigkeit nur bei einem IPD-Patienten nachweisbar. Auffällig war zudem eine negative Korrelation zwischen der Erkrankungsdauer und dem SNAP (Korrelationskoeffizient -0,367, p<0,03). In der Auswertung der Hautbiopsien konnte eine statistisch signifikante Reduktion der myelinisierten Bündel am Unterschenkel der IPD-Patienten festgestellt werden. Bei zehn von 30 IPD-Patienten, jedoch bei keinem der Probanden mit einem atypischen Parkinson-Syndrom, konnte eine verminderte IENF-Dichte nachgewiesen werden. In der statistischen Überprüfung wurde außerdem am Unterschenkel ein signifikanter Unterschied zwischen den IPD-Patienten und der Kontrollkohorte sowie eine negative Korrelation zwischen der Krankheitsdauer und der IENF-Dichte (Korrelationskoeffizient -0,320, p<0,05) festgestellt. Die QST konnte dagegen keinen statistisch signifikanten Unterschied zwischen den einzelnen Kohorten aufzeigen. Im Kontrast dazu fand sich eine längenunabhängige Reduktion der CGRP-positiven und der Substanz P-positiven IENF-Dichte bei den Patienten mit einem idiopathischen Parkinson-Syndrom. Bemerkenswert war zudem eine signifikante Verminderung der Substanz P-positiven intraepidermalen Nervenfasern am Oberschenkel und Rücken bei den APD-Patienten. Eine statistisch signifikante Abweichung der CGRP- und Substanz P-positiven Bündel konnte dagegen nicht festgestellt werden. In der laborchemischen Untersuchung war ein Zusammenhang zwischen den bestimmten Vitamin-Spiegeln und der kumulativen Levodopa-Dosis sowie zwischen den Vitaminen und der IENF-Dichte lediglich bei dem Vitamin B6 nachweisbar. Zusammengefasst erscheint eine Beteiligung des peripheren Nervensystems beim idiopathischen Parkinson als wahrscheinlich, wohingegen bei den atypischen Parkinson-Syndromen vor allem von einer zentralen Genese ausgegangen werden kann. Basierend auf den Ergebnissen der Suralisneurographie und der Bestimmung der myelinisierten Bündel erscheint eine krankheitsbedingte Large-fiber-Beeinträchtigung beim M.Parkinson möglich. Die nachgewiesene längenabhängige Small-fiber-Reduktion bei IPD-Patienten wird vermutlich durch eine axonale Transportstörung verursacht. Einen krankheitsbedingten Erklärungsansatz für die längenunabhängige Reduktion der CGRP-positiven und der Substanz P-positiven IENF-Dichte bei IPD-Patienten liefert der Nachweis von neurotoxischem α-Synuclein in den sensiblen Spinatganglien mit einem daraus resultierenden Untergang von sensorischen Nervenfasern. Aufgrund der geringen Anzahl an Parkinson-Patienten mit sensiblen Symptomen und dem fehlenden Nachweis eines statistisch signifikanten Unterschiedes in der QST liegt der Verdacht nahe, dass die ermittelte intraepidermale Nervenfaserreduktion der IPD-Patienten nicht stark genug ausgeprägt ist, um eine signifikante Abweichung der QST-Ergebnisse zu verursachen. Weiterhin konnte kein Zusammenhang zwischen der kumulativen Levodopa-Menge, den Vitaminen B12, Methylmalonsäure sowie Homocystein und dem Auftreten einer Nervenfaserverminderung nachgewiesen werden, was gegen eine iatrogene Beteiligung des peripheren Nervensystems als Nebenwirkung der Levodopa-Therapie spricht. Das idiopathische Parkinson-Syndrom geht mit einer Reduktion der kleinen Nervenfasern einher, welche vermutlich auf die Grunderkrankung selbst zurückzuführen ist. Die Untersuchung der Haut erscheint somit vielversprechend für die Erforschung der Pathogenese und für die Differentialdiagnostik des M. Parkinson. N2 - Small- and large-fiber-neuropathy in Parkinson's disease KW - Parkinson-Krankheit KW - Parkinson KW - Nervenfaser KW - Biopsie KW - Fluoreszenzmikroskopie KW - Hautbiopsie KW - Quantitative Sensorische Testung KW - Suralisneurographie KW - Neuropathie Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-124647 ER - TY - THES A1 - He, Lan T1 - Small fiber involvement in Fabry's disease N2 - Aim of Investigation: The neurological manifestations of Fabry’s disease, a rare, X-linked, multisystem disorder caused by alpha-galactosidase A deficiency and globotriosylceramide (Gb3) accumulation, include both peripheral and central nervous system symptoms. Here we evaluated a prospectively recruited cohort of patients with Fabry’s disease for pain, small nerve fiber function, and skin innervation. Methods: 66 patients (31 male and 35 female) were enrolled，31 patients were on ERT. All patients underwent quantitative sensory testing (QST), electrophysiological examination, and extra- and transcranial Doppler sonography. For pain and mood assessment standardized questionnaires were used. Skin biopsies were performed at the left distal leg in 38 patients for intraepidermal nerve fiber density (IENFD) assessment. Results: Age at examination did not differ significantly between women (40.2+/-16.2 years) and men (38.9+/-13.8; n.s.). 29/31 male and 19/35 female patients complained of acroparesthesias or neuropathic pain. QST abnormalities indicative of small fiber impairment were found in 26/31 male and 28/35 female patients. Electrophysiological examination of large fibers and autonomic fibers revealed pathological findings in 11/31 male and 3/35 female patients. All patients had normal Doppler sonography results. Indicators for depression were present in 14/31 male and 10/35 female patients. 20/31 male and 18/35 female patients had a skin biopsy, the IENFD was significantly reduced in male (2.0+/-2.8 fibers/mm) compared with female patients (6.7 +/- 4.4 fibers/mm). In 10 patients free from neurological symptoms, QST and IENFD abnormalities were still detected. Follow up examination after one year in 12 patients under ERT (2.1+/-1.7 years) showed improvement in some symptoms and in QST and neurophysiology in six patients with normal renal function. 20/35 female patients older than 40 y had concomitant diseases, while none of the 18 younger female patients did. The corresponding radio in male patients was 5/19 (>=40y) and 2/13 (<40y) respectively. Conclusions: Neuropathic pain and sensory deficits of the distal extremities are common in patients with Fabry’s disease. QST and IENFD analysis are important for early diagnosis of nerve involvement in Fabry’s disease. Small fiber function may improve under ERT in patients without severe renal impairment. KW - Fabry’s disease KW - neuropathic pain KW - QST KW - IENFD KW - ERT KW - Fabry’s disease KW - neuropathic pain KW - QST KW - IENFD KW - ERT Y1 - 2009 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-32844 ER - TY - JOUR A1 - Üçeyler, Nurcan A1 - Schröter, Nils A1 - Kafke, Waldemar A1 - Kramer, Daniela A1 - Wanner, Christoph A1 - Weidemann, Frank A1 - Sommer, Claudia T1 - Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease JF - PLoS ONE N2 - Background The X-chromosomally linked life-limiting Fabry disease (FD) is associated with deposits of the sphingolipid globotriaosylceramide 3 (Gb3) in various tissues. Skin is easily accessible and may be used as an additional diagnostic and follow-up medium. Our aims were to visualize skin Gb3 deposits in FD patients applying immunofluorescence and to determine if cutaneous Gb3 load correlates with disease severity. Methods At our Fabry Center for Interdisciplinary Therapy we enrolled 84 patients with FD and 27 healthy controls. All subjects underwent 5-mm skin punch biopsy at the lateral lower leg and the back. Skin samples were processed for immunohistochemistry using antibodies against CD77 (i.e. Gb3). Cutaneous Gb3 deposition was quantified in a blinded manner and correlated to clinical data. Results We found that Gb3 load was higher in distal skin of male FD patients compared to healthy controls (p<0.05). Men (p<0.01) and women (p<0.05) with a classic FD phenotype had higher distal skin Gb3 load than healthy controls. Men with advanced disease as reflected by impaired renal function, and men and women with small fiber neuropathy had more Gb3 deposits in distal skin samples than males with normal renal function (p<0.05) and without small fiber neuropathy. Gb3 deposits were not different between patients with and without enzyme replacement therapy. Conclusions Immunofluorescence on minimally invasive skin punch biopsies may be useful as a tool for assessment and follow-up in FD patients. KW - biopsy KW - neuropathy KW - Fabry disease KW - renal system KW - immunofluorescence KW - enzyme replacement therapy KW - skin diseases KW - nerve fibers Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-178856 VL - 11 IS - 11 ER - TY - JOUR A1 - Üçeyler, Nurcan A1 - Kewenig, Susanne A1 - Kafke, Waldemar A1 - Kittel-Schneider, Sarah A1 - Sommer, Claudia T1 - Skin cytokine expression in patients with fibromyalgia syndrome is not different from controls N2 - Background Fibromyalgia syndrome (FMS) is a chronic pain syndrome of unknown etiology. There is increasing evidence for small nerve fiber impairment in a subgroup of patients with FMS. We investigated whether skin cytokine and delta opioid receptor (DOR) gene expression in FMS patients differs from controls as one potential contributor to small nerve fiber sensitization. Methods We investigated skin punch biopsies of 25 FMS patients, ten patients with monopolar depression but no pain, and 35 healthy controls. Biopsies were obtained from the lateral upper thigh and lower calf. Gene expression of the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF), interleukin (IL)-6, and IL-8 and of the anti-inflammatory cytokine IL-10 was analyzed using quantitative real-time PCR and normalizing data to 18sRNA as housekeeping gene. Additionally, we assessed DOR gene expression. Results All cytokines and DOR were detectable in skin samples of FMS patients, patients with depression, and healthy controls without intergroup difference. Also, gene expression was not different in skin of the upper and lower leg within and between the groups and in FMS patient subgroups. Conclusions Skin cytokine and DOR gene expression does not differ between patients with FMS and controls. Our results do not support a role of the investigated cytokines in sensitization of peripheral nerve fibers as a potential mechanism of small fiber pathology in FMS. KW - Fibromyalgia syndrome KW - Skin biopsy KW - Monopolar depression KW - Cytokines KW - Opioid receptor Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-110624 ER - TY - JOUR A1 - Bohmann, Ferdinand O. A1 - Kurka, Natalia A1 - du Mesnil de Rochemont, Richard A1 - Gruber, Katharina A1 - Guenther, Joachim A1 - Rostek, Peter A1 - Rai, Heike A1 - Zickler, Philipp A1 - Ertl, Michael A1 - Berlis, Ansgar A1 - Poli, Sven A1 - Mengel, Annerose A1 - Ringleb, Peter A1 - Nagel, Simon A1 - Pfaff, Johannes A1 - Wollenweber, Frank A. A1 - Kellert, Lars A1 - Herzberg, Moriz A1 - Koehler, Luzie A1 - Haeusler, Karl Georg A1 - Alegiani, Anna A1 - Schubert, Charlotte A1 - Brekenfeld, Caspar A1 - Doppler, Christopher E. J. A1 - Onur, Oezguer A. A1 - Kabbasch, Christoph A1 - Manser, Tanja A1 - Pfeilschifter, Waltraud T1 - Simulation-based training of the rapid evaluation and management of acute stroke (STREAM) — a prospective single-arm multicenter trial JF - Frontiers in Neurology N2 - Introduction: Acute stroke care delivered by interdisciplinary teams is time-sensitive. Simulation-based team training is a promising tool to improve team performance in medical operations. It has the potential to improve process times, team communication, patient safety, and staff satisfaction. We aim to assess whether a multi-level approach consisting of a stringent workflow revision based on peer-to-peer review and 2–3 one-day in situ simulation trainings can improve acute stroke care processing times in high volume neurocenters within a 6 months period. Methods and Analysis: The trial is being carried out in a pre-test-post-test design at 7 tertiary care university hospital neurocenters in Germany. The intervention is directed at the interdisciplinary multiprofessional stroke teams. Before and after the intervention, process times of all direct-to-center stroke patients receiving IV thrombolysis (IVT) and/or endovascular therapy (EVT) will be recorded. The primary outcome measure will be the “door-to-needle” time of all consecutive stroke patients directly admitted to the neurocenters who receive IVT. Secondary outcome measures will be intervention-related process times of the fraction of patients undergoing EVT and effects on team communication, perceived patient safety, and staff satisfaction via a staff questionnaire. Interventions: We are applying a multi-level intervention in cooperation with three “STREAM multipliers” from each center. First step is a central meeting of the multipliers at the sponsor's institution with the purposes of algorithm review in a peer-to-peer process that is recorded in a protocol and an introduction to the principles of simulation training and debriefing as well as crew resource management and team communication. Thereafter, the multipliers cooperate with the stroke team trainers from the sponsor's institution to plan and execute 2–3 one-day simulation courses in situ in the emergency department and CT room of the trial centers whereupon they receive teaching materials to perpetuate the trainings. Clinical Trial Registration: STREAM is a registered trial at https://clinicaltrials.gov/ct2/show/NCT03228251. KW - CRM KW - thrombolysis (tPA) KW - stroke KW - emergency care KW - simulation training Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-369239 SN - 1664-2295 VL - 10 ER - TY - THES A1 - Raban, Rebecca Emmi Hildegard T1 - Sicherheit und Wirksamkeit von intrathekalem Triamcinolon bei Patienten mit chronisch-progredienter Multipler Sklerose : eine retrospektive Longitudinalstudie T1 - Safety and efficacy of intrathecal triamcinolone in chronic progressive multiple sclerosis - a retrospective longitudinal study N2 - Im Zeitraum von 2004 bis 2016 erhielten an der Neurologischen Universitätsklinik Würzburg Patienten mit einer chronisch progredienten Multiplen Sklerose insgesamt 595 Injektionen von intrathekalem Triamcinolonacetonid. Diese Arbeit befasst sich mit Sicherheit, Nebenwirkungen und Wirksamkeit der intrathekalen Therapieform. N2 - In the period from 2004 to 2016 patients with chronic progressive multiple sclerosis at the Neurological University Clinic Würzburg received a total of 595 injections of intrathecal triamcinolone acetonide. This work deals with safety, side effects and effectiveness of intrathecal therapy. KW - Intrathekale Applikation KW - Triamcinolon KW - Multiple Sklerose KW - intrathekal KW - intrathecal KW - Volon A KW - chronische Multiple Sklerose KW - triamcinolone acetonide KW - progressive multiple sclerosis Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-220478 ER - TY - JOUR A1 - Schulte, Annemarie A1 - Blum, Robert T1 - Shaped by leaky ER: Homeostatic Ca\(^{2+}\) fluxes JF - Frontiers in Physiology N2 - At any moment in time, cells coordinate and balance their calcium ion (Ca\(^{2+}\)) fluxes. The term ‘Ca\(^{2+}\) homeostasis’ suggests that balancing resting Ca2+ levels is a rather static process. However, direct ER Ca\(^{2+}\) imaging shows that resting Ca\(^{2+}\) levels are maintained by surprisingly dynamic Ca\(^{2+}\) fluxes between the ER Ca\(^{2+}\) store, the cytosol, and the extracellular space. The data show that the ER Ca\(^{2+}\) leak, continuously fed by the high-energy consuming SERCA, is a fundamental driver of resting Ca\(^{2+}\) dynamics. Based on simplistic Ca\(^{2+}\) toolkit models, we discuss how the ER Ca\(^{2+}\) leak could contribute to evolutionarily conserved Ca\(^{2+}\) phenomena such as Ca\(^{2+}\) entry, ER Ca\(^{2+}\) release, and Ca\(^{2+}\) oscillations. KW - Ca2+ homeostasis KW - Ca2+ ion analysis KW - ER Ca2+ store KW - ER Ca2+ imaging KW - SERCA KW - store-operated Ca2+ entry KW - Ca2+ leak KW - Ca2+ oscillation Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-287102 SN - 1664-042X VL - 13 ER - TY - JOUR A1 - Berve, Kristina A1 - West, Brian L. A1 - Martini, Rudolf A1 - Groh, Janos T1 - Sex- and region-biased depletion of microglia/macrophages attenuates CLN1 disease in mice JF - Journal of Neuroinflammation N2 - Background The neuronal ceroid lipofuscinoses (CLN diseases) are fatal lysosomal storage diseases causing neurodegeneration in the CNS. We have previously shown that neuroinflammation comprising innate and adaptive immune reactions drives axonal damage and neuron loss in the CNS of palmitoyl protein thioesterase 1-deficient (Ppt1\(^{-/-}\)) mice, a model of the infantile form of the diseases (CLN1). Therefore, we here explore whether pharmacological targeting of innate immune cells modifies disease outcome in CLN1 mice. Methods We applied treatment with PLX3397 (150 ppm in the chow), a potent inhibitor of the colony stimulating factor-1 receptor (CSF-1R) to target innate immune cells in CLN1 mice. Experimental long-term treatment was non-invasively monitored by longitudinal optical coherence tomography and rotarod analysis, as well as analysis of visual acuity, myoclonic jerks, and survival. Treatment effects regarding neuroinflammation, neural damage, and neurodegeneration were subsequently analyzed by histology and immunohistochemistry. Results We show that PLX3397 treatment attenuates neuroinflammation in CLN1 mice by depleting pro-inflammatory microglia/macrophages. This leads to a reduction of T lymphocyte recruitment, an amelioration of axon damage and neuron loss in the retinotectal system, as well as reduced thinning of the inner retina and total brain atrophy. Accordingly, long-term treatment with the inhibitor also ameliorates clinical outcomes in CLN1 mice, such as impaired motor coordination, visual acuity, and myoclonic jerks. However, we detected a sex- and region-biased efficacy of CSF-1R inhibition, with male microglia/macrophages showing higher responsiveness toward depletion, especially in the gray matter of the CNS. This results in a better treatment outcome in male Ppt1\(^{-/-}\) mice regarding some histopathological and clinical readouts and reflects heterogeneity of innate immune reactions in the diseased CNS. Conclusions Our results demonstrate a detrimental impact of innate immune reactions in the CNS of CLN1 mice. These findings provide insights into CLN pathogenesis and may guide in the design of immunomodulatory treatment strategies. KW - Neuronal ceroid lipofuscinosis KW - Microglia KW - Macrophages KW - T lymphocytes KW - Neurodegeneration KW - Axon degeneration Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-230234 VL - 17 ER - TY - JOUR A1 - Notz, Quirin A1 - Lotz, Christopher A1 - Herrmann, Johannes A1 - Vogt, Marius A1 - Schlesinger, Tobias A1 - Kredel, Markus A1 - Muellges, Wolfgang A1 - Weismann, Dirk A1 - Westermaier, Thomas A1 - Meybohm, Patrick A1 - Kranke, Peter T1 - Severe neurological complications in critically ill COVID‑19 patients JF - Journal of Neurology N2 - No abstract available. KW - COVID-19 KW - neurological complications Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-232429 SN - 0340-5354 ER - TY - JOUR A1 - Traub, Jan A1 - Otto, Markus A1 - Sell, Roxane A1 - Göpfert, Dennis A1 - Homola, György A1 - Steinacker, Petra A1 - Oeckl, Patrick A1 - Morbach, Caroline A1 - Frantz, Stefan A1 - Pham, Mirko A1 - Störk, Stefan A1 - Stoll, Guido A1 - Frey, Anna T1 - Serum phosphorylated tau protein 181 and neurofilament light chain in cognitively impaired heart failure patients JF - Alzheimer's Research & Therapy N2 - Background Chronic heart failure (HF) is known to increase the risk of developing Alzheimer’s dementia significantly. Thus, detecting and preventing mild cognitive impairment, which is common in patients with HF, is of great importance. Serum biomarkers are increasingly used in neurological disorders for diagnostics, monitoring, and prognostication of disease course. It remains unclear if neuronal biomarkers may help detect cognitive impairment in this high-risk population. Also, the influence of chronic HF and concomitant renal dysfunction on these biomarkers is not well understood. Methods Within the monocentric Cognition.Matters-HF study, we quantified the serum levels of phosphorylated tau protein 181 (pTau) and neurofilament light chain (NfL) of 146 extensively phenotyped chronic heart failure patients (aged 32 to 85 years; 15.1% women) using ultrasensitive bead-based single-molecule immunoassays. The clinical work-up included advanced cognitive testing and cerebral magnetic resonance imaging (MRI). Results Serum concentrations of NfL ranged from 5.4 to 215.0 pg/ml (median 26.4 pg/ml) and of pTau from 0.51 to 9.22 pg/ml (median 1.57 pg/ml). We detected mild cognitive impairment (i.e., T-score < 40 in at least one cognitive domain) in 60% of heart failure patients. pTau (p = 0.014), but not NfL, was elevated in this group. Both NfL (ρ = − 0.21; p = 0.013) and pTau (ρ = − 0.25; p = 0.002) related to the cognitive domain visual/verbal memory, as well as white matter hyperintensity volume and cerebral and hippocampal atrophy. In multivariable analysis, both biomarkers were independently influenced by age (T = 4.6 for pTau; T = 5.9 for NfL) and glomerular filtration rate (T = − 2.4 for pTau; T = − 3.4 for NfL). Markers of chronic heart failure, left atrial volume index (T = 4.6) and NT-proBNP (T = 2.8), were further cardiological determinants of pTau and NfL, respectively. In addition, pTau was also strongly affected by serum creatine kinase levels (T = 6.5) and ferritin (T = − 3.1). Conclusions pTau and NfL serum levels are strongly influenced by age-dependent renal and cardiac dysfunction. These findings point towards the need for longitudinal examinations and consideration of frequent comorbidities when using neuronal serum biomarkers. KW - Alzheimer’s dementia KW - heart failure KW - cognitive impairment KW - neurofilament light chain KW - phosphorylated tau protein KW - renal function KW - age Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-300515 VL - 14 ER - TY - JOUR A1 - Traub, Jan A1 - Otto, Markus A1 - Sell, Roxane A1 - Homola, György A. A1 - Steinacker, Petra A1 - Oeckl, Patrick A1 - Morbach, Caroline A1 - Frantz, Stefan A1 - Pham, Mirko A1 - Störk, Stefan A1 - Stoll, Guido A1 - Frey, Anna T1 - Serum glial fibrillary acidic protein indicates memory impairment in patients with chronic heart failure JF - ESC Heart Failure N2 - Aims Cognitive dysfunction occurs frequently in patients with heart failure (HF), but early detection remains challenging. Serum glial fibrillary acidic protein (GFAP) is an emerging biomarker of cognitive decline in disorders of primary neurodegeneration such as Alzheimer's disease. We evaluated the utility of serum GFAP as a biomarker for cognitive dysfunction and structural brain damage in patients with stable chronic HF. Methods and results Using bead-based single molecule immunoassays, we quantified serum levels of GFAP in patients with HF participating in the prospective Cognition.Matters-HF study. Participants were extensively phenotyped, including cognitive testing of five separate domains and magnetic resonance imaging (MRI) of the brain. Univariable and multivariable models, also accounting for multiple testing, were run. One hundred and forty-six chronic HF patients with a mean age of 63.8 ± 10.8 years were included (15.1% women). Serum GFAP levels (median 246 pg/mL, quartiles 165, 384 pg/mL; range 66 to 1512 pg/mL) did not differ between sexes. In the multivariable adjusted model, independent predictors of GFAP levels were age (T = 5.5; P < 0.001), smoking (T = 3.2; P = 0.002), estimated glomerular filtration rate (T = −4.7; P < 0.001), alanine aminotransferase (T = −2.1; P = 0.036), and the left atrial end-systolic volume index (T = 3.4; P = 0.004). NT-proBNP but not serum GFAP explained global cerebral atrophy beyond ageing. However, serum GFAP levels were associated with the cognitive domain visual/verbal memory (T = −3.0; P = 0.003) along with focal hippocampal atrophy (T = 2.3; P = 0.025). Conclusions Serum GFAP levels are affected by age, smoking, and surrogates of the severity of HF. The association of GFAP with memory dysfunction suggests that astroglial pathologies, which evade detection by conventional MRI, may contribute to memory loss beyond ageing in patients with chronic HF. KW - Glial fibrillary acidic protein KW - GFAP KW - Chronic heart failure KW - Cognitive decline KW - Memory dysfunction KW - Brain atrophy Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-312736 VL - 9 IS - 4 ER - TY - THES A1 - Schramm, Axel T1 - Sensomotorische Integration bei zervikalen Dystonien T1 - Sensorimotor integration in cervical dystonia N2 - Zervikale Dystonien gehören zu den häufigsten Formen fokaler Dystonien. Diese sind durch anhaltende, unwillkürliche Muskelkontraktionen gekennzeichnet, welche zu verdrehenden oder repetitiven Bewegungen oder abnormalen Haltungen des Kopfes führen. Ein seit über 100 Jahren beobachtetes Phänomen stellt hierbei die Möglichkeit dar, mittels sogenannter "sensibler Trickmanöver", welche meistens in einer leichten Berührung von Arealen im Kopfbereich bestehen, die pathologische Muskelaktivität zu reduzieren und damit die Kopfposition zu normalisieren. Ziel der vorliegenden Arbeit war es, eine breite und vor allem erstmalig quantitative Charakterisierung von wirksamen Trickmanövern vorzunehmen und so verschiedene Einflußgrößen auf die Wirksamkeit solcher Tricks zu untersuchen. Hierzu wurden die Muskelaktivitäten der vier wichtigsten den Kopf drehenden Muskeln mittels Oberflächen-EMG abgeleitet und die Veränderungen bei Trickapplikation unterschiedlicher Lokalisation, Modalität und bei verschiedenen Ausgangspositionen ermittelt. 1) Hinsichtlich der Lokalisation ergaben sich über alle Patienten gemittelt keine signifikante Seitendifferenz, und auch bei individuellem Vergleich zeigten sich bei rund 50% der Patienten keine signifikanten Unterschiede zwischen kontralateraler und ipsilateraler Trickapplikation. Unter den getesteten Applikationsorten grenzte sich das Areal "Wange" mit durchschnittlich 33%iger Reduktion der gesamten EMG-Aktivität signifikant gegen die Areale "Kinn" (-23%) und "Hals" (-23%) ab und war bei 79% der Patienten am besten wirksam. 2) Bei weiterer Untersuchung verschiedener Trickmodalitäten auf dem für jeden Patienten individuell wirksamsten Areal waren neben dem klassischen Trickmanöver (-42%) auch die Verwendung eines Plastikstabes durch den Patienten (-43%) oder Untersucher (-32%), sowie nicht-sensible Manöver wie das Heben des Armes ohne eigentliche Berührung (-18%) und die bloße Vorstellung einer Trickapplikation (-20%) hochsignifikant wirksam. Allerdings korrelierten sensible und (wie die beiden letztgenannten) nicht-sensible Tricks nicht miteinander, was auf einen prinzipiell unterschiedlichen Wirkmechanismus hinweisen könnte. Visuelle Rückkopplung über einen Spiegel hatte im Gegensatz dazu keine Wirkung. 3) Bezüglich der Bedeutung der Kopfposition für Muskelaktivität und Trickwirksamkeit zeigte sich bereits bei willkürlicher Einnahme einer Neutralposition ohne Trickanwendung eine signifikante Reduktion agonistischer Muskelaktivität (-30%), die allerdings von einer leichten antagonistischen Aktivierung begleitet war (+2,4%). Überraschenderweise war die Applikation eines Tricks um so wirksamer, je weiter der Kopf zu Beginn auf die zur dystonen Drehrichtung kontralateralen Seite gedreht war. Demgegenüber ließ sich bei Trickapplikation in dystoner Maximalposition kaum mehr eine Wirkung nachweisen (-12%). Die vorliegenden Ergebnisse sprechen aufgrund der unspezifischen Wirkung verschiedenster Trickmanöver (2) und Lokalisationen (1) für die Einbeziehung höherer sensomotorischer Integrationszentren wie z. B. des Parietalcortex in den Wirkmechanismus. Sensible Trickmanöver könnten bei auf die pathologische Kopfposition adaptierten sensiblen Afferenzen Zusatzinformationen über die Kopfposition im Vergleich zum Rumpf liefern. Möglicherweise sind diese umso wirksamer, je weiter sich der Kopf noch auf der kontralateralen Seite befindet (3), da in dieser Situation die dystone Muskelaktivität noch gering und das sensible Mismatch, über welches sensible Stimuli modulierend einwirken könnten, maximal ist. Nach den vorgelegten Ergebnissen läßt sich erstmals ein zweiphasiger Ablauf der Trickwirkung postulieren: Der in einer ersten Phase teils willkürlich in eine günstige Ausgangsposition gebrachte Kopf kann durch die Anwendung sensibler Stimuli oder Imagination in einer zweiten Phase mit geringerer Anstrengung und unter Ausnutzung kortikaler sensomotorischer Servomechanismen stabilisiert werden. Im Rahmen der vorgelegten Studie konnte das Verständnis für therapeutisch nutzbare sensible Trickmanöver verbessert und somit Patienten unterschiedliche Trickstrategien an die Hand gegeben werden. Die Identifikation der zentralen Rolle höherer integrativer Zentren wie dem Parietalcortex im Rahmen des Wirkmechanismus, könnte dabei Ausgangspunkt für neue Therapieansätze in Form einer gezielten Beeinflussung solcher Areale sein. N2 - Sensory tricks in cervical dystonia frequently lead to a marked reduction of dystonic muscle activity, a fact that has been described as „geste antagonistique“ more than a century ago. In order to evaluate the impact of the degree of head rotation as well as mode and location on the efficacy of such sensory tricks, agonistic and antagonistic muscle activities in 26 patients with predominantly rotational torticollis have been systematically analyzed using a 4-channel surface EMG. In the subgroup of 19 patients with a clinically effective trick, touching the neck, chin or cheek on the ipsi- and contralateral side of head rotation all led to a significant (p<0.002) reduction of agonistic and antagonistic EMG activity. Patients without a clinically effective trick showed no significant change in EMG-activity. There was a strong correlation between the efficacy of a trick manoeuvre and the head position. No significant reduction during trick application was seen at the maximum dystonic head position while trick application in a neutral or even contralateral position led to a highly reduction of EMG-activity. Besides typical trick manoeuvres such as manually touching the sensitive area, other stimuli also led to significant reduction of EMG activity: use of a plastic stick instead of the finger by the patient (p<0.001) or by the investigator (p<0.001), elevating the arm and holding the finger close to the respective skin area without touching it (p<0,002), as well as mere thinking of performing the trick manoeuvre (p<0.002). As conclusion trigger mechanisms for tricks in cervical dystonia seem to be rather unspecific involving higher centres of sensorimotor integration. Based on these findings a 2-phase-model is proposed: In a first step normalization of head posture by stronger counterpressure or volitional antagonistic muscle activity might partly reduce dystonic activity, so that in a second step stabilisation of this head position applying a sensory trick manoeuvre is possible. Challenging the central adaption on distorted sensorimotor information in the nearby neutral head position seems to be the critical mechanism. KW - Dystonie KW - Torticollis KW - Trick KW - Geste KW - sensomotorisch KW - dystonia KW - torticollis KW - sensory KW - trick KW - geste Y1 - 2002 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-4722 ER - TY - THES A1 - Nehring, Claudia T1 - Sensitivität elektrophysiologischer Parameter bei der chronischen inflammatorischen demyelinisierenden Polyneuropathie (CIDP) in der Beurteilung des Langzeitverlaufes T1 - Sensitivity of electrophysiologic parameters of CIDP in the judgement of the long term course N2 - Die Chronische Inflammatorische Demyelinisierende Polyneuropathie (CIDP) ist eine seltene autoimmune Erkrankung des peripheren Nervensystems. In der vorliegenden Dissertation wurden die Akten von 23 CIDP – Patienten der Neurologischen Klinik der Universität Würzburg aus dem Zeitraum von 1990 bis 1999 ausgewertet und die elektrophysiologischen Parameter sowohl mit den klinischen Befunden als auch mit den Biopsiebefunden in Beziehung gestellt. Folgende Schlussfolgerungen konnten gezogen werden : - In dem untersuchten Patientenkollektiv war die sensomotorische Form der CIDP mit überwiegend motorischen Symptomen die häufigste Ausprägungsform. Hingegen treten rein motorische und rein sensible Formen sehr selten auf. - Die Krankheit manifestierte sich überwiegend an den distalen Extremitäten. - Die oberen Extremitäten waren selten und in keinem Fall isoliert betroffen. - Die systematische Auswertung des klinischen Schwergrades erfolgte anhand des Modifizierten Rankin Scores, der sowohl motorische als auch sensible Symptome berücksichtigt. Zusätzlich erfolgte der Entwurf eines sensiblen Scores, bei dem die sensiblen Symptome der Patienten in Zahlenwerten ausgedrückt sind. - Der Vergleich des klinischen Schweregrades mit den neurophysiologischen Befunden ergab vier unterschiedliche Korrelationstypen, die von sehr enger Korrelation bis hin zu nur geringen Übereinstimmungen reichten. - Der Schwergrad der Beeinträchtigung der Patienten war im Langzeitverlauf mit dem axonalen Verlust korreliert. Es fand sich eine gute Korrelation der Muskelsummenaktionspotentiale (CMAP) des Nervus medianus und des Nervus tibialis sowie der sensiblen Nervenaktionspotentiale (SNAP) des Nervus suralis mit dem Score. - Es ergab sich ein signifikanter Zusammenhang zwischen der Amplitude des Nervus suralis NAP`s und dem Ausmaß des Axonverlustes, wohingegen zwischen der Nervenleitungsgeschwindigkeit des Nervus suralis und dem Axonverlust nur eine geringe Abhängigkeit besteht. - Der Grad der Demyelinisierung korrelierte mit der Anzahl der endoneuralen Makrophagen. - Zwischen der Nervenleitgeschwindigkeit des Nervus suralis und dem Grad der Demyelinisierung im Biopsat konnte keine eindeutige Abhängigkeit nachgewiesen werden. - Es besteht ein Zusammenhang zwischen der Spontanaktivität im EMG und im Verlauf abnehmenden Nervenleitgeschwindigkeiten des Nervus medianus, der aber statistisch nicht signifikant ist. - Insbesondere ist die NLG- Abnahme in den ersten Wochen ein prognostisch ungünstiges Zeichen. - Eine Analogie zwischen einer durch das EMG nachgewiesenen Spontanaktivität und der Amplitude des Nervus suralis besteht. - Zwischen den Amplituden der motorischen Summenaktionspotentiale des Nervus tibialis oder den Amplituden der sensiblen Nervenaktionspotentiale des Nervus suralis auf der einen Seite und dem Ausmaß der Spontanaktivität im EMG auf der anderen Seite bestehen erkennbare Korrelationen. N2 - The CIDP is a rare autoimmune disease of the peripheral nervous system. In this dissertation there have been evaluated charts of patients of the neurological clinic of the university of Würzburg in the period from 1990 to 1999. From them were analyzed the electrophysiological parameters, the clinical items and the nerve biopsy results and compared with each other. The following conclusions have been found: - In this collective of patients the sensomotor form of CIDP with mainly motor symptoms was the most frequent one. Purely motor or sensible forms were rare. - The disease was manifesting itself predominantly on the distal extremities. - The upper extremities were rare and in no case isolate disabled. - For the systematic utilization of the clinical disability grade was made in use of the Modified Rankin Score, which took into consideration both the motor as well as the sensible symptoms. In addition there was developed a Sensible Score, with whom sensible symptoms are expressed in numbers. - The comparison of the clinical disability grade showed four different correlation types, which ranked from very narrow correlation to only small agreements. - The disability grade of the patients was in the long term course correlated with the axonal loss. There was a good correlation between the compound muscle action potential (CMAP) of the nervus medianus and the nervus tibialis and the nerve action potential (SNAP) of the nervus suralis with the score. - The degree of demyelination correlated with the number of endoneural macrophages. - No unequivocal dependence could be proven between the nerve conduction velocity of the nervus suralis and the degree of demyelination in the biopsy. - There was found a connection between the spontaneous activity (a diagnostic parameter of the EMG) and nerve conduction velocities of the nervus medianus, which were droped off in the course of the illness. The coherence was not statistically significant. - The removal of nerve conduction velocity in the first weeks is a prognostic unfavourable sign. - There exists an analogy between the spontaneous activity, found with the EMG, and the amplitude of the nervus suralis. - Between the amplitudes of the sensible nerve action potential of the nervus tibialis or the amplitudes of the sensible nerve action potentials of the nervus suralis on one hand and the amount of spontaneous activity on the other there were found correlations. KW - CIDP KW - PNP KW - EMG KW - NLG KW - Nervenbiopsie KW - CIDP KW - PNP KW - EMG KW - nerve conduction studies KW - nerve biopsy Y1 - 2003 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-7659 ER - TY - JOUR A1 - Magg, Barbara A1 - Riegler, Christoph A1 - Wiedmann, Silke A1 - Heuschmann, Peter A1 - Sommer, Claudia A1 - Üçeyler, Nurcan T1 - Self-administered version of the Fabry-associated pain questionnaire for adult patients JF - Orphanet Journal of Rare Diseases N2 - Background Fabry-associated pain may be the first symptom of Fabry disease (FD) and presents with a unique phenotype including mostly acral burning triggerable pain attacks, evoked pain, pain crises, and permanent pain. We recently developed and validated the first Fabry Pain Questionnaire (FPQ) for adult patients. Here we report on the validation of the self-administered version of the FPQ that no longer requires a face-to-face interview but can be filled in by the patients themselves allowing more flexible data collection. Methods At our Würzburg Fabry Center for Interdisciplinary Treatment, Germany, we have developed the self-administered version of the FPQ by adapting the questionnaire to a self-report version. To do this, consecutive Fabry patients with current or past pain history (n = 56) were first interviewed face-to-face. Two weeks later patients’ self-reported questionnaire results were collected by mail (n = 55). We validated the self-administered version of the FPQ by assessing the inter-rater reliability agreement of scores obtained by supervised administration and self-administration of the FPQ. Results The FPQ contains 15 questions on the different pain phenotypes, on pain development during life with and without therapy, and on impairment due to pain. Statistical analysis showed that the majority of questions were answered in high agreement in both sessions with a mean AC1-statistic of 0.857 for 55 nominal-scaled items and a mean ICC of 0.587 for 9 scores. Conclusions This self-administered version of the first pain questionnaire for adult Fabry patients is a useful tool to assess Fabry-associated pain without a time-consuming face-to-face interview but via a self-reporting survey allowing more flexible usage. KW - Fabry disease KW - Fabry-associated pain KW - pain questionnaire Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-145294 VL - 10 IS - 113 ER - TY - JOUR A1 - Ben-Kraiem, Adel A1 - Sauer, Reine-Solange A1 - Norwig, Carla A1 - Popp, Maria A1 - Bettenhausen, Anna-Lena A1 - Atalla, Mariam Sobhy A1 - Brack, Alexander A1 - Blum, Robert A1 - Doppler, Kathrin A1 - Rittner, Heike Lydia T1 - Selective blood-nerve barrier leakiness with claudin-1 and vessel-associated macrophage loss in diabetic polyneuropathy JF - Journal of Molecular Medicine N2 - Diabetic polyneuropathy (DPN) is the most common complication in diabetes and can be painful in up to 26% of all diabetic patients. Peripheral nerves are shielded by the blood-nerve barrier (BNB) consisting of the perineurium and endoneurial vessels. So far, there are conflicting results regarding the role and function of the BNB in the pathophysiology of DPN. In this study, we analyzed the spatiotemporal tight junction protein profile, barrier permeability, and vessel-associated macrophages in Wistar rats with streptozotocin-induced DPN. In these rats, mechanical hypersensitivity developed after 2 weeks and loss of motor function after 8 weeks, while the BNB and the blood-DRG barrier were leakier for small, but not for large molecules after 8 weeks only. The blood-spinal cord barrier remained sealed throughout the observation period. No gross changes in tight junction protein or cytokine expression were observed in all barriers to blood. However, expression of Cldn1 mRNA in perineurium was specifically downregulated in conjunction with weaker vessel-associated macrophage shielding of the BNB. Our results underline the role of specific tight junction proteins and BNB breakdown in DPN maintenance and differentiate DPN from traumatic nerve injury. Targeting claudins and sealing the BNB could stabilize pain and prevent further nerve damage. KW - macrophages KW - neuropathy KW - barrier KW - pain Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-265237 VL - 99 IS - 9 ER - TY - JOUR A1 - Volkmann, Jens A1 - Albanese, Alberto A1 - Antonini, Angelo A1 - Chaudhuri, K. Ray A1 - Clarke, Karl E. A1 - de Bie, Rob M. A. A1 - Deuschl, Günther A1 - Eggert, Karla A1 - Houeto, Jean-Luc A1 - Kulisevsky, Jaime A1 - Nyholm, Dag A1 - Odin, Per A1 - Ostergaard, Karen A1 - Poewe, Werner A1 - Pollak, Pierre A1 - Rabey, Jose Martin A1 - Rascol, Olivier A1 - Ruzicka, Evzen A1 - Samuel, Michael A1 - Speelman, Hans A1 - Sydow, Olof A1 - Valldeoriola, Francesc A1 - van der Linden, Chris A1 - Oertel, Wolfgang T1 - Selecting deep brain stimulation or infusion therapies in advanced Parkinson’s disease: an evidence-based review JF - Journal of Neurology N2 - Motor complications in Parkinson’s disease (PD) result from the short half-life and irregular plasma fluctuations of oral levodopa. When strategies of providing more continuous dopaminergic stimulation by adjusting oral medication fail, patients may be candidates for one of three device-aided therapies: deep brain stimulation (DBS), continuous subcutaneous apomorphine infusion, or continuous duodenal/jejunal levodopa/carbidopa pump infusion (DLI). These therapies differ in their invasiveness, side-effect profile, and the need for nursing care. So far, very few comparative studies have evaluated the efficacy of the three device-aided therapies for specific motor problems in advanced PD. As a result, neurologists currently lack guidance as to which therapy could be most appropriate for a particular PD patient. A group of experts knowledgeable in all three therapies reviewed the currently available literature for each treatment and identified variables of clinical relevance for choosing one of the three options such as type of motor problems, age, and cognitive and psychiatric status. For each scenario, pragmatic and (if available) evidence-based recommendations are provided as to which patients could be candidates for either DBS, DLI, or subcutaneous apomorphine. KW - Parkinson’s disease KW - apomorphine KW - deep brain stimulation KW - duodenal levodopa infusion Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-132373 VL - 260 ER - TY - JOUR A1 - Samper Agrelo, Iria A1 - Schira-Heinen, Jessica A1 - Beyer, Felix A1 - Groh, Janos A1 - Bütermann, Christine A1 - Estrada, Veronica A1 - Poschmann, Gereon A1 - Bribian, Ana A1 - Jadasz, Janusz J. A1 - Lopez-Mascaraque, Laura A1 - Kremer, David A1 - Martini, Rudolf A1 - Müller, Hans Werner A1 - Hartung, Hans Peter A1 - Adjaye, James A1 - Stühler, Kai A1 - Küry, Patrick T1 - Secretome analysis of mesenchymal stem cell factors fostering oligodendroglial differentiation of neural stem cells in vivo JF - International Journal of Molecular Sciences N2 - Mesenchymal stem cell (MSC)-secreted factors have been shown to significantly promote oligodendrogenesis from cultured primary adult neural stem cells (aNSCs) and oligodendroglial precursor cells (OPCs). Revealing underlying mechanisms of how aNSCs can be fostered to differentiate into a specific cell lineage could provide important insights for the establishment of novel neuroregenerative treatment approaches aiming at myelin repair. However, the nature of MSC-derived differentiation and maturation factors acting on the oligodendroglial lineage has not been identified thus far. In addition to missing information on active ingredients, the degree to which MSC-dependent lineage instruction is functional in vivo also remains to be established. We here demonstrate that MSC-derived factors can indeed stimulate oligodendrogenesis and myelin sheath generation of aNSCs transplanted into different rodent central nervous system (CNS) regions, and furthermore, we provide insights into the underlying mechanism on the basis of a comparative mass spectrometry secretome analysis. We identified a number of secreted proteins known to act on oligodendroglia lineage differentiation. Among them, the tissue inhibitor of metalloproteinase type 1 (TIMP-1) was revealed to be an active component of the MSC-conditioned medium, thus validating our chosen secretome approach. KW - neural stem cells KW - mesenchymal stem cells KW - transplantation KW - oligodendroglia KW - glial fate modulation KW - myelin KW - spinal cord KW - secretome KW - TIMP-1 Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-285465 SN - 1422-0067 VL - 21 IS - 12 ER - TY - JOUR A1 - Rauschenberger, Lisa A1 - Knorr, Susanne A1 - Pisani, Antonio A1 - Hallett, Mark A1 - Volkmann, Jens A1 - Ip, Chi Wang T1 - Second hit hypothesis in dystonia: Dysfunctional cross talk between neuroplasticity and environment? JF - Neurobiology of Disease N2 - One of the great mysteries in dystonia pathophysiology is the role of environmental factors in disease onset and development. Progress has been made in defining the genetic components of dystonic syndromes, still the mechanisms behind the discrepant relationship between dystonic genotype and phenotype remain largely unclear. Within this review, the preclinical and clinical evidence for environmental stressors as disease modifiers in dystonia pathogenesis are summarized and critically evaluated. The potential role of extragenetic factors is discussed in monogenic as well as adult-onset isolated dystonia. The available clinical evidence for a "second hit" is analyzed in light of the reduced penetrance of monogenic dystonic syndromes and put into context with evidence from animal and cellular models. The contradictory studies on adult-onset dystonia are discussed in detail and backed up by evidence from animal models. Taken together, there is clear evidence of a gene-environment interaction in dystonia, which should be considered in the continued quest to unravel dystonia pathophysiology. KW - dystonia KW - second hit KW - pathophysiology KW - gene-environment interaction Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-265028 VL - 159 ER - TY - THES A1 - Teuteberg, Philipp Wilhelm Friedemann T1 - Schmerzhafte Mononeuropathie an C57BL/6 Mäusen: Studien mit neutralisierenden Antikörpern gegen Tumor-Nekrose-Faktor Alpha an zwei verschiedenen Läsionsmodellen T1 - XX N2 - Die vorliegende Arbeit befaßt sich mit zwei Modellen einer schmerzhaften Mononeuropathie an der C57BL/6-Maus sowie deren Beeinflussung durch neutralisierende AK gegen TNF. Dafür wurden die Nn. ischiadici der Mäuse operativ manipuliert, zum einen in Form der CCI durch drei den Nerven einschnürende Ligaturen und zum anderen in Form der PST durch Heraustrennen eines Drittels des Nervendurchmessers. Beide Operationsmodelle lösten bei den Mäusen eine schmerzhafte Neuropathie aus. Es wurde untersucht, inwieweit zum Zeitpunkt der jeweiligen Operation oder am 4. postoperativen Tag applizierte TNF-AK das Schmerz-assoziierte Verhalten beeinflussen konnten und ob diese Behandlung einen Einfluß auf die Zytokinexpression im Endoneurium, auf den Makrophageneinstrom und auf die Nervenregeneration hatte. Hierzu wurden Verhaltenstests sowie immunhistochemische und morphometrische Methoden verwendet. Aus den vorliegenden Ergebnissen kann geschlossen werden, daß der bei CCI vermutete Einfluß der epineuralen Entzündung auf das Schmerz-assoziierte Verhalten kleiner ist als ursprünglich angenommen. Die Tatsache, daß zumindest auf einen Parameter (Hitzehyperalgesie) nicht nur die präventive sondern auch die therapeutische TNF-Hemmung wirksam war, läßt auf einen Einsatz von TNF-Hemmern bei bestimmten Formen des neuropathischen Schmerzes zur Therapieergänzung hoffen. Obwohl die TNF-Hemmung in den hier verwendeten Dosen und Applikationsweisen keinen Einfluß auf die endoneurale Zytokinexpression, Makrophagendichte und Regeneration hatte, sollten zukünftige Studien diese Parameter unter variierten Applikationsbedingungen genauer untersuchen. KW - Mononeuropathie KW - Tumor-Nekrose-Faktor KW - Allodynie KW - Hyperalgesie KW - Neuropathic Pain KW - Chronic Constriction Injury KW - Partial Sciatic Transection Y1 - 2003 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-5346 ER - TY - THES A1 - Papagianni, Aikaterini T1 - Schmerz-assoziierte elektrisch evozierte Potentiale (PREP) bei Patienten mit neuropathischen Schmerzsyndromen T1 - Pain-related evoked potentials (PREP) in patients with neuropathic pain N2 - In der vorliegenden Studie wurden 32 Patienten (19 Frauen, 13 Männer, medianes Alter 50 Jahren, Spanne: 26-83 Jahre) mit einem klinisch akralen neuropathischen Schmerzsyndrom unterschiedlicher Genese mittels QST, PREP und Hautbiopsie untersucht. Unser Patientenkollektiv bestand aus drei Subgruppen: sechsen Patienten erfüllten die Kriterien einer SFN, acht Patienten hatten eine Neuropathie der großkalibrigen Nervenfasern mit zusätzlicher Beeinträchtigung der kleinkalibrigen Nervenfasern und weitere acht Patienten hatten ein akrales Schmerzsyndrom mit neuropathischen Charakteristika, ohne vorbekannte Diagnose einer Neuropathie der groß- oder kleinkalibrigen Nervenfasern. Die Patienten wurden mittels klinischer neurologischer Untersuchung, elektrophysiologischer Tests, QST, PREP und Hautbiopsie untersucht. Die Patientendaten wurden jeweils mit Daten großer Kontrollgruppen verglichen, die wir in unserer Klinik unter Angehörigen und Freunden unserer Patienten mit deren Einwilligung rekrutiert hatten. QST und die Hautbiopsie waren bei Patienten mit SFN und PNP jeweils auffällig, bei akralem Schmerzsyndrom unklarer Ätiologie hingegen unauffällig. Nach elektrischer kutaner Stimulation aller drei Körperregionen zeigte sich eine Amplitudenminderung der PREP-Reizantwort in allen Patientensubgruppen (7,5 µV in der SFN-Gruppe, 3,8 µV in der PNP-Gruppe, und 11,3 µV bei den Patienten mit akralem Schmerzsyndrom). Somit konnten wir zeigen, dass eine Kleinfaserpathologie in der Studienpopulation von Patienten mit neuropathischem Schmerzsyndrom besteht. Nur die Amplitudenminderung der PREP bildet diese Pathologie ab. Diese Daten erlauben uns die eingangs aufgestellte Hypothese, dass PREP zur Diagnostik bei Frage nach Kleinfaserbeteiligung geeignet ist, positiv zu belegen. PREP ist eine nicht-invasive Methode für die Evaluation der Funktion v.a. der Aδ-Faser mit standardisiertem Ablaufprotokoll zur Erhebung von reproduzierbaren Daten. Sie kann bei Patienten mit der Anamnese eines akralen neuropathischen Schmerzsyndroms einen objektiven Hinweis auf eine Dysfunktion der kleinkalibrigen Nervenfasern, auch wenn bereits etablierte Methoden (QST und Hautbiopsie) unauffällig bleiben, erbringen. Entsprechend können die PREP eine wertvolle Ergänzung der klinischen Untersuchungsbatterie für die Evaluation der Funktion der kleinkalibrigen Nervenfasern sein. N2 - 32 adult patients (19 female, 13 male, median age 50 years, range 26-83) suffering from acral neuropathic pain were examined with QST, PREP and skin punch biopsy. Applying current diagnostic criteria and the results of the neurophysiological studies, 16/32 (50%) patients were classified as having idiopathic SFN (Devigili et al., 2008), 8/32 (25%) patients had a mixed fiber neuropathy (MFN, i.e. large and small fiber neuropathy), and 8/32 (25%) patients had neuropathic pain without signs of a large fiber neuropathy or SFN. Patients with SFN and mixed fiber neuropathy were having pathological findings in the skin punch biopsy (reduction of the intraepidermal nerve fiber density-IENFD), while normal findings were seen in patients with acral neuropathic pain Pain related evoked potentials after electrical skin stimulation at three body regions (face, hand, foot) revealed reduction of the peak-to-peak amplitude (PPA) in all patient-groups. Therefore, PREP was the only test providing findings of a small fiber impairment in patients with acral neuropathic pain even when QST and skin punch biopsy remained normal. PREP, as non-invasive method for the evaluation of the Aδ-pathways can be proposed as a valuable additional test for the evaluation of small fiber dysfunction in patients with neuropathic pain syndromes. KW - PREP KW - neuropathischer Schmerz KW - small-fiber-Neuropathie KW - pain related evoked potentials KW - small fiber neuropathy KW - neuropathic pain KW - Schmerz-assoziierte elektrisch evozierte Potentiale Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-159728 ER - TY - THES A1 - Auchter, Antonia T1 - Schlafassoziierte Veränderung der lokalen Feldpotential Aktivität im Nucleus subthalamicus bei Patienten mit Morbus Parkinson T1 - Sleep-associated changes in local field potential activity in the nucleus subthalamicus in patients with Parkinson's disease N2 - Die tiefe Hirnstimulation ist eine etablierte und hocheffiziente operative Behandlungsmethode für Patienten mit idiopathischem Parkinson- Syndrom (IPS). Als Zielgebiet dient in den meisten Fällen der Nucleus subthalamicus. Die Indikationen zur Implantation einer tiefen Hirnstimulation (THS) sind medikamentös nicht behandelbare motorische Fluktuationen und Dyskinesien oder ein medikamentös nicht kontrollierbarer Tremor. Bislang erfolgt eine kontinuierliche Stimulation. Little et al. konnten jedoch bereits in ihrer 2013 veröffentlichen Studie zeigen, dass eine adaptive Stimulation, gemessen am UPDRS, um 27 % effektiver war und entsprechend die Stimulationszeit um 56 % gesenkt werden konnte. Voraussetzung für die Anwendbarkeit einer adaptiven Stimulation im klinischen Alltag ist der Nachweis eines oder mehrerer Physiomarker, welche als Rückkopplungssignal für den Stimulationsbeginn dienen. Diese Marker müssen verlässlich mit dem Auftreten und der Ausprägung der Bewegungsstörungen korrelieren. Die Systeme müssen die Signale auslesen und entsprechend darauf reagieren können, damit ein sogenanntes Closed- loop- Verfahren entstehen kann. Bei diesen Markern handelt es sich um sogenannte lokale Feldpotenzialaktivitäten, das heißt niederfrequente Potentialänderungen von Zellen in subkortikalen Arealen des Gehirns, welche über Elektroden der THS abgeleitet werden können. Der Stimulator Activa PC+S (Medtronic) ermöglicht es erstmalig Aufzeichnungen von LFP- Daten, außerhalb eines experimentellen Laboraufbaus, mittels dauerhaft implantiertem Gerät vorzunehmen und damit auch Langzeitanalysen durchzuführen. Erkenntnisse vergangener Studien ergaben, dass die synchronisierte, pathologisch gesteigerte oszillatorische Aktivität im Beta-Frequenzband (13- 35 Hz) eine bedeutende Rolle im Bezug auf die Pathophysiologie des IPS spielt und als krankheitsspezifische Aktivität gilt. Es konnte bereits belegt werden, dass die Verbesserung der motorischen Symptome (Bradykinese und Rigor) mit dem Ausmaß der Suppression der Betaband- Aktivität korreliert. Die Betabandaktivität als lokale Feldpotentialaktivität kann als Physiomarker einer adaptiven Stimulation dienen. Unser Hauptaugenmerk galt daher der Analyse der Betabandaktivität oder anderer Frequenzbereiche während des Schlafes um hier die THS bedarfsgerecht einzusetzen. Hierfür wurden nächtliche subkortikale LFP- Aufzeichnungen parallel zur Schlaf- Polysomnographie durchgeführt. Zudem erfolgte in der vorliegenden Arbeit sowohl in unserem Vorversuch als auch in unserem Hauptversuch die Anwendung des UPDRS Teil III zur Erfassung der motorischen Symptome, sowie die Durchführung von Fragebögen zur Erfassung der nicht- motorischen Symptome, insbesondere des Schlafes vor und nach Implantation der tiefen Hirnstimulation. Wir konnten belegen, dass es nach Implantation der THS zu einer Erhöhung der Schlafeffizienz und zu einer Erhöhung des Anteils der Schlafstadien II und III und damit einhergehend zu einer Steigerung der Schlafqualität kommt. Übereinstimmend mit anderen Studien konnten wir zeigen, dass sich die Motorik unter Stimulation deutlich verbessert. Im Vorversuch reduzierte sich der mittlere präoperative MDS- UPDRS III im MedsOFF verglichen mit dem mittleren postoperativ MDS- UPDRS III im MedsOFF/StimON um 37 %. In der PC+S- Studie imponierte eine Reduktion um 67%. Zudem zeigte sich eine Reduktion der nicht- motorischen Symptome durch die THS, insbesondere in der Kategorie Schlaf. Die Ergebnisse der vorliegenden Arbeit ergaben außerdem, dass die Betabandaktivität im Schlafstadium II und vor allem im Schlafstadium III am geringsten ist. Im Schlafstadium I und REM ist die Betabandaktivität höher als im Schlafstadium II und III. Hierbei war entscheidend, dass die Patienten eine klar abgrenzbare Betabandaktivität im Wachstadium aufwiesen und die Elektrodenkontakte im dorsolateralen Kerngebiet des STN lokalisiert waren. Gegenläufig dazu verhält sich die Deltaaktivität. Sie ist im Schlafstadium II und besonders im Stadium III am höchsten. Stadium I ist mit durchschnittlich um 7,3 % niedriger als im Wachstadium. Am geringsten ist sie jedoch im REM-Schlafstadium. Indem wir mit der Betabandaktivität und Deltaaktivität in den einzelnen Schlafstadien einen stabilen und reproduzierbaren Physiomarker finden konnten, sind wir unserem Ziel der adaptiven THS ein Stück näher gekommen. N2 - Deep brain stimulation is an established and highly efficient surgical treatment modality for patients with idiopathic Parkinson's syndrome (IPS). The target area in most cases is the subthalamic nucleus. The indications for implantation of deep brain stimulation (THS) are motor fluctuations and dyskinesias that cannot be treated with medication or tremor that cannot be controlled with medication. To date, continuous stimulation has been used. However, Little et al. were already able to show in their study published in 2013 that adaptive stimulation was 27% more effective, as measured by UPDRS, and that the stimulation time could be reduced by 56% accordingly. A prerequisite for the applicability of adaptive stimulation in clinical practice is the detection of one or more physiomarkers that serve as feedback signals for the onset of stimulation. These markers must correlate reliably with the occurrence and severity of movement disorders. The systems must be able to read out the signals and react to them accordingly, so that a so-called closed-loop procedure can be created. These markers are so-called local field potential activities, i.e. low-frequency potential changes of cells in subcortical areas of the brain, which can be derived via electrodes of the THS. The Activa PC+S stimulator (Medtronic) makes it possible for the first time to record LFP data outside of an experimental laboratory setup using a permanently implanted device and thus also to perform long-term analyses. Findings of past studies revealed that synchronized, pathologically enhanced oscillatory activity in the beta frequency band (13- 35 Hz) plays a significant role in relation to the pathophysiology of IPS and is considered disease-specific activity. It has already been demonstrated that the improvement of motor symptoms (bradykinesia and rigor) correlates with the extent of suppression of beta-band activity. Beta-band activity as local field potential activity may serve as a physiomarker of adaptive stimulation. Therefore, our main focus was on the analysis of beta-band activity or other frequency ranges during sleep in order to apply THS as needed. For this purpose, nocturnal subcortical LFP recordings were performed in parallel to sleep polysomnography. In addition, the UPDRS Part III was used to record motor symptoms in our preliminary trial as well as in our main trial, and questionnaires were administered to record nonmotor symptoms, especially sleep before and after implantation of deep brain stimulation. We were able to prove that after implantation of THS there is an increase in sleep efficiency and an increase in the proportion of sleep stages II and III and thus an associated increase in sleep quality. Consistent with other studies, we demonstrated that motor function improves significantly under stimulation. In the preliminary trial, the mean preoperative MDS- UPDRS III in MedsOFF was reduced by 37% compared with the mean postoperative MDS- UPDRS III in MedsOFF/StimON. In the PC+S- study, a reduction of 67% was impressive. In addition, THS showed a reduction in non-motor symptoms, especially in the sleep category. The results of the present work also revealed that beta-band activity is lowest in sleep stage II and especially in sleep stage III. In sleep stage I and REM, beta-band activity is higher than in sleep stage II and III. Here, it was crucial that the patients showed a clearly delineable beta-band activity in the waking stage and that the electrode contacts were localized in the dorsolateral nucleus area of the STN. Opposite to this is the delta activity. It is highest in sleep stage II and especially in stage III. Stage I is lower than in the waking stage, with an average of 7.3%. However, it is lowest in the REM sleep stage. By finding a stable and reproducible physiomarker with beta band activity and delta activity in the individual sleep stages, we have come a step closer to our goal of adaptive THS. KW - Parkinson KW - Lokale Feldpotentialaktivität KW - Nucleus subthalamicus Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-237822 ER - TY - JOUR A1 - Steinhardt, Maximilian J. A1 - Cejka, Vladimir A1 - Chen, Mengmeng A1 - Bäuerlein, Sabrina A1 - Schäfer, Julia A1 - Adrah, Ali A1 - Ihne-Schubert, Sandra M. A1 - Papagianni, Aikaterini A1 - Kortüm, K. Martin A1 - Morbach, Caroline A1 - Störk, Stefan T1 - Safety and tolerability of SGLT2 inhibitors in cardiac amyloidosis — a clinical feasibility study JF - Journal of Clinical Medicine N2 - Sodium-glucose transport protein 2 inhibitors (SGLT2i) slow the progression of renal dysfunction and improve the prognosis of patients with heart failure. Amyloidosis constitutes an important subgroup for which evidence is lacking. Amyloidotic fibrils originating from misfolded transthyretin and light chains are the causal agents in ATTR and AL amyloidosis. In these most frequent subtypes, cardiac involvement is the most common organ manifestation. Because cardiac and renal function frequently deteriorate over time, even under best available treatment, SGLT2i emerge as a promising treatment option due to their reno- and cardioprotective properties. We retrospectively analyzed patients with cardiac amyloidosis, who received either dapagliflozin or empagliflozin. Out of 79 patients, 5.1% had urinary tract infections; 2 stopped SGLT2i therapy; and 2.5% died unrelated to the intake of SGLT2i. No genital mycotic infections were observed. As expected, a slight drop in the glomerular filtration rate was noted, while the NYHA functional status, cardiac and hepatic function, as well as the 6 min walk distance remained stable over time. These data provide a rationale for the use of SGLT2i in patients with amyloidosis and concomitant cardiac or renal dysfunction. Prospective randomized data are desired to confirm safety and to prove efficacy in this increasingly important group of patients. KW - heart failure KW - chronic kidney disease KW - amyloidosis KW - SGLT2 inhibitors Y1 - 2024 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-356024 SN - 2077-0383 VL - 13 IS - 1 ER - TY - JOUR A1 - Vogt, Marius L. A1 - Kollikowski, Alexander M. A1 - Weidner, Franziska A1 - Strinitz, Marc A1 - Feick, Jörn A1 - Essig, Fabian A1 - Neugebauer, Herrmann A1 - Haeusler, Karl Georg A1 - Pham, Mirko A1 - Maerz, Alexander T1 - Safety and Effectiveness of the New Generation APERIO® Hybrid Stent-retriever Device in Large Vessel Occlusion Stroke JF - Clinical Neuroradiology N2 - Background It is unknown whether technological advancement of stent-retriever devices influences typical observational indicators of safety or effectiveness. Methods Observational retrospective study of APERIO® (AP) vs. new generation APERIO® Hybrid (APH) (Acandis®, Pforzheim, Germany) stent-retriever device (01/2019–09/2020) for mechanical thrombectomy (MT) in large vessel occlusion (LVO) stroke. Primary effectiveness endpoint was successful recanalization eTICI (expanded Thrombolysis In Cerebral Ischemia) ≥ 2b67, primary safety endpoint was occurrence of hemorrhagic complications after MT. Secondary outcome measures were time from groin puncture to first pass and successful reperfusion, and the total number of passes needed to achieve the final recanalization result. Results A total of 298 patients with LVO stroke who were treated by MT matched the inclusion criteria: 148 patients (49.7%) treated with AP vs. 150 patients (50.3%) treated with new generation APH. Successful recanalization was not statistically different between both groups: 75.7% for AP vs. 79.3% for APH; p = 0.450. Postinterventional hemorrhagic complications and particularly subarachnoid hemorrhage as the entity possibly associated with stent-retriever device type was significantly less frequent in the group treated with the APH: 29.7% for AP and 16.0% for APH; p = 0.005; however, rates of symptomatic hemorrhage with clinical deterioration and in domo mortality were not statistically different. Neither the median number of stent-retriever passages needed to achieve final recanalization, time from groin puncture to first pass, time from groin puncture to final recanalization nor the number of cases in which successful recanalization could only be achieved by using a different stent-retriever as bail-out device differed between both groups. Conclusion In the specific example of the APERIO® stent-retriever device, we observed that further technological developments of the new generation device were not associated with disadvantages with respect to typical observational indicators of safety or effectiveness. KW - APERIO Hybrid KW - mechanical thrombectomy KW - stent-retriever device KW - stroke KW - APERIO Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-264817 VL - 32 IS - 1 ER - TY - JOUR A1 - Tony, Hans-Peter A1 - Burmester, Gerd A1 - Schulze-Koops, Hendrik A1 - Grunke, Mathias A1 - Henes, Joerg A1 - Kötter, Ina A1 - Haas, Judith A1 - Unger, Leonore A1 - Lovric, Svjetlana A1 - Haubitz, Marion A1 - Fischer-Betz, Rebecca A1 - Chehab, Gamal A1 - Rubbert-Roth, Andrea A1 - Specker, Christof A1 - Weinerth, Jutta A1 - Holle, Julia A1 - Müller-Ladner, Ulf A1 - König, Ramona A1 - Fiehn, Christoph A1 - Burgwinkel, Philip A1 - Budde, Klemens A1 - Sörensen, Helmut A1 - Meurer, Michael A1 - Aringer, Martin A1 - Kieseier, Bernd A1 - Erfurt-Berge, Cornelia A1 - Sticherling, Michael A1 - Veelken, Roland A1 - Ziemann, Ulf A1 - Strutz, Frank A1 - von Wussow, Praxis A1 - Meier, Florian MP A1 - Hunzelmann, Nico A1 - Schmidt, Enno A1 - Bergner, Raoul A1 - Schwarting, Andreas A1 - Eming, Rüdiger A1 - Schwarz-Eywill, Michael A1 - Wassenberg, Siegfried A1 - Fleck, Martin A1 - Metzler, Claudia A1 - Zettl, Uwe A1 - Westphal, Jens A1 - Heitmann, Stefan A1 - Herzog, Anna L. A1 - Wiendl, Heinz A1 - Jakob, Waltraud A1 - Schmidt, Elvira A1 - Freivogel, Klaus A1 - Dörner, Thomas A1 - Hertl, Michael A1 - Stadler, Rudolf T1 - Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID) JF - Arthritis Research & Therapy N2 - Introduction: Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective of this study was to evaluate the safety and clinical outcomes of rituximab in several standard-of-care-refractory autoimmune diseases (within rheumatology, nephrology, dermatology and neurology) other than rheumatoid arthritis or non-Hodgkin’s lymphoma in a real-life clinical setting. Methods: Patients who received rituximab having shown an inadequate response to standard-of-care had their safety and clinical outcomes data retrospectively analysed as part of the German Registry of Autoimmune Diseases. The main outcome measures were safety and clinical response, as judged at the discretion of the investigators. Results: A total of 370 patients (299 patient-years) with various autoimmune diseases (23.0% with systemic lupus erythematosus, 15.7% antineutrophil cytoplasmic antibody-associated granulomatous vasculitides, 15.1% multiple sclerosis and 10.0% pemphigus) from 42 centres received a mean dose of 2,440 mg of rituximab over a median (range) of 194 (180 to 1,407) days. The overall rate of serious infections was 5.3 per 100 patient-years during rituximab therapy. Opportunistic infections were infrequent across the whole study population, and mostly occurred in patients with systemic lupus erythematosus. There were 11 deaths (3.0% of patients) after rituximab treatment (mean 11.6 months after first infusion, range 0.8 to 31.3 months), with most of the deaths caused by infections. Overall (n = 293), 13.3% of patients showed no response, 45.1% showed a partial response and 41.6% showed a complete response. Responses were also reflected by reduced use of glucocorticoids and various immunosuppressives during rituximab therapy and follow-up compared with before rituximab. Rituximab generally had a positive effect on patient well-being (physician’s visual analogue scale; mean improvement from baseline of 12.1 mm) KW - GRAID Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-142856 VL - 13 IS - R75 ER - TY - JOUR A1 - Wurmb, Thomas Erik A1 - Schlereth, Stefan A1 - Kredel, Markus A1 - Muellenbach, Ralf M. A1 - Wunder, Christian A1 - Brederlau, Jörg A1 - Roewer, Norbert A1 - Kenn, Werner A1 - Kunze, Ekkehard T1 - Routine Follow-Up Cranial Computed Tomography for Deeply Sedated, Intubated, and Ventilated Multiple Trauma Patients with Suspected Severe Head Injury JF - BioMed Research International N2 - Background. Missed or delayed detection of progressive neuronal damage after traumatic brain injury (TBI) may have negative impact on the outcome. We investigated whether routine follow-up CT is beneficial in sedated and mechanically ventilated trauma patients. Methods. The study design is a retrospective chart review. A routine follow-up cCT was performed 6 hours after the admission scan. We defined 2 groups of patients, group I: patients with equal or recurrent pathologies and group II: patients with new findings or progression of known pathologies. Results. A progression of intracranial injury was found in 63 patients (42%) and 18 patients (12%) had new findings in cCT 2 (group II). In group II a change in therapy was found in 44 out of 81 patients (54%). 55 patients with progression or new findings on the second cCT had no clinical signs of neurological deterioration. Of those 24 patients (44%) had therapeutic consequences due to the results of the follow-up cCT. Conclusion. We found new diagnosis or progression of intracranial pathology in 54% of the patients. In 54% of patients with new findings and progression of pathology, therapy was changed due to the results of follow-up cCT. In trauma patients who are sedated and ventilated for different reasons a routine follow-up CT is beneficial. KW - Computertomographie Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-120084 IS - 361949 ER - TY - JOUR A1 - Albert-Weissenberger, Christiane A1 - Mencl, Stine A1 - Hopp, Sarah A1 - Kleinschnitz, Christoph A1 - Siren, Anna-Leena T1 - Role of the kallikrein-kinin system in traumatic brain injury JF - Frontiers in Cellular Neuroscience N2 - Traumatic brain injury (TBI) is a major cause of mortality and morbidity worldwide. Despite improvements in acute intensive care, there are currently no specific therapies to ameliorate the effects of TBI. Successful therapeutic strategies for TBI should target multiple pathophysiologic mechanisms that occur at different stages of brain injury. The kallikrein-kinin system is a promising therapeutic target for TBI as it mediates key pathologic events of traumatic brain damage, such as edema formation, inflammation, and thrombosis. Selective and specific kinin receptor antagonists and inhibitors of plasma kallikrein and coagulation factor XII have been developed, and have already shown therapeutic efficacy in animal models of stroke and TBI. However, conflicting preclinical evaluation, as well as limited and inconclusive data from clinical trials in TBI, suggests that caution should be taken before transferring observations made in animals to humans. This review summarizes current evidence on the pathologic significance of the kallikrein-kinin system during TBI in animal models and, where available, the experimental findings are compared with human data. KW - bradykinin KW - factor XII KW - kallikrein–kinin system KW - kinin receptor KW - traumatic brain injury Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-118226 SN - 1662-5102 VL - 8 ER - TY - THES A1 - Subramanian, Narayan T1 - Role of NaV1.9 in activity dependent axon growth in embryonic cultured motoneurons T1 - Die Rolle der NaV1.9 in Aktivität abhängig Axonwachstum in embryonalen kultivierten Motoneuronen N2 - Spontaneous neural activity has been shown to regulate crucial events in neurite growth including axonal branching and path finding. In animal models of spinal muscular atrophy (SMA) cultured embryonic mouse motoneurons show distinct defect in axon elongation and neural activity. This defect is governed by abnormal clustering of Ca2+ channels in the axonal regions and the protruding growth cone area. The mechanisms that regulate the opening of calcium channels in developing motoneurons are not yet clear. The question was addressed by blocking neural activity in embryonic cultured motoneurons by pharmacological inhibition of voltage-gated sodium channels (VGSC) by saxitoxin (STX) and tetrodotoxin (TTX). Low dosages of STX resulted in significant reduction of axon growth and neural activity in cultured motoneurons. This pharmacological treatment did not affect survival of motoneurons in comparison to control motoneurons that was grown in the presence of survival neurotrophic factors BDNF and CNTF. It was also found that STX was 10 times more potent than TTX a common inhibitor of VGSC with a reduced activity on the TTX-insensitive sodium channels NaV1.5, NaV1.8 and NaV1.9. Reverse Transcriptase-PCR experiments revealed the presence of NaV1.9 as the likely candidate that begins to express from embryonic stage sixteen in the mouse spinal cord. Immunolabelling experiments showed that the channel is expressed in the axonal compartments and axonal growth cones in cultured motoneurons. Suppression of NaV1.9 in cultured motoneurons by lentivirus mediated short hairpin-RNA (shRNA) resulted in shorter axon length in comparison with uninfected and scrambled constructs. Further, embryonic motoneurons cultured from NaV1.9 knockout mice also showed a significant reduction in neural activity and axon growth. The findings of this work highlight the role of NaV1.9 as an important contender in regulating activity dependent axon growth in embryonic cultured motoneurons. NaV1.9 could therefore be considered as a prospective molecule that could play an important role in regulating axon growth in motoneuron disease models like spinal muscular atrophy (SMA). N2 - Spontane neuronale Aktivität reguliert essentielle Ereignisse im Neuritenwachstum, wie beispielsweise die axonale Verzweigung und die Erkennung des Wachstumspfades. Motoneurone, die aus Tiermodellen der Spinalen Muskelatrophie (SMA) gewonnen werden, zeigen einen auffälligen Defekt im Streckenwachstum von Axonen und in der neuronalen Aktivität. Dieser Defekt wird von anormaler Clusterbildung von Ca2+ Kanälen in axonalen Regionen und in Wachstumskegeln begleitet. Die Mechanismen, die das Öffnen von Kalziumkanälen in embryonalen Motoneuronen in der Entwicklung regulieren, und die für das aktivitätsabhängige Axonwachstum benötigt werden, sind nicht bekannt. Diese Frage wurde in dieser Studie bearbeitet, indem neuronale Aktivität in embryonalen Motoneuronen durch pharmakologische Inhibition von spannungsabhängigen Natriumkanälen durch Saxitoxin (STX) und Tetrodotoxin blockiert wurde. Geringe Dosen von Saxitoxin bewirkten eine deutliche Reduktion des Axonwachstums und der neuronalen Aktivität in kultivierten Motoneuronen. Diese pharmakologische Behandlung beeinflusste nicht das Überleben von Motoneuronen im Vergleich zu Kontroll-Motoneuronen, die in der Anwesenheit der neurotrophen Faktoren BDNF und CNTF kultiviert wurden. Saxitoxin war etwa 5-10-mal potenter als TTX, ein üblicher Blocker spannungsabhängiger Natriumkanäle mit einer verminderte Aktivität auf die TTX-insensitiven Natriumkanäle NaV1.5, NaV1.8, und NaV1.9. Reverse-Transkriptase-PCR Experimente bestätigten die Anwesenheit von NaV1.9 am Tag E16 (embryonaler Tag 16) im Rückenmark der Maus. NaV1.9 ist ein einzigartiger Typus von einem Natriumkanal welcher in der Lage ist neuronale Erregbarkeit in der Nähe des Ruhemembranpotentials zu steuern. Deshalb war NaV1.9 ein guter Kandidat für einen Kanal, der spontane Erregung in Motoneuronen vermittelt. Immunofärbungen zeigten, dass NaV1.9 in axonalen Kompartimenten und axonalen Wachstumskegeln von kultivierten Motoneuronen exprimiert ist. Die Unterdrückung von NaV1.9 in kultivierten Motoneuronen durch lentiviralexprimierte short hairpin-RNA (shRNA) resultierte in kürzerer Axonlänge, im Vergleich zu nicht-infizierten Motoneuronen oder Motoneuronen, die eine sinnlose Kontroll-shRNA Sequenz exprimierten. Embryonale, kultivierte Motoneurone von NaV1.9 knockout Mäusen zeigten eine signifikante Verringerung der neuronalen Aktivität und verkürzte Axone. Diese Ergebnisse weisen auf eine Bedeutung von NaV1.9 im aktivitätsabhängigen Axonwachstum hin KW - Axon KW - Embryonalentwicklung KW - Motoneuron KW - Natriumkanal KW - Motoneuronen KW - NaV1.9 KW - motoneuron KW - Nav1.9 KW - axon growth Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-57536 ER - TY - THES A1 - Kroner-Milsch, Antje T1 - Role of immune cells in hereditary myelinopathies T1 - Rolle von Immunzellen in hereditären Myelinopathien N2 - Myelin mutations in the central and peripheral nervous system lead to severely disabling, currently untreatable diseases. In this study, we used transgenic PLP overexpressing mice (PLPtg) as a model for central inherited myelinopathies, such as leukodystrophies, and heterozygously P0 deficient (P0+/-) mice as models for peripheral hereditary polyneuropathies. Both models are characterized by low grade nervous tissue inflammation. Macrophages and CD8+ T- lymphocytes contribute to the myelin pathology as shown by crossbreeding experiments with immunodeficient mice. Having shown the relevance of CD8+ T- lymphocytes in PLPtg mice, we investigated the influence of one major cytotoxic molecule (granzyme B) on neural damage. By generation of granzyme B deficient PLPtg bone marrow chimeras, we could demonstrate a reduction of myelin pathology and oligodendrocyte death. Taken together, granzyme B is at least partly responsible for the cytotoxicity induced neural damage in PLPtg mice. To further explore the role of immune modulation, we focussed on the influence of the coinhibitory molecule PD-1, a CD28-related receptor expressed on activated T- and B-lymphocytes. By investigating myelin mutants of the CNS and PNS (PLPtg and P0+/-) with an additional PD-1 deficiency, induced by crossbreeding or bone marrow chimerization, we found a significant increase of CD8+ T- lymphocytes and massive increase of the myelin pathology in both the CNS and PNS model. In PLPtg mice, absence of PD-1 increased oligodendrocyte apoptosis, clonal expansions and a higher propensity of CNS but not peripheral CD8+ T- cells to secrete proinflammatory cytokines. In P0+/- mice, absence of PD-1 lead to moderate motor and sensory disturbances, confirming the important role of PD-1 in immune homeostasis. Taken together, we identified granzyme B as an important effector agent of cytotoxic T-lymphocytes in PLPtg mice and PD-1 as a crucial player in regulating the effector cells in our models of central and peripheral myelinopathy. Alterations of this regulatory pathway lead to overt neuroinflammation of high pathogenetic impact. These results might help to understand mechanisms responsible for high clinical variability of polygenic or even monogenic disorders of the nervous system. N2 - Myelinmutationen des zentralen und peripheren Nervensystems verursachen erheblich behindernde und bislang nicht heilbare Erkrankungen. In dieser Arbeit verwendeten wir transgene PLP überexprimierende Mäuse (PLPtg) als Modell für zentrale Myelinopathien und heterozygot P0 defiziente (P0+/-) Mäuse als Modell für hereditäre Neuropathien des peripheren Nervensystems. Beide Modelle zeigen eine niedriggradige Inflammation des Nervengewebes. Durch Verpaarung mit immundefizienten Mausstämmen konnten wir die Relevanz von Makrophagen und T- Lymphozyten in der Entstehung der Myelinpathologie zeigen. Nachdem wir beweisen konnten, dass CD8+ T- Lymphozyten maßgeblich zur Pathologie in PLPtg Mäusen beitragen untersuchten wir den Einfluss eines wichtigen zytotoxischen Moleküls, Granzym B, auf den neuralen Schaden. Durch Generierung von Granzym B defizienten PLPtg Knochenmarkschimären konnten wir eine deutliche Reduktion des glialen Schadens und der Oligodendrozytenapoptose nachweisen. Granzym B ist also zumindest teilweise verantwortlich für die Schädigung, die durch T- Lymphozyten hervorgerufen wird. Um die zusätzliche Informationen über die Rolle der Immunmodulation in unseren Modellen zu gewinnen, untersuchten wir das koinhibitorische Molekül PD-1, einen CD-28 verwandten Rezeptor, der auf B- und T- Lymphozyten exprimiert wird. Bei der Untersuchung von Myelinmutanten des ZNS und PNS (PLPtg und P0+/-), die zusätzlich PD-1 defizient waren, konnten wir einen signifikanten Anstieg von CD8+ T- Lymphozyten und eine deutliche Verschlechterung des glialen Schadens beobachten. In PLPtg Mäusen induzierte die Abwesenheit von PD-1 verstärkte Oligodendrozytenapoptose und klonale Expansion. Außerdem neigen ZNS- Lymphozyten aber nicht periphere CD8+ T- Zellen zur verstärkten Sekretion von proinflammatorischen Zytokinen. In P0+/- Mäusen führt Abwesenheit von PD-1 zu moderaten motorischen und sensorischen Störungen, was die wichtige Rolle von PD-1 in immunologischen Regulationsmechanismen unterstreicht. Zusammenfassend kann man festhalten, daß Granzym B ein wichtiges Effektormolekül zytotoxischer T- Zellen in PLPtg Mäusen ist. PD-1 spielt eine wichtige Rolle in der Regulation von Effektorzellen in unseren Modellen für zentrale und periphere Myelinopathien. Veränderungen dieser Regulation können deutliche Neuroinflammation mit starker Myelinpathologie hervorrufen. Diese Ergebnisse können dazu beitragen, die starke klinische Variabilität von polygenen und sogar monogenen neurologischen Erkrankungen zu erklären. KW - Myelinopathie KW - T- Lymphozyt KW - Multiple Sklerose KW - Neuropathie KW - PD-1 KW - Myelinopathy KW - neuropathy KW - T-lymphocyte KW - multiple sclerosis Y1 - 2008 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-28976 ER - TY - JOUR A1 - Häuser, Winfried A1 - Walitt, Brian A1 - Fitzcharles, Mary-Ann A1 - Sommer, Claudia T1 - Review of pharmacological therapies in fibromyalgia syndrome JF - Arthritis Research & Therapy N2 - This review addresses the current status of drug therapy for the management of fibromyalgia syndrome (FMS) and is based on interdisciplinary FMS management guidelines, meta-analyses of drug trial data, and observational studies. In the absence of a single gold-standard medication, patients are treated with a variety of drugs from different categories, often with limited evidence. Drug therapy is not mandatory for the management of FMS. Pregabalin, duloxetine, milnacipran, and amitriptyline are the current first-line prescribed agents but have had a mostly modest effect. With only a minority of patients expected to experience substantial benefit, most will discontinue therapy because of either a lack of efficacy or tolerability problems. Many drug treatments have undergone limited study and have had negative results. It is unlikely that these failed pilot trials will undergo future study. However, medications, though imperfect, will continue to be a component of treatment strategy for these patients. Both the potential for medication therapy to relieve symptoms and the potential to cause harm should be carefully considered in their administration. Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-121598 SN - 1465-9913 VL - 16 IS - 201 ER - TY - JOUR A1 - Aster, Hans-Christoph A1 - Romanos, Marcel A1 - Walitza, Susanne A1 - Gerlach, Manfred A1 - Mühlberger, Andreas A1 - Rizzo, Albert A1 - Andreatta, Marta A1 - Hasenauer, Natalie A1 - Hartrampf, Philipp E. A1 - Nerlich, Kai A1 - Reiners, Christoph A1 - Lorenz, Reinhard A1 - Buck, Andreas K. A1 - Deserno, Lorenz T1 - Responsivity of the striatal dopamine system to methylphenidate — A within-subject I-123-β-CIT-SPECT study in male children and adolescents with attention-deficit/hyperactivity disorder JF - Frontiers in Psychiatry N2 - Background: Methylphenidate (MPH) is the first-line pharmacological treatment of attention-deficit/hyperactivity disorder (ADHD). MPH binds to the dopamine (DA) transporter (DAT), which has high density in the striatum. Assessments of the striatal dopamine transporter by single positron emission computed tomography (SPECT) in childhood and adolescent patients are rare but can provide insight on how the effects of MPH affect DAT availability. The aim of our within-subject study was to investigate the effect of MPH on DAT availability and how responsivity to MPH in DAT availability is linked to clinical symptoms and cognitive functioning. Methods Thirteen adolescent male patients (9–16 years) with a diagnosis of ADHD according to the DSM-IV and long-term stimulant medication (for at least 6 months) with MPH were assessed twice within 7 days using SPECT after application of I-123-β-CIT to examine DAT binding potential (DAT BP). SPECT measures took place in an on- and off-MPH status balanced for order across participants. A virtual reality continuous performance test was performed at each time point. Further clinical symptoms were assessed for baseline off-MPH. Results On-MPH status was associated with a highly significant change (−29.9%) of striatal DAT BP as compared to off-MPH (t = −4.12, p = 0.002). A more pronounced change in striatal DAT BP was associated with higher off-MPH attentional and externalizing symptom ratings (Pearson r = 0.68, p = 0.01). Striatal DAT BP off-MPH, but not on-MPH, was associated with higher symptom ratings (Pearson r = 0.56, p = 0.04). Conclusion Our findings corroborate previous reports from mainly adult samples that MPH changes striatal DAT BP availability and suggest higher off-MPH DAT BP, likely reflecting low baseline DA levels, as a marker of symptom severity. KW - methylphenidate KW - attention deficit/hyperactivity disorder (ADHD) KW - striatum KW - single photon emission computed tomography (SPECT) KW - responsivity KW - caudate nucleus KW - dopamine transporter (DAT) Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-270862 SN - 1664-0640 VL - 13 ER - TY - JOUR A1 - Korn, Thomas A1 - Kleinschnitz, Christoph A1 - Magnus, Tim A1 - Meuth, Sven G. A1 - Linker, Ralf A. T1 - Report on the 7th scientific meeting of the Association for the Advancement of Young Academics in Neurology (NEUROWIND e.V.) held in Motzen, Germany, October 30–November 1, 2015 JF - Experimental and Translational Stroke Medicine N2 - From October 30–November 1, 2015, the 7th NEUROWIND e.V. meeting was held in Motzen, Brandenburg, Germany. Seventy doctoral students and postdocs from over 25 different groups working in German and Swiss University Hospitals or Research Institutes attended the meeting to discuss their latest experiments and findings in the fields of neuroimmunology, neurodegeneration and neurovascular research. This meeting report summarizes the many diverse presentations and the new preclinical to clinical neurology research data that were shared by the participants at the meeting. KW - NEUROWIND Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-146595 VL - 8 IS - 3 ER - TY - JOUR A1 - Kleinschnitz, Christoph A1 - Linker, Ralf A. A1 - Magnus, Tim A1 - Korn, Thomas A1 - Meuth, Sven G. T1 - Report on the 6th scientific meeting of the “Verein zur Förderung des Wissenschaftlichen Nachwuchses in der Neurologie” (NEUROWIND e.V.) held in Motzen, Germany, Oct. 31th – Nov. 2nd, 2014 JF - Experimental & Translational Stroke Medicine N2 - From October 31th – November 2nd, 2014, the 6th NEUROWIND e.V. meeting was held in Motzen, Brandenburg, Germany. 70 doctoral students and postdocs from over 25 different groups working in German and Swiss university hospitals or research institutes attended the meeting to discuss their latest experiments and findings in the fields of neuroimmunology, neurodegeneration and neurovascular research. The meeting was regarded as a very well organized platform to support research of young investigators in Germany and all participants enjoyed the stimulating environment for lively in depth discussions. According to the major aim of NEUROWIND e.V. to support younger researchers in Germany the 4th NEUROWIND YOUNG SCIENTIST AWARD for experimental neurology was awarded to Michael Breckwoldt on his work in the group of Thomas Misgeld (Institute of Neuronal Cell Biology, Technische Universität München, Germany). The successful project was published in Nature Medicine entitled “Multiparametric optical analysis of mitochondrial redox signals during neuronal physiology and pathology in vivo”. This outstanding paper deals with a molecular imaging approach in living mice to optically analyze the role of mitochondrial redox signals in axons in health and disease. The award is endowed with 20.000 Euro sponsored by Merck Serono GmbH, Darmstadt, Germany (unrestricted educational grant). This year’s keynote lecture was given by Bernhard Hemmer, Head of the Department of Neurology at the Klinikum rechts der Isar, Technische Universität München. Dr. Hemmer highlighted the particular role of B cells and (auto)antibodies in multiple sclerosis (MS). As a new highlight Dr. Urbahns, head of global discovery technologies at Merck research laboratories, gave insights from research practice in the pharmaceutical industry and introduced a shift in the view on present-day drug discovery paradigms. Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-125049 VL - 7 IS - 1 ER - TY - JOUR A1 - Linker, Ralf A. A1 - Magnus, Tim A1 - Korn, Thomas A1 - Kleinschnitz, Christoph A1 - Meuth, Sven G. T1 - Report on the 5‘th scientific meeting of the “Verein zur Förderung des Wissenschaftlichen Nachwuchses in der Neurologie” (NEUROWIND e.V.) held in Motzen, Germany, Oct. 25th – Oct. 27th, 2013 JF - Experimental & Translational Stroke Medicine N2 - From october 25th - 27th 2013, the 5th NEUROWIND e.V. meeting was held in Motzen, Brandenburg, Germany. This year more than 60 doctoral students and postdocs from over 25 different groups working in German university hospitals or research institutes attended the meeting to discuss their latest findings in the fields of neuroimmunology, neurodegeneration and neurovascular research. All participants appreciated the stimulating environment in Motzen, Brandenburg, and people took the opportunity for scientific exchange, discussion about ongoing projects and already started further collaborations. Like in the previous years, the symposium was regarded as a very well organized platform to support research of young investigators in Germany. According to the major aim of NEUROWIND e.V. to support younger researchers in Germany the 3rd NEUROWIND YOUNG SCIENTIST AWARD for experimental neurology was awarded to Ruth Stassart working in the group of Klaus Armin Nave and Wolfgang Brück (MPI Göttingen and Department of Neuropathology, Göttingen Germany). The successful work was published in Nature Neuroscience entitled “A role for Swann cell-derived neuregulin-1 in remyelination”. This outstanding paper deals with the function of Schwann cell neuregulin as an endogenous factor for myelin repair. The award is endowed with 20.000 Euro sponsored by Merck Serono GmbH, Darmstadt, Germany (unrestricted educational grant). This year’s keynote lecture was given by Albert Ludolph, Head of the Department of Neurology at the University Clinic of Ulm. Dr. Ludolph highlighted the particular role of individual scientists for the development of research concepts in Alzheimer´s disease (AD) and frontotemporal dementia (FTD). KW - NEUROWIND Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-129230 VL - 5 IS - 15 ER - TY - RPRT A1 - Linker, Ralf, A. A1 - Meuth, Sven G. A1 - Magnus, Tim A1 - Korn, Thomas A1 - Kleinschnitz, Christoph T1 - Report on the 4'th scientific meeting of the "Verein zur Förderung des Wissenschaftlichen Nachwuchses in der Neurologie" (NEUROWIND e.V.) held in Motzen, Germany, Nov. 2'nd - Nov. 4'th, 2012 [meeting report] N2 - From November 2nd - 4th 2012, the 4th NEUROWIND e.V. meeting was held in Motzen, Brandenburg, Germany. Again more than 60 participants, predominantly at the doctoral student or postdoc level, gathered to share their latest findings in the fields of neurovascular research, neurodegeneration and neuroinflammation. Like in the previous years, the symposium provided an excellent platform for scientific exchange and the presentation of innovative projects in the stimulating surroundings of the Brandenburg outback. This year’s keynote lecture on the pathophysiological relevance of neuronal networks was given by Christian Gerloff, Head of the Department of Neurology at the University Clinic of Hamburg-Eppendorf. Another highlight of the meeting was the awarding of the NEUROWIND e.V. prize for young scientists working in the field of experimental neurology. The award is donated by the Merck Serono GmbH, Darmstadt, Germany and is endowed with 20.000 Euro. This year the jury decided unanimously to adjudge the award to Michael Gliem from the Department of Neurology at the University Clinic of Düsseldorf (group of Sebastian Jander), Germany, for his outstanding work on different macrophage subsets in the pathogenesis of ischemic stroke published in the Annals of Neurology in 2012. KW - Medizin Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-76407 ER - TY - JOUR A1 - Kleinschnitz, Christph A1 - Meuth, Sven G. A1 - Magnus, Tim A1 - Korn, Thomas A1 - Linker, Ralf A. T1 - Report on the 3'rd scientific meeting of the "Verein zur Förderung des Wissenschaftlichen Nachwuchses in der Neurologie" (NEUROWIND e.V.) held in Motzen, Germany, Nov. 4'th - Nov. 6'th, 2011 N2 - From November 4th- 6th 2011, the 3rd NEUROWIND e.V. meeting was held in Motzen, Brandenburg, Germany. Like in the previous years, the meeting provided an excellent platform for scientific exchange and the presentation of innovative projects for young colleagues in the fields of neurovascular research, neuroinflammation and neurodegeneration. As kick-off to the scientific sessions, Reinhard Hohlfeld, Head of the Institute for Clinical Neuroimmunology in Munich, gave an illustrious overview on the many fascinations of neuroimmunologic research. A particular highlight on the second day of the meeting was the award of the 1’st NEUROWIND e.V. prize for young academics in the field of experimental neurology. This award is posted for young colleagues under the age of 35 with a significant achievement in the field of neurovascular research, neuroinflammation or neurodegeneration and comprises an amount of 20.000 Euro, founded by Merck Serono GmbH, Darmstadt. Germany. The first prize was awarded to Ivana Nikic from Martin Kerschensteiner’s group in Munich for her brilliant work on a reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis, published in Nature Medicine in 2011. This first prize award ceremony was a great incentive for the next call for proposals now upcoming in 2012. KW - Medizin Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-75388 ER - TY - RPRT A1 - Magnus, Tim A1 - Linker, Ralf A. A1 - Meuth, Sven G. A1 - Kleinschnitz, Christoph A1 - Korn, Thomas T1 - Report on the 2nd scientific meeting of the "Verein zur Foerderung des Wissenschaftlichen Nachwuchses in der Neurologie" (NEUROWIND e.V.) held in Motzen, Germany, Oct. 29'th - Oct. 31'st, 2010 N2 - Summary of the scientific contributions to the NEUROWIND meeting 2010: Contributions in the fields of neuroimmunology and neurodegeneration KW - Wissenschaftlicher Nachwuchs KW - Neurologie Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-68789 ER -